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ABSTRACT
Both genotoxic and non-genotoxic processes can lead to thyroid follicular cell carcinogenesis. 
Whereas the latter are threshold mediated and are therefore able to be regulated by a margin of 
safety approach, the former are not. Discrimination between these two processes is critical in long­
term biosassays in animals that are used for the purpose of hazard assessment in the chemical 
industry. These data are then considered in relation to exposure to enable an evaluation of risk to 
human health.
Mechanistic studies have been performed which show that non-genotoxic thyroid carcinogenesis is
the consequence of an increased plasma thyrotropin (TSH). Using phénobarbital as a reference
material of known clinical safety and no evidence of human thyroid follicular cell neoplasia,
disruptive events have been shown to occur in the hypothalamic-pituitary-thyroid axis of rats.
Interestingly, the primary action appears to have occurred in the liver, resulting remotely in an
indirect, secondary effect in the thyroid gland. This pattern of perturbation was noted w ith a
number of new candidate plant protection products - liver weight increases, hepatocyte
hypertrophy, changes in thyroid gland morphology progressing from reductions in colloid to
follicular cell hypertrophy, hyperplasia, adenoma and carcinoma after some 18 months to 2 years.
Parallel changes, which began very early (within 24 hours), were seen in biochemical and hormonal
markers such as thyroxine (T4) tri-iodothyronine (T3), and TSH. Nevertheless, the evidence of
increased thyroid hormone clearance resulting from increased hepatic (peripheral) metabolism
''TlllS
became less evident after 2 to 4 weeks. The was assumed to be due to compensation by the thyroid 
as the result of an increase in glandular activity to regain normal homeostasis. This raised the
question whether hypothalamic-pituitary control was activated by hormone level (reductions were 
uncommon) or by clearance rate possibly mediated by some unclear receptor mechanism.
To distinguish primary from secondary thyroid effects, use was made of the perchlorate discharge 
test. This in-line with other authors was considered a robust method for establishing whether 
appropriate levels of iodine uptake and organification were taking place.
It is proposed that early evidence of liver weight increase, cytochrome R-450 induction and an 
increase in hepatic microsomal uridine diphosphoglucuronyl transferases (UDRGT) in the first two 
weeks of xenobiotic administration are likely to lead to increased thyroid hormone metabolism. 
Concurrent reduction in T4 and/or T3 together with an increase in TSH, in association with 
morphological evidence of an effect on the thyroid, supports the hypothesis that the hypothalamic- 
pituitary thyroid axis has been disrupted. This may help explain the mechanism of action for 
subsequent thyroid tumour formation and w ill help in the process of new product development and 
risk assessment for man. A proposed diagnostic algorithm for evaluating such indirect effects on 
thyroid function is presented.
STRUCTURE OF THESIS
The thesis is divided into the follow ing chapters and subsections.
Chapter 1
This is a historical review of the subject designed to orientate the reader. It comprises sections on 
thyroid physiology and details the biosynthetic mechanisms involved in the formation of thyroid 
hormones. In particular, potential sites of interference with the latter processes are defined. It 
summarises direct and indirect mechanisms of goitrogenesis and focuses on the effects of 
microsomal enzyme induction on this process. The structure and physiology of the liver are 
described along with details of the many subclasses of microsomal enzyme inducing agents.
Chapter 2
This is a summary of the materials and methods used. It defines all the principal methods and 
analytical procedures. Exceptions to this include method development procedures for a rat-specific 
TSH assay with solid-phase, second antibody and for a microcentrifugal analysis of phénobarbital. 
These methods are included in Appendix 1.
Chapter 3
In this Chapter are the summaries of the studies conducted. Each is presented with a rationale, a 
description of the study design, a synopsis of the results obtained and a summary of the principal 
findings. The main sections relate to:
i) A two year carcinogenicity study with the archetypal microsomal enzyme inducing agent, 
phénobarbital
ii) Measurements of sub-chronic effects on thyroid and hepatic function, for a number of 
compounds studied and methods for their classification according to enzyme induction subclass.
Chapter 4
The effects of microsomal enzyme inducing agents on the testis are reviewed in this chapter. During 
the course of the thesis the pathogenesis of thyroid tumours was seen to be sexually differentiated. 
Discussions with colleagues in other industrial laboratories suggested that for some microsomal 
enzyme inducing agents the testis might be another target for effects. A retrospective examination of 
tissues from the two year toxicity study with phénobarbital, described in Chapter 3, supported this 
theory and showed unexpected but convincing effects. These warranted description.
Chapter 5
The concluding chapter discusses the background to the thesis and discusses the results obtained in 
the light of current literature. Significant observations published by other authors are presented and 
some thoughts on future areas of research are discussed. In particular, the influence of TSH in 
thyroid follicular cell growth processes and the progression of thyroid tumours is discussed.
The chapter also contains a clinical algorithm. This is a proposed testing sequence that permits 
comprehensive evaluation of test materials against the principal sites of potential interference with 
thyroid function.
Appendix 1
A bibliography that lists the research papers and books referred to in the course of the thesis.
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QUOTATION
Vital mechanisms have one object- 
preserving constant the internal environment
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PREFACE
Certain naturally occurring substances and synthetic chemicals are capable of increasing the 
detoxifying potential of the liver by stimulating the de novo synthesis of a range of oxidative 
enzymes. This normal, adaptive process, known as microsomal enzyme induction, is thought to be 
a defence mechanism that normally facilitates the rapid detoxification and excretion of potentially 
harmful chemicals. The microsomal enzyme systems that are induced have broad substrate 
specificity, which besides xenobiotics, includes naturally occurring endogenous substances such as 
hormones and vitamins. Paradoxically, it would appear that in certain circumstances microsomal 
enzyme induction may actually cause adverse effects by disrupting normal physiological processes. 
For the endocrine system, such disruption may lead to cancer.
In our laboratory, many novel plant protection products are seen to be cytochrome P450 inducing 
agents. A number of these have shown effects on thyroid function in rats, particularly males. 
Persistence of these changes in certain long-term studies, is associated with proliferative lesions in 
thyroid follicular cells. The effect, which seems species-specific or at least very exaggerated in the 
rat, is thought to involve a consequential, secondary increase in thyroid hormone turnover due to 
enhanced liver metabolism. This leads to a chronic thyrotropin (TSH) stimulation of the thyroid 
gland via normal physiological feedback control and it is this that ultimately leads to thyroid 
follicular cell neoplasia. Thus, the homeostatic disruption, caused by treatment with high doses of 
the compound, not the compound itself leads to cancer.
The occurrence of cancer caused by such disruption is not readily predictable. Yet, such a finding 
at the end of long-term studies of the toxicology pesticidal products is of major consequence to the 
Company involved. The Delaney clause of the United States, Federal Food, Drug and Cosmetic 
Act (US. FDC, 1958) prevents the registration of any "food additive", which includes pesticidal 
residues in certain crops. The Act broadly states that any chemical found to statistically increase
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the incidence of any benign or malignant tumours in laboratory animals must not be added to 
human food supplies. This effectively prevents the registration of such products in the USA, if by 
food processing, e.g., citrus fruit juice production, the pesticidal residue in the raw agricultural 
commodity is likely to be concentrated.
In other countries, regulatory authorities take a more reasoned approach. If satisfactory reasoning 
can be given, which shows evidence of a mechanism for an increased incidence of tumours and 
shows lack of relevance to man, registration is usually granted. In the case of thyroid proliferative 
lesions, such a mechanism could be evidence of high dose interference with hormone production, 
metabolism or disposal. What therefore are the potential mechanistic causes of proliferative lesions 
observed after treatment with xenobiotics and how might the potential to cause thyroid neoplasia be 
predicted?
A literature search suggested at least four mechanisms could account for thyroid proliferative change 
and these could be divided into two classes. In the first class are compounds that directly interact 
with DNA, the genotoxic carcinogens. The second class, which enhance cell proliferation are the 
nongenotoxic carcinogens (Figure 1). Chemicals in this class can be further subdivided into;
I. Compounds that may directly affect the hypothalamus or pituitary and lead to TRH or TSH (like) 
stimulation of the pituitary'or thyroid by direct neuroendocrine interference.
II. The direct acting goitrogens that inhibit certain aspects of thyroid hormone biosynthesis.
III.The indirect acting goitrogens in which the normally functioning thyroid gland is affected by 
secondary mechanisms such as enhanced metabolic turnover of thyroid hormones.
In all three cases, dramatic suppression of thyroid function or stimulation of the pituitary could 
cause indirect, non-genotoxic, follicular cell neoplasia due to constant, feedback stimulation by 
pituitary TSH.
Figure 1 : Mechanisms of Thyroid proliferative Change
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Mechanisms of Thyroid Follicular Cell Proliferative change
Phénobarbital, a classic microsomal enzyme inducing agent is believed to fall into the final class (III) 
(Conney, 1967) since it indirectly affects the thyroid gland by increasing the hepatic uptake and rate 
of thyroid hormone catabolism (Oppenheimer eta/., 1968). The thyroid gland is controlled by a 
delicate feedback control mechanism. This involves interaction between circulating plasma 
hormone levels, pituitary receptor occupancy and increased thyroid hormone synthesis that is 
activated by thyroid stimulating hormone (TSH) released by the pituitary. An increased rate of 
thyroid hormone metabolism prompts the feedback control mechanism to secrete TSH. It is 
hypothesised that this could lead to neoplasia by constant, compensatory, TSH-stimulation of the 
thyroid, if the dose of phénobarbital was high enough.
In rodent toxicity studies involving novel xenobiotics, this type of interference with hypothalamic- 
pituitary-thyroid feedback control would not, at first sight, explain the apparent sex and species 
related incidence of thyroid follicular proliferative change discussed above. It also fails to explain 
why the effect is not seen with all microsomal enzyme inducing xenobiotics.
In the rat, clear sex differences in microsomal enzyme activity towards certain substrates have been 
observed. The species appears unique in this respect, since this distinction is not apparent in other 
experimental animals or humans (Kato, 1977). In toxicological terms, this highly significant, rat-
specific phenomenon could, by differentially influencing thyroid hormone metabolism, provide a 
clear, indirect mechanism for thyroid follicular cell neoplasia, in the male. However, since such 
effects are not seen in other species or with all xenobiotic inducing agents the mechanism must 
clearly be dependent on specific, undefined mechanisms or generic factors related to dose level, 
induction class or magnitude of effect.
To put the problems highlighted above in perspective, consider the case of modern, environmentally 
compatible pesticides. These compounds, which are being developed to replace existing and 
frequently more toxic alternatives, are well tolerated and have little or no target organ toxicity in 
animal studies. To register such new products for marketing, safety evaluation studies are necessary 
to comply with international regulatory guidelines. These require compounds to be tested at dose 
levels up to and including a maximally tolerated dose (MTD).
The MTD is a historical concept, derived from the development of older-style, inherently more toxic 
pesticides. When applied to toxicity studies, involving modern, less-toxic equivalents, it can be 
argued that excessively high dose levels result. The sheer mass of compound administered, which 
has to be metabolised and excreted, can lead to secondary physiological effects. This is particularly 
true of microsomal enzyme inducing agents that can enhance the metabolism of endogenous 
physiological substances at the same time as dosed compound. Clearly, such effects, which may be 
more apparent in the male rat due to the inherently higher potential for induced, oxidative 
metabolism in this sex, may not be a true reflection of the actual toxicity of the chemical. At much 
lower doses, which far exceed the probable human exposure level, no such changes are observed. 
Hence, thyroid follicular cell hyperplasia and neoplasia observed in rats, due to profound 
microsomal enzyme induction, could be considered to be of dubious relevance to man.
Although only a few existing chemicals are known to cause cancer in humans, most of them can be 
readily demonstrated in rodent carcinogenicity studies. Defining the potential risk of novel 
chemicals to man is more problematical, since a large number show an apparent carcinogenic
response in such studies. The toxicological threat that rodent carcinogens pose to man is currently 
the subject of much scientific debate. A pivotal aspect of the problem is that 20 of the 23 known 
human carcinogens have been shown to be genotoxic (Shelby, 1988). On the other hand, many 
rodent carcinogens appear to act via non-genotoxic, extra-chromosomal mechanisms (Ames and 
Gold, 1990). These could include interference with intracellular communication, chronic 
endocrine imbalance or chronic tissue injury. Such secondary effects can clearly be related to dose. 
Frequently, the tumourigenic response of non-genotoxic agents can only be demonstrated in rodent 
carcinogenicity studies when they are administered at a sub-lethal, maximally tolerated doses 
administered throughout the lifetime of the animal. Tumours are usually not seen at doses one order 
of magnitude lower (Rush, unpublished observation).
The dilemma for the toxicologist is that in order to meet regulatory requirements, compounds have 
to be administered at a maximally tolerated dose throughout a carcinogenicity study. Any resultant 
treatment-related increase in tumour incidence observed in such studies has to be mechanistically 
explained before regulatory approval is likely to be granted. Even then in countries like the USA, 
the presence of rodent carcinogens in processed human food is sufficient to prevent registration at 
all. This has a profound impact on pesticide development and use and has resulted in the same 
product being registered in one country and unavailable in another.
Consider the following example. Figure 2, summarises the hepatic and endocrine response 
observed short-term studies in male Sprague-Dawley rats with a novel substituted tetrazine dosed at 
30 000 ppm in the diet. Significant effects on thyroid function, presumed to be due to microsomal 
enzyme induction can be seen at this extremely high dose-level. This compound is successfully 
registered in Europe but not the USA due to an increased incidence of thyroid fo llicular cell tumours 
observed in a two year carcinogenicity study. The data presented were used to support the 
mechanistic theory that the compound produced thyroid follicular cell neoplasia by an indirect 
extrathyroidal mechanism. Results show that following a mild, early reduction in triiodothyronine
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(T3) and tetraiodothyronine (T4) the animals responded with a physiologically significant increase in 
TSH. By day 4, this was seen to correlate with increased liver weight, elevated liver uridine 
diphosphoglucuronyltransferase (UDPGT), increased thyroid weight and raised thyroidal mitotic 
activity. Colloid depletion, hypertrophy and hyperplasia of the thyroid followed by day 7. Other 
studies showed that thyroid hormones were being metabolised faster and that the thyroid was not 
directly blocked by treatment. No equivalent effects were seen in any other species.
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Figure 2: Hepatic and Endocrine Response of Male Rats to Treatment with a Substituted Tetrazine 
Dosed at 30 000 ppm in the Diet
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It would be of major benefit, if in the safety assessment and risk prediction of pesticidal crop 
protection products, it could be shown that the above observations resulted from a species-specific, 
sex-related, secondary effect of microsomal enzyme induction. It would also be important to 
understand why the enzyme induction profile of this compound ultimately led to thyroid tumours in 
male rats dosed at 400 ppm in a two year carcinogenicity study; yet, treatment with other pesticidal 
products with broadly similar induction profiles and markedly higher microsomal enzyme activities, 
have no observable consequence on thyroid histopathology.
AIMS OF THESIS
Prompted by the observations cited above, it was decided that an archetypal cytochrome P450 
inducing agent could be used in studies designed to examine the biochemical background to 
thyroid effects. It was hoped that evidence could be provided to support the follow ing hypothesis. 
"Rat thyroid follicular cell proliferative lesions observed in toxicity studies involving microsomal 
enzyme inducing agents and shown mechanistically to be due to secondary effects, are of no 
consequence to man". It was also hoped that links could be established between thyroid toxicity 
and the class and/ or magnitude of the enzyme induction profile observed. It was thought that such 
comparisons might help in the definition of parameters used to predict the potential to cause thyroid 
effects in future toxicity tests. Such parameters could then be applied in the pesticide development 
process to aid selection of novel chemicals.
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TEST MATERIALS
Phénobarbital (PB)
This compound was first patented in 1911 and was selected for two reasons. Firstly, it is an 
archetypal cytochrome P-450, inducing agent, which has been shown to have effects on thyroid 
hormone metabolism but has not been shown to cause thyroid follicular neoplasia in laboratory 
animals. Secondly, it has been used safely in human therapeutic medicine for over 60 years without 
evidence of thyroid carcinogenicity (IARC Monographs, 1977 and 1987). Hence, it was considered 
to be an ideal reference compound with which to study some of the relationships between altered 
thyroid hormone metabolism and possible non-genotoxic carcinogenesis caused by microsomal 
enzyme induction.
Propylthiouracil
This thiourea compound was selected as an example of a direct thyroid blocking agent. It was first 
synthesised in 1945 and is used to treat hyperthyroidism due to the inhibitory effect it has on thyroid 
hormone biosynthesis. It is known to cause thyroid tumours in rats, mice, guinea pigs and hamsters 
after prolonged treatment.
Plant Protection Products
Novel, developmental, plant protection products were selected on the basis of their effects on 
thyroid and hepatic pathology. The compounds were used in studies designed to characterise and 
compare their enzyme induction sub-class with phénobarbital to see if any significant correlation 
between profiled subclass and the magnitude of any thyroid effect could be observed. Due to the 
confidentiality of these products they are referred to only by coded number.
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Compound A l 2
This cereal herbicide was an azole, thought to act by protoporphyrinogen-IX-synthetase inhibition.
It had low acute oral, dermal and inhalational toxicity. Carcinogenicity studies for regulatory 
submission were not completed because the compound was not further developed. However, sub­
chronic studies showed effects on the thyroid gland in the rat. Colloid depletion and follicular cell 
hypertrophy were seen in both sexes and hyperplasia was seen in males. No effect on liver weight 
was recorded. The compound was withdrawn prior to the conduct of enzyme induction studies. 
Based on histopathological evidence, the compound was not thought to be an enzyme inducing 
agent.
Compound B10
This fungicidal compound was a pyrimidine with very little acute oral dermal or inhalational 
toxicity. It caused centrilobular hepatocyte enlargement in rats and has been shown to be a liver 
microsomal enzyme inducing agent of the phénobarbital class. Long-term treatment at a maximally 
tolerated dose (MTD) of 5 000 ppm in this species, led to abnormal thyroid pathology. Benign 
follicular cell neoplasia was observed in 9/70 males and 7/70 females compared with 3/70 and 
0/70 in control males and females respectively. This observation was not statistically significant in a 
pair-wise comparison but there was a positive trend in both sexes. One treated male animal had a 
malignant thyroid follicular cell tumour. There was no increase in the incidence or number of any 
malignant tumours occurring at any other site. No effect on the thyroid gland was seen in other 
species tested.
Compound C59
This fungicide, a quinazolinone, had moderate acute toxicity by all routes. It is a potent liver 
microsomal enzyme inducing agent of the phénobarbital class. Long-term toxicity studies in rats 
dosed at an MTD (100 ppm) showed a higher incidence of thyroid follicular cell tumours
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particularly in males. The total incidence of benign and malignant tumours was 17/50 males (of 
which 7/50 were malignant) and 4/50 females (of which 2/50 were malignant). The corresponding 
incidence in control animals was 2/50 males (0/50 malignant) and 0/50 in females. The compound 
also caused liver cell tumours in females and hyaline droplet nephropathy in males at this dose 
level. No effect on the thyroid gland was seen in other species tested.
Compound D21
This acaricide was a substituted tetrazine with very low acute toxicity by all routes. It caused 
centrilobular hepatocyte enlargement and was an enzyme inducing agent of the phénobarbital class. 
In a two year carcinogenicity study, increased, but not statistically significant, numbers of thyroid 
follicular cell tumours were seen in male rats dosed at the MTD (400 ppm). The observed incidence 
of follicular cell hyperplasia was 5/70 compared with 2/70 in controls. The combined incidence of 
tumours was 8/70 (of which 5 were probably malignant). In 70 corresponding controls one benign 
and one malignant tumour was observed. No effect on the thyroid gland was observed in other 
species tested.
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1.1. THE THYROID GLAND
The thyroid gland is frequently the target of insult in toxicity studies. Understanding the 
mechanism of such effects is essential in the determination of potential risks to man. In order 
to examine how a particular class of chemical modulates thyroid hormone biosynthesis, 
secretion, distribution, activity and disposal, it is necessary to consider what regulates and 
maintains the homeostatic control of thyroid function. The follow ing review serves to 
highlight key areas in these processes where potential interference might occur. It also serves 
to identify comparative differences in thyroid function between rat and man since these are 
essential for the extrapolation of toxic effects into risk estimates.
1.1.1 Review of thyroid structure and function
Thyroid follicular cells synthesise and secrete the hormones L-thyroxine (T4) and 3,5,3', 
triiodo-L-thyronine (T3). These are essential for the coordinated regulation of many 
physiological pathways in mammals (Doniach, 1967). Target cells in all tissues are 
dependent on a constant supply of thyroid hormones. To meet this fundamental requirement 
the thyroid gland has evolved with unique structural and metabolic features.
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1.1.1.1 Thyroid Structure
The mammalian thyroid gland is composed of two classes of cells (follicular and 
parafollicular), which are derived from distinct cell types and which control two separate 
hormone systems (Capen, 1977). This thesis is principally concerned with the physiology of 
the follicular cells that secrete the iodine containing hormones. The parafollicular cells, also 
known as light or clear cells (C-cells) because they have pale-staining cytoplasm, secrete 
calcitonin. This function of the thyroid, which serves to regulate serum calcium levels by 
modifying osteoclastic activity in the bone (McIntyre, 1967), w ill not be considered.
The thyroid gland is unique to vertebrates. It is different to other endocrine glands in that it 
has an acinar structure and very large amounts of hormones are stored extracellularly, in an 
inactive form, within hollow balls of cells known as follicles.
Embryologically the thyroid is derived from a down-growth of the primitive oral cavity. It is 
bi-lobed structure (joined by a narrow isthmus) that lies across the upper part of the trachea.
In certain species very small amounts of thyroid tissue can be found in other positions. For 
example, in the rat, thyroid follicles may occur both near the thymus and along the aorta 
(Benirschke eta/., 1978).
Thyroid follicles are irregular spheres of cells composed of a single layer of cuboidal 
epithelium. They are bounded by a basement membrane and contain a homogenous, pink- 
staining proteinaceous material called colloid. Thyroid follicles vary in size according to the 
state of activity. Inactive, resting follicles are large, full of dense colloid and have flattened 
epithelium whilst active follicles are small, lack colloid and have columnar epithelium. Thus, 
the histological appearance of the thyroid may be substantially modified by the degree of 
glandular activity.
In the thyroid gland of most mammals a uniform range of follicular sizes is observed. The rat 
is unique in that there is variation in the size of the lobes; in the size of follicles w ithin the
same lobe and in the intensity of staining and structure of colloid within follicles. The largest
follicles, which are usually found around the edges of the lobes, vary in size as the animal
ages. In young rats, the size of large follicles does not usually exceed 100 pm, but this
increases to 300 pm when the animal is 1 year old and then progressively decreases with
usually
time. When animals are over two years of age/m ly small follicles are present. These features, 
which are dependent on age, strain, diet, environmental conditions and even season of the 
year, can cause significant variation in thyroid weight in groups of normal animals (Napalkov, 
1976). In toxicity testing, this normal variation in histological appearance w ithin a single 
gland or between the glands of different animals, makes subtle changes in thyroid function 
difficult to diagnose by morphological examination.
1.1.1.2 Thyroid Function and hormone synthesis
Thyroid hormones are iodinated amino acids that circulate in plasma in an inactive form 
(reversibly bound to plasma proteins) and as free amino acids with full biological potency. 
Kendall, in 1915, was the first to isolate the major thyroid hormone thyroxine (T4) and 
subsequently the chemical structure was identified by Harington (1926). A quarter of a 
century later, with the aid of modern radiochemical and chromatographic techniques, the 
most biologically potent thyroid hormone 3,5,3'-tri!odothyron!ne (T3) was identified 
simultaneously by Gross and Pitt-Rivers (1952) and Roche et a i, (1952 a, b).
The mechanism of thyroid hormone biosynthesis, which is only partly understood, is believed 
to be dependent on the following sequential process of iodine and thyroglobulin metabolism 
(See Figure 1.1). Initially, iodine is concentrated within the thyroid gland where it is oxidised 
and used to iodinate amino acid residues within thyroglobulin (TG) to form monoiodotyrosine 
(MIT) and diiodotyrosine (DIT). Specific spatial arrangements of the TG molecule allow these 
iodotyrosine residues to couple to form the iodothyronines T4 and T3. One molecule of DIT 
combines with one DIT to form T4 and one MIT with one DIT to form T3. Reduced
circulating levels of these thyroid hormones cause a feedback mechanism to activate, which 
stimulates the pituitary to release Thyrotropin, better known as thyroid stimulating hormone 
(TSH). TSH in turn, acts on the thyroid gland to release hormones (iodothyronines) and 
hormone precursors (iodotyrosines), into the circulation. This occurs by the intracellular 
proteolysis of thyroglobulin (TG). The majority of the iodotyrosines that are produced are 
processed by intrathyroidal deiodination mechanisms to permit recirculation of the amino 
acid tyrosine and the scarce element iodine
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Figure 1.1: Thyroid Hormone Biosynthesis
Thyroid follicular cells actively accumulate iodide from the plasma ahd oxidise to iodine. This reactive species enables the 
iodination of tyrosine residues present in thyroglobulin, which is synthesised in the follicular cells and stored in the lumen. Mono 
and diiodotyrosine groups thus formed couple to form T4 and T3. Synthesised hormones are then enzymatically released by 
proteolytic activity in the fo llicle lumen and are transported to the plasma. Full details of the hormone synthetic pathway are given
in the text.
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The biological actions of the thyroid hormones are manifold. They modulate the production 
of heat (calorigenesis) and affect the metabolism of proteins, carbohydrates, 
mucopolysaccharides, lipids, vitamins and inorganic ions. They are also essential for the 
normal activity of nervous tissue. For example cretinism, which results from thyroid 
deficiency in early life, leads to irreversible cerebral damage due to hypoplasia of cerebral 
and cerebellar cortices. In humans, clinical hyperthyroidism leads to weight loss, 
tachycardia, increased cardiac output, and mental agitation. On the other hand, 
hypothyroidism results in weight gain, muscle weakness, fatigue, cold intolerance, and 
slowed mental processes.
It can be seen that thyroid hormones play a fundamental role in the coordination and 
regulation of primary metabolic and other physiological processes. To meet these 
requirements, thyroid hormone synthesis and secretion are controlled by a complex and finely 
tuned process.
1.1.1.3 Homeostatic control
Thyroid hormone homeostasis is controlled by the interaction of several components in a 
cortico-hypothalamic-pituitary-thyroid axis (See Figure 1.2). This complex system is sensitive 
to minor changes in circulating thyroid hormone levels and serves to hold plasma hormone 
concentrations w ithin very narrow limits for any one individual.
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Figure 1.2: Orchestration of Thyroid Hormone Biosynthesis, Metabolism and Excretion
The following diagram depicts the multiple sites of control and interaction, which are known to be involved in control of thyroid 
function. It can be seen that the process is highly complex and interactive. Details of the interaction are described more fully in the 
text.
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To m a in ta in  this d e lic a te  contro l it is th o u g h t th at the p itu ita ry  reacts to a red u ced  (b ut usually  
n orm al) c ircu la tin g  level o f p lasm a th yro id  horm ones. Feed back  in teraction  at the  
h y p o th a la m ic  level leads to secretion o f the th yro tro p in  re leasing  h o rm o n e  - th y ro lib e rin  
(T R H ) and  the p itu ita ry  is s tim u lated  to secrete the th yro id  s tim u la tin g  h o rm o n e  - th yro tro p in  
(TSH ) into  the b lo o d  stream . In the th yro id  g land , TSH  activates the ingestion o f c o llo id  from  
the fo llic u la r  lu m en . This  leads to the fo rm a tio n  o f c o llo id  vesicles w ith in  the fo llic u la r  cells. 
These subsequently  fuse w ith  lysosom es to fo rm  phagolysosom es c o n ta in in g  p ro te o ly tic  
enzym es, w h ic h  break  d o w n  th yro g lo b u lin  (TG ) and  release m o n o io d o ty ro s in e  (M IT ) and  
d iio d o tyro s in e  (D IT ) together w ith  the tri- and te tra io d o th yro n in es  (T3 and  T 4 ). The
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iodotyrosines are cleared by deiodination, to release free iodine, which is recycled for 
subsequent iodination of TG. The T4 and T3 are secreted into the bloodstream to provide 
negative feedback control of pituitary TSH release.
The simplistic overview described above gives no guide to the complexity of the processes of 
thyroid hormone synthesis, secretion, distribution and metabolism. W hilst the whole system 
is orchestrated by pituitary TSH, a large number of factors impact on the control mechanisms 
involved. Homeostasis is dependent on
1. The relative mass of pituitary and thyroid tissue present;
2. The interaction of biochemical processes in these tissues;
3. The metabolism and disposal of hormones
4. The effects of a number of other hormones, neurotransmitters and growth regulating 
factors.
Inevitably, interference with the homeostatic mechanism can result from modulation of one or 
more of these integrated processes. The detailed mechanisms involved in thyroid hormone 
synthesis and disposal are expressed diagrammatically in Figure 1.1 and the main focal points 
where interference might occur are discussed in Section 1.2.
1.1.1.4 Thyroid follicular cell neoplasia
Carcinoma of the thyroid in humans is a rare neoplasm. The frequency observed in the 
Western world is less than 4 cases per 100,000 of the population. It more frequently occurs 
in females (Woolner eta/., 1961) although the prognosis is less favourable in males due to the 
effects of male sex hormones (Eisenberg, 1969; Franssila, 1975). Most thyroid tumours in 
humans appear to be papillary carcinomas, which are very rare in rats (Ron and Modan,
1982)
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In rats, data on the incidence of spontaneous thyroid carcinoma are variable and inconsistent 
across strains. It appears widely accepted that the incidence of true follicular cell neoplasia in 
most rat strains is very low. In the Fischer 344 rat Haseman and workers (1984) found an 
incidence of about 2% follicular cell neoplasia. Bullock and Curtis (1930) and Axel rad and 
Leblond (1955) described very few thyroid neoplasms when they examined large groups of 
animals and these were light cell or C-cell not follicular cell tumours. Follicular cell tumours 
do not occur with any frequency unless a chemical agent is used to induce them.
Unlike humans, male rats are more likely to develop follicular cell tumours. Studies using 
radiation induced neoplasia have shown that twice as many male rats develop thyroid 
tumours as females (Lindsay and Chaikoff, 1964). As in humans, the adverse effect of male 
sex hormones has also been reported (Napalkov, 1963).
Radiation, particularly one of the 19 radionuclides of iodine, is goitrogenic as a result of 
direct ionisation damage to the thyroid gland. Indeed, it is still widely accepted that radiation 
is the only proven human thyroid carcinogen (Doniach, 1970).
In experimental animals, any procedure that leads to an increase in the circulating level of 
TSH has been shown to produce thyroid tumours. This includes iodine deficiency (Axelrod 
and Leblond, 1955), goitrogenesis due to treatment with chemicals or with radiation, and sub­
total thyroidectomy (Dent et a i, 1956).
Although TSH is known to be the principal mediating agent in experimentally induced thyroid 
carcinogenesis, the sequence of events that leads to the development of thyroid tumours is not 
well understood. In a study of radiation induced thyroid carcinoma, Palloyan et a i, (1982) 
noted that the incidence of thyroid follicular carcinoma was 58% in male rats and only 28% 
in females. Paradoxically, the mean TSH values in irradiated females were almost double 
those observed in irradiated males. This suggests that sex hormones play a more important 
role than TSH in the development of thyroid cancer in the rat. The complex interaction
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between the sex hormones and the hormones of the thyroid-pituitary-liver axis has yet to be 
fully defined.
The size and rate of growth of the thyroid gland are controlled by a number of interrelated 
physiological factors. The primary level of control is based on the intrinsic number of thyroid 
follicular cells multiplied by their hormone production rate. The hormone production rate is 
driven by the circulating plasma hormone level and an as yet undefined pituitary comparator. 
This comparator establishes whether or not thyroid follicular cells should be present in greater 
or fewer numbers, or be producing more or less hormone by switching on or switching off 
hormone secretion.
All these processes are driven by the release of thyrotropin and despite large differences in 
analytical techniques, leads to remarkably similar plasma thyroid hormone levels across 
species. Table 1, lists some of the values seen in the published literature. It can be seen that 
the mean set-point of both T4 and T3 is approximately 75 n mo I/I and 1.5 nmol/l for each 
parameter respectively. A similar comparison for TSH is not possible. The m ultiplicity of 
antibodies and analytical standards used across species produce results that are not 
equivalent.
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Table 1: Plasma Thyroxine and Triiodothyronine Values in Various Species
Species T4 nmol/l T3 nmol/l
RAT
Sprague Dawley M + F 38-90 0.4-1.5
Wistar M 32-90 0.5-1.5
Long-Evans M + F 60-71 0.9-1.3
Black-hooded/Ztn M 40-42 0.8-1.4
MOUSE
C3H M 55-63 1.1-1.8
DDY M 78-88 2.0-2.2
OTHER SPECIES
HAMSTERS M + F 38-90 0.5-1.2
GUINEA PIGS M 29-45 0.6-0.9
RABBIT M + F 22-31 1.9-2.2
CAT M + F 32-51 0.9-3.1
DOG M + F 19-46 0.7-2.4
COW M + F 51-99 1.9-2.1
RHESUS MONKEY M 10-85 0.8-1.8
F 17-97 1.0-4.5
SQUIRREL MONKEY M 22-65 0.3-1.4
F 13-94 0.3-2.6
AFRICAN GREEN M 50-73 1.4-2.7
F 38-108 1.4-5.4
HUMAN M + F 65-160 0.6-2.7
Data derived from Loeb and Quimby, 989
Mechanisms of thyroid growth appear to be similar across species. When an intact animal is 
exposed to prolonged exposure to TSH the thyroid increases in size and weight and if 
stimulated for a prolonged period can become neoplastic. Christov (1975) showed that the 
growth process was not progressive but followed a pattern of initial rapid growth followed 
by a new steady state. Under goitrogenic regimes the growth response, measured as a 
metaphase index, has been shown to reach a plateau after about six weeks (Wynford-Thomas 
et a/., 1982a) and then returns to normal. The same workers (Wynford-Thomas et a i, 1982b) 
proposed that the response to TSH measured in terms of thyroid size and functional output of 
the gland becomes uncoupled. Indeed, they showed that withdrawal of goitrogen followed
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by readministration did not lead to a second phase of thyroid growth. In further work the 
same authors concluded the response was not a reversible change such as simple down 
regulation of TSH receptor activity (Wynford-Thomas etal., 1982c). It was concluded that a 
growth desensitising mechanism prevented uncontrolled neoplastic growth above a certain 
size threshold. In the context of thyroid cancer it was assumed that this growth desensitising 
mechanism (GDM) involved the production of an unknown growth factor that limits 
proliferation.
It has been shown that thyroid growth, which results from a sustained elevation of circulating 
TSH, occurs in three phases. The first phase occurs over the first two months, when there is a 
rapid growth. This is followed by the second phase that lasts for 3-6 months. During this 
time growth is limited and reaches a plateau due to the Growth Desensitising Mechanism 
(GDM), (Smith etal., 1986, Stringer etal., 1985 and Wynford-Thomas etal., 1982). This is 
followed in the final phase by the appearance of follicular cell tumours that appear to result 
from an altered sensitivity to certain growth factors. It has been shown that normal human 
thyroid cells grown in culture show a combined dependence for TSH and interstitial cell 
growth factor (IGF). On the other hand, cells from adenomatous tissue have the ability to 
proliferate in vitro with either TSH or IGF by independent mechanisms (Williams et al.,
1987).
Whatever the cause of thyroid follicular cell proliferation and growth, the principal regulator 
appears to be an elevated plasma TSH level. The complexity of thyroid gland orchestration 
and control means that there are a number of reasons why TSH becomes elevated. The 
following sections review the many sites of interference with thyroid function.
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1.1.2 Potential Sites of Interference with Thyroid Function.
1.1.2.1 Introduction
Many chemicals are capable of affecting thyroid function. Simionescu et al., (1977) suggested 
that the thyroid gland may be one of the most reactive tissues to modulation by environmental 
chemicals.
Anti thyroid compounds can be broadly classed according to site of influence. One group acts 
directly on the thyroid by direct interference with one or more steps in the synthesis and 
secretion of hormones. Others affect the peripheral metabolism and disposition of the thyroid 
hormones by modifying rates of disposal or interfering with peripheral deiodination. A third 
group inhibits the effects of thyroid hormones by acting as analogues. Table 2, lists examples 
of each type according to the system affected.
Methimazole, aminotriazole and the thioureas are examples of chemicals that act directly on 
the thyroid gland itself. These are the true goitrogens. By inhibiting the peroxidase enzymes 
involved in thyroid hormone synthesis they decrease hormone production and invoke 
thyrotropin (TSH) release through the pituitary feedback mechanism. Radiation induced 
goitrogenesis falls into this class since it blocks normal hormone synthetic processes by 
destruction of thyroid tissue.
A more subtle effect on thyroid function has been attributed to treatment with microsomal 
enzyme inducing agents. The structural diversity of the chemicals causing this phenomenon 
is so great that, unlike the goitrogens, direct chemical action is improbable. It is likely that the 
modulating effects on the thyroid are caused by increased peripheral metabolism and 
excretion of thyroid hormones. This leads to reduced circulating hormone levels which 
trigger TSH release.
The biochemical mechanism or mechanisms that lead to an alteration of thyroid function in
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rats treated with microsomal enzyme inducing agents have not been defined. Indeed it is 
doubtful that a single mechanism exists. The published literature suggests that increased 
hepatic accumulation and peripheral disposal of thyroid hormones accounts for the observed 
effects. However, interference with the thyroid homeostasis may occur at a number of 
different sites. These can be central, i.e. by direct neural stimulation, can occur in the 
thyroid gland itself or may arise peripherally from effects on a number of different tissues.
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Table 2: Classes of Antithyroid Compounds
PATHWAY INFLUENCED COMPOUND TYPES
Direct acting goitrogens
Iodine Uptake Complex anions; thio cyan ate, pertechnate, 
dithiocarbamates
Iodination Thioureas, thionamides, dithiocarbamates, 
substituted phenols
Coupling Thioureas, sulphonamides, 
dithiocarbamates, propylthiouracil
Secretion Iodine, lithium, polychlorinated biphenyls
Iodotyrosine deiodination Nitrotyrosines
Indirect acting goitrogens
Hormone inactivation Phénobarbital, benzopyrene, corticosteroids
Peripheral deiodination Thiouracil, thiohydantoin, radio-contrast 
media
Enterohepatic circulation Cholestyramine, cholestipol, dietary agents
Analogues
Hormone receptor sites Reverse T3, iodopropionic acids
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1.1.2.2 Direct Neuroendocrine Effects
1.1.2.2.1, Stress
In animals, stress can lead to increased plasma thyroid hormone levels. For example in cold 
stress, exposure to reduced ambient temperatures results in TSH secretion and therefore 
thyroid hyperplasia in rodents. This does not appear to be the case in man since this effect 
has only been seen in the human neonate (Charters etal., 1969). The response in animals is 
presumed to involve secretion of TRH via interaction with hypothalamic "heat-sensing 
centres" (Hefco et al., 1975) but there is little evidence to support this. In rats, chronic 
exposure to cold increases thyroxine disposal by augmented cellular binding, increased 
deiodination and higher faecal excretion (Balsam and Leppo, 1974). Increased disposal may 
partially be accounted for by loss due to the greater faecal bulk that results from higher food 
intake under cold-stress situations. Interestingly, phénobarbital, which activates the thyroid 
by increased peripheral metabolism of thyroxine, blocks hypothalamic neuroendocrine 
activity and prevents cold-activation of the thyroid by this mechanism (Kotani et al., 1973).
1.1.2.2.2 Hypothalamic Stimulation
Any non-physiological alteration in hypothalamic TRH secretion w ill lead to a dramatic effect 
on the thyroid gland. Normal pituitary function is reliant on the interaction of TRH with the 
TSH secreting cells - the thyrotrophs. Although TRH is distributed throughout the brain it is 
only that hormone synthesised by the paraventricular nuclei of the hypothalamus, which 
specifically governs TSH secretion. In a study using antibody to TRH, Harris et al., (1978) 
demonstrated that the action of TRH on pituitary secretion was dependent on thyroid status. 
Hypothyroid animals with elevated TSH levels were not affected by treatment with antibody
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raised against TRH, yet basal levels in euthyroid animals could be significantly reduced within 
two hours.
Somatostatin, a hypothalamic polypeptide that inhibits the secretion of somatotropin (growth 
hormone) is also implicated in the regulation of pituitary TSH release. Arimura and Schally 
(1976) have shown that there is an increase in both basal and TRH-stimulated secretion of 
TSH when rats are treated with anti-somatostatin antibodies.
1.1.2.2.3 Pituitary Stimulation
The pituitary gland is a key regulator of thyroid gland function due to the various effects of 
TSH. TSH modulates iodine concentration, oxidation, binding, hormone synthesis, colloid 
resorption and thyroid hormone biosynthesis by independent but coordinated mechanisms 
(Dumont, 1971). These are not well defined. According to Pastan et a i, (1966), TSH reacts 
at a superficial site on the thyroid. This idea was supported by Lissitsky et a i, (1973) who 
suggested that it interacts with a specific binding site on the plasma membrane of the thyroid 
gland. It has been established that there is correlation between TSH binding and TSH 
stimulated adenylate cyclase within the cell. So it is likely that the steps involved in thyroid 
hormone biosynthesis and excretion are controlled by the classic mechanism described by 
Sutherland and Robinson (1966). They suggested that binding of the hormone on the outer 
surface of the cell stimulated the activation of adenyl cyclase on the inner surface. Activated 
adenyl cyclase then catalyses the transformation of ATP into cyclic AMP (cAMP), which 
regulates the intracellular, metabolic end-points of hormonal action such as enzyme synthesis. 
TSH is synthesised in the thyrotroph cells of the anterior pituitary where it is stored in 
secretory granules. It comprises two glycoprotein sub-units a  and G, which are non- 
covalently but tightly linked. The a chain is common to all glycoprotein hormones, i.e. 
follicle stimulating hormone - follitropin (FSH), luteinising hormone - lutropin (LH) and
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chorionic gonadotropin (CG). The G sub-unit, on the other hand, which is highly specific to 
each hormone is the component that confers receptor specificity. Rat TSH comprises a family 
of "isohormones" not one specific hormone. The physiological relevance of this observation 
has not been defined. Thyroid hormone excess does not stop TSH secretion. This could 
imply an additional physiological role for TSH or suggests that not all immunologically 
reactive TSH is biologically active. The significance of this observation is not known. The 
family of "isohormones" may be inactive degradation products, various contaminants, 
components of the biosynthetic pathway or even non-TSH materials. Hence, little 
significance can at present be placed on this.
In the rat, although pituitary TSH, hypothalamic TRH, and serum T3 and T4 concentrations 
are similar in each sex, thyroid function is sexually differentiated. Untreated and TRH-treated 
male rats have been shown to have significantly higher plasma TSH levels than age-matched 
females (Christianson eta/., 1981). This sex difference is maintained for the lifetime of the 
animal but is lessened by age. One exception to this occurs in cases of pituitary adenoma 
where tumour bearing animals have a lower pituitary TSH content (Chen, 1984). This is very 
interesting since up to 80% of normal, untreated female rats develop pituitary tumours. The 
corresponding pituitary tumour incidence in normal males is only 40%. Females are therefore 
less likely to develop thyroid tumours for this reason alone.
Prostaglandins are intimately involved in the control of thyroid function. By interacting with 
the plasma membrane of the thyroid gland they are able to stimulate cAMP and therefore 
mimic TSH in several stages of the hormone synthetic process. In the rat, the non-steroidal 
anti-inflammatory drug (NSAID), indomethacin, can reduce circulating T4 and T3. It is 
believed that this effect is caused by an inhibition of thyroid responsiveness to TSH 
(Thompson et a i, 1977). This is probably due to interference with prostaglandin synthesis via
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effects on prostaglandin synthetase. This observation is significant because in humans 
indomethacin lacks effect on thyroid hormone levels. This demonstrates that there are 
significant differences between the rat and human in the interactive control processes 
involving prostaglandins.
1.1.2.3 Direct Goitrogenesis
In this section, each stage of the thyroid hormone synthetic pathway w ill be reviewed in 
detail. The precise mechanisms involved, which are only partly understood, are believed to 
be dependent on the sequential process of iodine and thyroglobulin metabolism described in 
Section 1.2
1.1.2.3.1 Iodine Uptake
The rate lim iting step in the biosynthesis of thyroid hormones is the transport of iodine into 
the thyroid gland. When iodine is readily available in the diet the thyroid is able to 
concentrate iodine to such an extent that a thyroid to serum ratio in excess of 30:1 is possible. 
For no apparent reason, other organs such as the intestine, mammary gland and placenta also 
have the ability to concentrate iodine but lack the organification pathways that result in 
hormone synthesis.
The iodine concentrating capacity of the thyroid is an active transport process. Movement of 
iodine through cell membranes is achieved against both chemical and electrical gradients. 
Related substances, such as fluorides and chlorides, are not transported by this pathway and 
do not accumulate in the thyroid gland. Uncouplers of oxidative phosphorylation and other 
compounds that interfere with aerobic metabolic processes in the cell, such as cardiac 
glycosides, can prevent the uptake of iodine. This suggests that high energy phosphate bonds 
supply the energy for the active transport process.
Thyrotropin (TSH) is the hormone that activates thyroidal iodine accumulation in all species
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studied. Knopp et a/., (1970) demonstrated that the classic pathway of hormone action was 
induced by TSH, i.e. receptor activation stimulates the release of cAMP and hence ribose 
nucleic acid (RNA) and protein synthesis. The exact biochemical role for this protein 
synthetic process has yet to be determined, as has the mechanism that switches off iodine 
accumulation after the effective 30:1 thyroid: plasma ratio is reached.
Monovalent anions, including bromide, thiocyanate, pertechnate, perchlorate, perhenate, 
tetrafluoroborate and nitrate inhibit iodine transport into the thyroid (Wyngaarden et a/.,
1953). They act in competition for the iodine uptake pathway. Like iodine they accumulate 
but are not subsequently organified. All have a greater affinity with the active transport 
pathway than iodine. An order of affinity for certain of these anions was defined by W olff 
(1964). This showed pertechnate to have the highest affinity with the iodine pathway, 
followed by perchlorate, perrhenate, and tetrafluoroborate. Certain thyroid phospholipids 
have been isolated that can bind monovalent anions (See review by Bastomsky, 1974). Since 
the orders of their binding characteristics are similar to the order of affinity described above it 
has been suggested that these phospholipids are the endogenous carriers of iodide.
In addition to competing for the iodine transport mechanisms, perchlorate also actively 
stimulates the discharge of any iodine that has not been bound by the organification process. 
This property has made the compound suitable for use as a diagnostic tool in measuring 
organification defects. In normal humans, approximately 90% of a dose of iodine absorbed 
by the thyroid gland is organified within 1 hour. If there are defects in the organification 
process, administration of perchlorate w ill discharge the unbound iodine and release it into 
the circulation. Using radioiodine such uptake and discharge can be measured, e.g. the 
perchlorate discharge test (Gray et a/., 1973)..
Thiocyanate is also a potent inhibitor of the active transport pathway but does not share the 
same mechanistic characteristics as the monovalent anions. It is metabolised by the thyroid in
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vivo and by cell free preparations in vitro and therefore it does not accumulate within the 
gland. The mode of action is believed to be by interference with the iodine transport process 
but it also has a disruptive effect on the organification process (Scranton et a/., 1963).
Iodine, the element essential in the production and synthesis of the thyroid hormones, acts as 
an antithyroid compound when administered at doses greatly in excess of daily requirement, 
i.e., >2 mg/day (Braverman and Ingbar, 1963). The mechanism, known as the Wolff-Chaikoff 
block, is poorly understood but can produce either hypothyroidism or hyperthyroidism in 
susceptible individuals (Wolff and Chaikoff, 1948).
Lithium carbonate, widely used as a psychotrophic drug in depressive illness, also affects the 
thyroid gland (Pousset et a/., 1973). It appears that lithium is concentrated by thyroid tissue, 
in a manner similar to the accumulation of iodide. It reduces thyroid hormone release by the 
inhibition of TSH and cyclic AMP stimulated proteolysis of TG. Clinical hypothyroidism is 
not usually present but in a survey of a group of patients receiving lithium therapy some 30% 
had increased TSH levels (Emerson et al., 1973).
1.1.2.3.2 Oxidation of iodine
In 1953, Fawcett and Kirkwood suggested that the iodination of TG was solely a chemical, 
non-enzymic process in which molecular iodine was the active agent involved. Many 
subsequent studies (see Taurog, 1970 for review) have led to the current consensus that a 
membrane-bound, hydrogen peroxide dependent, thyroid peroxidase is involved. The 
enzyme is a haemprotein, with a molecular weight of about 60,000.
Any process that leads to the inhibition of the peroxidase enzyme w ill result in a suppression 
of thyroid function. Interestingly, the inhibitory mechanism does not result in the direct 
inhibition of peroxidase activity. Rather it is thought to involve chemical interaction with the 
enzyme product by formation of an active iodinated intermediate. This is likely to be a 
su I phenyl iodide. Interaction with this compound, to form an inactive mixed di-sulphide, is
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thought to be the mechanism by which thionamide compounds have antithyroid activity.
The thionamides are a family of chemicals that include goitrin (L-5-vinyl-2-thiooxazolidone)/ 
a naturally occurring substance, which was originally extracted from the seeds of the genus 
Brassicae - the family of plants that include the cabbage. Some members of the cabbage 
family, e.g., Turnips, which contain progoitrin, a mustard oil thioglycoside that is metabolised 
to the thionamide by bacteria in the gut (Langer and Michajlovskij, 1969). Thionamides all 
share the chemical grouping:
S = C - N =
The thiourelyenes, which have two nitrogen groups attached to the carbon atom, are the 
most potent. Compounds of this class include thiourea, thiouracil, propylthiouracil, 
methimazole and carbimazole. At low dose levels, all are such efficient inhibitors of thyroid 
function that they have been used in human medicine for the treatment of hyperthyroidism. 
Dithiocarbamate fungicides also fall into this class since they are metabolised to ethylene 
thiourea (Kuzan, 1975).
The thionamides do not inhibit iodine uptake but have been shown to inhibit peroxidase 
activity in several in vitro tests. Many different sites in the hormone synthetic pathway are 
affected and these all involve peroxidation processes (Taurog, 1970). Because of this, it is 
assumed that thionamides are goitrogenic by peroxidase inhibition.
1.1.2.3.3 Organification
The physical form and chemical structure of the iodinated glycoprotein, thyroglobulin (TG), 
are important in the organification process. Thyroglobulin is the major constituent of 
follicular colloid where, in most species, it is present at a concentration of some 70 pg/g wet
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tissue. The tertiary structure of the molecule is complex and has not been fully defined. It has 
a molecular weight of approximately 660,000 and comprises a number of sub-units. The 
number and form of these sub-units is dependent on the species, the level of iodination and 
the physical and chemical properties of the reagents used in the purification process.
Changes in ionic strength or pH or the concentration of detergents and dispersing agents in 
the extraction medium affect the number of sub-units produced.
The amino acid composition of TG derived from several species shows remarkable similarity 
in secondary and tertiary structure (Rolland et al., 1966). This tends to suggest that TG has a 
specific spatial conformation adapted to function. The molecule is composed of 10% 
carbohydrate and consists of two major oligosaccharide units. This carbohydrate contributes 
to the naturally occurring heterogeneity of the molecule that is seen even within different 
areas of the same thyroid lobe. Mannose, galactose, fucose, N-acetylglucosamine, N- 
acety I gal actosami ne, and sialic acid residues have all been identified.
The amino acid composition of TG is very interesting. Glutamic acid and leucine residues are 
abundant, whilst those of methionine, histidine and tryptophan are few. The function of the 
molecule in the manufacture and storage of thyroid hormones, is dependent on tyrosine the 
thyroid hormone precursor. For this reason, one would assume a high proportion of this 
amino acid to occur in the molecule. However, it is present at a concentration equivalent to 
only 3% of molecular weight. Surprisingly, this is similar to the percentage tyrosine present in 
other body proteins. This tends to emphasise that it is structure, not amino acid sequence, 
which confers the very specific functional properties to the TG molecule. Two simple 
experiments highlight this probability. Fibroin, a silk protein that has a very high tyrosine 
content, produces no thyroxine when iodinated in vitro. On the other hand, casein, the m ilk 
protein, which contains only an average number of tyrosine residues gives a high thyroxine 
yield under similar conditions.
26
The formation of TG is an ordered chemical process, taking approximately 3 hours. It occurs 
as the molecule migrates through the follicular cell, from the ribosomes to the cell lumen.
The first step is the formation of protein, on bound but not free ribosomes. This protein is 
then transported via the cysternae of the endoplasmic reticulum to the Golgi apparatus. 
Carbohydrate moieties are added step-wise throughout this migratory process. 
N-acetylglucosamine and mannose are added in the endoplasmic reticulum, soon after the 
protein is synthesised. Galactose and sialic acid residues are added in the distal part of the 
endoplasmic reticulum and within the Golgi apparatus. The final stage of migration to the 
follicular cell membrane, occurs within apical vesicles that are passed, by exocytosis, into the 
follicular lumen.
Iodination of TG is by far the most important event in the production of thyroid hormones. It 
is the principal site of action of the many thyroid inhibitors. Under normal physiological 
conditions the conversion of iodide to organic iodine within the thyroid is very rapid. Work 
by Pitt-Rivers (1960) showed that in rodents treated with 13"! Iodine, 50% of the dose 
accumulated by the thyroid gland had been converted to an organic form within 2 minutes. 
Using isotopic equilibrium studies it has been shown (Simon and Lissitzky, 1964) that non- 
dialysable iodine, mainly in TG, forms more than 90% of the total thyroid iodine.
1.1.2.3.4 Coupling of iodotyrosine residues
The final stage of the synthetic process requires that two molecules of diiodotyrosine (DIT), or 
one each of monoiodotyrosines (MIT) and DIT, are coupled to form T4 and T3 respectively. 
Almost half of the total thyroid iodine (45%) is present as DIT. Since the other principal 
components (MIT 15%, T4 15% and T3 3%) are present at much lower levels the resultant 
DIT to MIT ratio is 3:1. Since DIT couples with DIT form T4 and DIT couples with MIT to 
form T3, the high DIT: MIT ratio shows a preferential bias towards the formation of T4 
(Taurog, 1974).
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The coupling reaction involves two iodinated tyrosines that are present in peptide linkage, 
within the same or adjacent TG molecules. It is believed that free radicals are formed on the 
iodotyrosine residues by the action of thyroid peroxidases. These free radicals react to form 
an ether linkage and leave serine or alanine behind on the corresponding peptide chain 
(Taurog, 1974). Since the mechanism involves thyroid peroxidase, inhibitors of this enzyme, 
e.g. methimazole, also interfere with the coupling process.
1.1.2.3.5 Proteolysis and free hormone release.
The thyroid gland is unique to vertebrates and for a number of reasons is different to other 
endocrine glands. These reasons include; a unique requirement for a specific element iodine; 
a specific protein thyroglobulin that can effect the synthesis of hormones at very low iodine 
levels; storage of large amounts hormones, in an inactive form, within extracellular follicles; 
and a hormone secretion mechanism that involves the reabsorption from the follicles, of 
hormone by the same cells that originally produced them (Robbins, 1989). In contrast most 
other endocrine glands either store small quantities intracellularly or produce hormones 
according to physiological demand. In humans, to counter the possibility of hypothyroidism 
resulting from any cause, sufficient T4 and T3 residues are stored, to provide some 3 months 
reserve capacity (lngbar,1985).
Thyrotropin stimulation of the thyroid gland activates the uptake of colloid from the follicular 
cell lumen by pinocytosis. This process forms colloid vesicles that subsequently fuse with 
lysosomes. The resultant phagolysosomes contain peptidase and glycosidase enzymes that 
break down thyroglobulin (TG) to release both iodotyrosines (MIT and DIT) and 
iodothyronines (T3 and T4). Taurog et a/., (1964) suggested that only the free thyroid 
hormones are secreted into the circulation. More recent work suggests that although the 
iodotyrosines are cleared by deiodination within the thyroid, a certain amount of MIT and 
DIT is present in the serum of normal individuals (Shalom,1966: Nelson et a/., 1974).
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In any follicular cell the process of colloid production, i.e. the synthesis of TG and secretion 
into the lumen, occurs simultaneously with colloid uptake, i.e. the reabsorption of iodinated 
TG, containing iodotyrosines and iodothyronines. These processes, which involve the 
transport of vesicles containing TG into and out of the follicular cell, are regulated in such a 
way that under normal circumstances TG is neither excessively accumulated nor depleted.
The regulatory mechanism that controls this has not been defined. Colchicine disrupts 
microtubules and this inhibits TSH-stimulated endocytosis and thyroid hormone release in 
vivo and /n vitro. For this reason, Williams and W olff (1970) have suggested a role for 
microtubules in thyroid hormone secretion and uptake.
1.1.2.3.6 Recirculation of iodide
Iodine is a scarce element and animals have developed an intricate means of retaining 
absorbed material. Deiodination of MIT and DIT, released by the digestion of iodinated TG, is 
important in the iodine economy of the cell. In the rat, as much as 70% of the iodine 
originally incorporated into TG may be derived from the deiodination of these "waste" 
iodotyrosines (Simon, 1963). The iodotyrosines are deiodinated, within the thyroid, by a 
specific microsomal enzyme; iodotyrosine dehalogenase (Stanbury, 1960). In humans a 
congenital deficiency of this enzyme leads to iodine-deficient, goitrous, hypothyroidism. 
Patients with this defect excrete approximately 50% of a daily dose o f 127iodine in the urine 
as iodotyrosines (Lissitsky et a/., 1965).
1.1.2.4 Indirect Goitrogenesis
1.1.2.4.1 Modification of enterohepatic circulation
The reabsorption of faecal thyroid hormones plays an important role in pituitary-thyroid
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homeostasis. The biliary excretion and rate of reabsorption vary significantly according to 
dietary constituents, dietary bulk, age, sex, physical activity and types of bacteria in the 
intestinal flora (Van Middlesworth, 1974). Any alteration in bile flow, the rate of hepatic 
glucuronidation, the relative ratio of T4 to T3 in the plasma, or in the binding characteristics 
of the plasma proteins w ill influence faecal excretion rate.
Certain drugs and dietary agents are goitrogenic because they increase the faecal excretion of 
thyroid hormones. For example, treatment of rats with soya beans leads to increased faecal 
excretion of thyroxine due to impaired reabsorption (Beck, 1958). Similar effects can be seen 
after treatment with cholestyramine. This is a basic anion exchange resin, which is used as a 
hypolipidaemic agent, since it sequesters bile acids in the intestine and prevents reabsorption. 
It similarly prevents the reabsorption of thyroid hormones and can lead to goitrous 
hypothyroidism due to loss of iodine.
1.1.2.4.2 Hormone analogues
Several naturally occurring substances act as hormonal analogues (For review see De Groot, 
1979). These include monoiodotyrosine (MIT), diiodotyrosine (DIT), monoiodothyronine 
(T1), diiodothyronine (T2), tetraiodothyroacetic acid (TETRAC), and triiodothyroacetic 
(TRIAC). All have some degree of thyroid hormone activity although this is less than T4 and 
an order of magnitude less than T3. Increased peripheral metabolism of hormones to these 
less active compounds leads to apparent hypothyroidism with concomitant elevation of 
plasma TSH.
Many thyroid hormone analogues have been tested for potency as therapeutic agents in 
humans (See Table 3 on Page 32). It is assumed that all hormones or analogues must be 
converted to T3 or react with T3 receptor sites to be biologically active. It must be 
emphasised, however that different tissues or different species may have varying requirements 
for particular hormones and may have different sensitivities to the various analogues.
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Table 3: Comparative Activities of Some Thyroxine Analogues
Compound Percentage of Thyroxine- ike Activity
Goitre prevention Calorigenic
activity
3,5,3', 5'tetraiodothyronine T4 100 100
3,5,3' triiodothyronine T3 500-800 300-500
3,3', 5' triiodothyronine RT3 <1 <1
3,3' diiodothyronine T2 <2 <2
3'Bromo-3', 5' diiodothyronine 130-200
3,5,3', 5' tetraiodothyroacetic acid TETRAC 57 10-15
1.1.2.4.3 Peripheral deiodination
Triiodothyronine (T3) is the principal thyroid hormone and T4 is deiodinated to generate T3 
in peripheral tissues. Some chemicals are known to interfere with this mechanism (Geffner et 
al., 1975: Saber! et al., 1975). Such interference leads to goitrous peripheral T3 insufficiency. 
The pituitary is prompted to secrete TSH - yet circulating thyroxine levels are normal or even 
elevated. This effect can occur for two reasons. Firstly, a decrease in peripheral T3 production 
can occur due to a blockage of the deiodination pathway, e.g., by iopanoic acid. Secondly 
because complete peripheral deiodination or partial metabolism of the major thyroid 
hormones (T4 and T3) can lead to the production of a range of inactive metabolites. These 
include reverse-T3 (RT3), diiodothyronine (T2), mono-iodotyrosine (MIT) and tetra acetic acid 
(TETRAC). These are known to circulate in the plasma and are usually of limited significance. 
However, pathologically increased peripheral deiodination leads to apparent hypothyroidism 
with concomitant elevation of plasma TSH due to tissue hypothyroidism.
1.1.2.4.4 Peripheral Hormone Disposal
At the cellular level, the concentration of free thyroid hormones in the plasma is the lim iting 
factor in the control of metabolic processes and the feedback regulation of TSH secretion. Any
alteration in free hormone that is available to the peripheral tissues w ill have an apparent 
effect on thyroid status.
In humans, thyroid hormones are transported in the plasma principally by an alpha-globulin - 
thyroxine binding globulin (TBG) and to a lesser extent by thyroxine binding pre-albumin and 
albumin itself. Treatment with certain xenobiotics can affect the circulating levels of these 
proteins and therefore affect thyroid hormone levels. For example, anabolic steroids, 
androgens and corticosteroids reduce the amount of TBG. This is probably due to inhibition 
of hepatic synthesis (Oppenheimer, 1968 and Federman et a/., 1958) and therefore lead to an 
apparent reduction in circulating thyroid hormone levels. Oestrogens and progestagens, on 
the other hand, increase TBG levels and lead to apparently higher levels (De Groot, 1979). 
Unlike humans, the rat does not have a specific binding protein for thyroid hormones (Refetoff 
et al., 1970). Hormones are carried by plasma proteins in a non-specific fashion. This is 
believed to account for the large difference in half-life recorded for the principal thyroid 
hormones. The half-life of T4 in the rat approximates 17 hours whilst in humans it is 
approximately 7 days (De Groot, 1979).
Several compounds can displace thyroid hormones from the plasma binding proteins. This 
leads a lower half-life, faster disposal rate and hence to a reduction in the circulating level. A 
classic example of this occurs after treatment with diphenylhydantoin (DPN). This compound 
lowers plasma thyroxine levels by displacing the hormone from TBG (Oppenheimer, 1961). It 
has been suggested that patients receiving DPN are euthyroid (Cullen, 1973). Other workers 
however, have measured an increased circulating TSH due to reduction in both free T3 and 
free T4 that suggests that the patients are hypothyroid (Hansen et a i, 1974). Recent research 
shows that treatment with DPN reduces the half-life of thyroid hormones by more than would 
be expected by simple protein binding displacement. Enhanced peripheral metabolism due to 
hepatic microsomal enzyme induction is the probable cause of this discrepancy.
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The metabolism of thyroid hormones occurs via two major and two minor pathways (For 
review see Visser, 1988).
1 Deiodination: Deiodination is the most important pathway since it both activates and 
inactivates thyroid hormones. The active T3 and inactive RT3 both being produced by 
the deiodination of T4. These reactions occur primarily in the liver and kidney. 
Qualitatively, pituitary deiodination is the most biologically significant since it forms the 
basis for the negative feedback control of circulating hormone levels.
2 Conjugation: The principal conjugation pathways occur in the liver where T3 is 
preferentially sulphated and T4 is glucuronidated.
3 Deamination: This minor pathway, which includes both deamination and 
decarboxylation occurs in a number of tissues.
4 Ether bond cleavage: This is a relatively insignificant pathway that may be induced in 
periods of greater peroxidase activity in the tissues, e.g., in stimulated macrophages 
(Burger, 1986)
Microsomal enzyme inducing agents are known to modify the biological effectiveness of 
thyroid hormones by enhancing metabolic excretion rates (Oppenheimer et a i, 1968; 
Schwartz et a l, 1969). Phénobarbital has been shown to increase the hepatic accumulation 
of thyroxine (Bernstein et a/., 1968). This observation may partly be accounted for by 
increased liver mass. In addition, phénobarbital increases bile flow  and biliary excretion of 
T4, by independent mechanisms (Capron and Erlinger, 1975). A concomitant increase in 
plasma TSH has been observed in the rat (Lees et a/., 1967) but contradictory effects on 
plasma thyroid hormone levels have been reported. For example, no reduction in serum 
protein-bound 125iodine (a measure of total plasma thyroid hormone) has been reported 
(Oppenheimer et a i, 1968; Bernstein et al., 1968). Whilst paradoxically, a reduction in both
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T4 and triiodothyronine (T3) has also been observed (Negrie et a/., 1979). In our laboratory 
preliminary investigation of thyroid function, in rats treated with a novel, microsomal enzyme 
inducing pesticide, supports this paradox. The serum levels of thyroid hormones frequently 
suggest a euthyroid state whilst morphological changes and TSH levels indicate thyroid 
hyperactivity. In order to stimulate a biologically significant increase in TSH there ought to 
be a comparable reduction in amount of circulating thyroid hormone. Repeated observations 
of this disparity lead me to believe that the set-pointof plasma thyroid hormone levels and the 
rate of thyroid hormone synthesis are controlled by independent mechanisms. By responding 
to an increased rate of hormone turnover, rather than to a sustained reduction in the 
circulating plasma hormone levels, the pituitary is stimulated to produce TSH when plasma 
thyroid hormone levels are normal. Regardless of mechanism the end result is an elevation of 
plasma TSH.
1.1.3 SUMMARY
The metabolism, excretion, and regulation of thyroid hormone synthesis are exquisite and 
fine-tuned processes, which are orchestrated (at least) by the interactions of TRH, TSH and 
thyroid hormones within the hypothalamic-pituitary-thyroid axis. Many substances, when 
administered to mammals, have the potential to interfere with this process and thyroid 
homeostasis is readily and frequently perturbed. Effects can be either by direct interaction 
with hormone synthetic processes or occur indirectly by interference with the multifaceted 
mechanisms involved in homeostasis or disposition of thyroid hormones. Despite the variety 
of chemical compounds causing these effects and the range of potential sites of action, the 
single major end-point of these treatment regimes is an increase in circulating TSH.
An elevated plasma TSH is a very significant observation since in experimental animals, raised 
levels for half, or more of the life-span leads to the development of thyroid follicular cell 
adenomas and carcinomas (Doniach, 1974). Such an effect occurs in iodine deficiency
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(Axelrod and Leblond, 1955), and sub-total thyroidectomy (Dent et al., 1956). In both these 
examples no xenobiotic or other exogenous agent has been added to the experimental 
environment. This suggests that TSH itself is the physiological mitogen involved in certain 
classes of thyroid follicular cell neoplasia in experimental animals.
Enzymes involved in the deiodination and the metabolisms of thyroid hormones are located 
in the smooth endoplasmic reticulum. Hence microsomal enzyme induction by xenobiotics 
in toxicity studies has a significant impact on the thyroid hormone economy. The increased 
turnover of thyroid hormones caused by treatment with microsomal enzyme inducing agents 
leads to increased peripheral demand for these essential biological commodities. Since the 
thyroid and pituitary glands do not appear to be functionally impaired by treatment, both are 
able to respond by increased hormone secretion. Hence, plasma thyroid hormones are 
usually held constant at normal set-point levels. Paradoxically, in order to sustain the 
increased rate of thyroid hormone synthesis the circulating TSH level remains elevated. This 
in the longer-term may result in thyroid follicular cell neoplasia by the mechanism described 
above.
Microsomal enzyme inducing agents can be grouped into several different classes each of 
which may have differing effects on thyroid hormone economy. The following review serves 
to highlight the principal characteristics of hepatic microsomal enzyme inducing agents. It 
briefly defines the structure and functions of the liver and focuses on more detailed aspects of 
the cytochrome P450 family of enzymes.
1.2. HEPATIC MICROSOMAL ENZYME INDUCTION
1.2.1 Introduction
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Beneath the endothelial cells are found occasional specialised storage cells known as Ito cells. 
They contain fat and fat-soluble vitamins such as Vitamin A and excrete extracellular matrix 
components such as collagen, laminin and certain growth factors. Under certain pathological 
conditions these are excreted in great excess and lead to the hepatic fibrosis that characterises 
cirrhosis.
1.2.1.1 Origin and structure of liver
The liver arises from the embryonic foregut and is the largest organ in mammals. It is 
composed of three principal cell types. Hepatic parenchymal cells, which are remarkably 
uniform in size in the normal animal, comprise some 60% of the population (90% of the 
volume). The remainder are mainly phagocytic Kupffer and endothelial cells.
The morphological unit in the liver is a polyhedric lobule, which is classically depicted as a 
hexagon (See Figure 1.3). The intrahepatic branches of the bile duct, hepatic artery and the 
portal vein, found peripherally at the angle of the polygon, are known as portal triads. One 
cell thick plates of hepatocytes radiate from the terminal hepatic vein found in the centre of 
each lobule. These unite and are continuous with the plates found in adjacent lobules. 
Between the plates of hepatocytes are the hepatic sinusoids that are lined with endothelial 
cells and Kupffer cells. | See paragraph opposite
The liver is well supplied with blood from two major vessels. The main supply is directed via 
the gut and spleen through the portal vein and after a meal, is loaded with high 
concentrations of nutrients. The other smaller supply is via the hepatic artery and provides 
the liver with oxygen. Both supplies unite in the liver sinusoids and are eventually drained 
the into the inferior vena cava via the hepatic veins.
Bile is secreted by the hepatocytes into the biliary cananiculi formed between the adjacent 
plates of hepatocytes and flows across the liver in the opposite direction to the blood supply. 
Contraction of the cytoskeleton of the hepatocytes propels the bile towards and into the bile 
ducts located in the portal triads. W ithin each lobe of the liver these small bile ducts merge 
together to form larger vessels that eventually form the hepatic duct that drains into the bowel. 
The histological appearance of the liver is as described above. However, functionally, the 
liver can be considered as an acinus with functional zones around the portal tract. Zone 1, 
the periportal area, surrounds the portal tracts and is provided with an excellent oxygen
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supply. Zone two, is the intermediate or midlobular area, whilst Zone 3, the centrilobular 
area is closest to the central vein and has a relatively lower oxygen supply.
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Figure 1.3: Diagram of Liver Lobule/ Acinus
Terminal hepatic
venule
Portal Tract
Periportal region
intermediary Region
Centrilobular region
LIVER ACINUS
Morphologically, the liver lobule has a terminal hepatic venule w ith peripheral portal triads located in the angles 
of a hexagon.
Functionally, the acinus can be described in zones of progressively lower oxygen tension from periportal to 
centrilobular regions.
38
1.2.1.2 Function of the liver
The liver has a number of important physiological roles. This includes the control, storage, 
synthesis and regulation of carbohydrates, fats, amino acids and proteins. The liver also acts 
as a glycogen storage organ and it provides essential digestive secretions in the form of bile. 
The principal function to be considered in this thesis is the role of the liver in detoxification, 
i.e., processing endogenous and exogenous chemicals through metabolic excretion 
pathways.
In mammals, enzymes located in hepatic subcellular organelles, oxidise endogenous toxic 
substances and xenobiotics to polar more readily excreted metabolites. The primary site of 
these metabolic processes is w ithin the endoplasmic reticulum - a subcellular network of 
interconnected lipoprotein tubules extending from the plasma membrane to the nucleus and 
mitochondria.
1.2.1.2.1 Role in detoxification
The liver is quantitatively the most important site of detoxification. However, it is important 
to note that such reactions are not restricted to the liver. The detoxification process is 
considered to occur in two phases (Williams, 1967). In phase I reactions (functionalisation), 
lipophilic substances are made more water-soluble by the oxidative addition of polar groups. 
This serves to make the chemical more reactive and able to participate in phase II reactions 
(conjugation) in which endogenous substrates, such as glucuronides or sulphates are added. 
The resultant water-soluble conjugation products are more readily excreted in urine or faeces 
than the lipophilic parent compound.
Many naturally occurring substances and synthetic chemicals are capable of causing 
increased synthesis of a range of metabolic enzymes involved in these processes. This 
phenomenon, known as enzyme induction, facilitates the rapid excretion of the potentially
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toxic substance. Chemicals with enzyme inducing properties include naturally occurring 
substances such as certain plant and animal metabolites. For example steroids, as well as 
"synthetic" materials such as drugs, pesticides, food additives, plasticisers, and the chemical 
by-products of cooking processes have all been shown to have microsomal enzyme inducing 
properties. No structure-activity relationships link these different types of chemical but they 
all share the characteristics of being lipophilic at physiological pH.
Enzyme induction affects many biochemical pathways such as aromatic and aliphatic 
hydroxylation, dealkylation, Nitrogen, Sulphur, and Phosphorus oxidation as well as oxidative 
deamination, and desulphuration. These pathways are catalysed by a group of non-specific 
multisubstrate, cytochrome P450 dependent, monooxygenases that are an integral component 
of the endoplasmic membrane. When a cell is mechanically disrupted, membrane remnants 
of the endoplasmic reticulum agglutinate to form small spherical bodies known as 
microsomes. These can be isolated by ultracentrifugation and used to measure cytochromes 
P450 and other metabolic enzymes.
Microsomal enzyme induction can be quantified by a number of different methods. It is 
usually measured by using a variety of candidate xenobiotic substrates, such as 
ethoxyresorufin or pentoxyresorufin, which have conveniently measured fluorometric end­
points. More recent developments mean that specific gene products can be measured by 
immunological techniques such as Western blotting and enzyme linked immunosorbant 
assays (ELISA).
Since the most frequently used techniques for quantifying enzyme induction use non- 
physiological substrates, the normal physiological role of the induced enzymes tends to be 
neglected. It is very significant that multiple cytochrome P450 enzymes can act in varying 
degrees on a single substrate and that a single cytochrome P450 can metabolise multiple 
substrates. These features acting synchronously mean that the superfamily of cytochrome
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P450-dependent enzyme systems are capable of metabolising the infinite number of toxic and 
other substances that are consumed daily in a normal diet or are produced via intermediary 
metabolism.
1.2.2 Cytochrome P450 dependent monooxvgenases
Biological oxidations proceed via two different pathways. In one, involving the 
dehydrogenases, hydration or hydrolysis of the substrate occurs by incorporation of oxygen 
derived from a water molecule. In the other, oxidation occurs by the activation of molecular 
oxygen. This is catalysed by two separate classes of enzymes the oxidases and oxygenases. 
Oxidases transfer electrons to oxygen and are dependent on the number of electrons 
transferred from either superoxide anion, hydrogen peroxide or water. Oxygenases, on the 
other hand, transfer oxygen to a substrate after reductive I y splitting molecular oxygen. The 
electrons for this process are generated by the NADPH(NAD)-dependent cytochrome P450 
reductases.
A number of components are required for cytochrome P450-dependent activity in 
reconstituted systems (Coon et al., 1973; Estabrook et al., 1973; Strobe! et al., 1970). The 
essential constituents are NADPH, the haemprotein (cytochrome P450), a flavoprotein 
enzyme (NADPH-cytochrome c reductase, specifically NADPH-cytochrome P450 reductase), 
a phospholipid (phosphatidylcholine) and cytochrome bg. The biochemistry of the reaction 
has not been fully elucidated but is briefly summarised in the following figure.
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Figure 1.4: Cytochrome P450 Dependent Monooxygenases
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In microsomal oxidative reactions it is thought that the substrate binds to oxidised cytochrome P450. 
This initial step is follow ed by a reduction process catalysed by NADPH-cytochrom e P450 reductase, 
w hich leads to the formation of a reduced cytochrome-substrate complex. The complex then reacts 
with molecular oxygen and accepts an electron, probably derived from cytochrome bg, to yield the 
hydroxylated product and one molecule of water.
Studies have show n th a t C y to c h ro m e  P 4 5 0 -d e p e n d e n t m onooxygenases in d u c e d  by  
xen o b io tics  have b road  substrate specific ity , w h ic h  inc lu des  norm al phys io lo g ica l substances. 
M o re  im p o rta n tly , the in d u c e d  en zym es have a greater sp ec ific ity  fo r th e ir natural, 
endogenou s  substrates than for the in d u c in g  agent in v o lve d  (K un tzm an  et al., 1 9 6 5 ) . For 
e x a m p le , a re v ie w  by  K untzm an  (1 9 6 9 ) refers to several p u b lic a tio n s  th a t show  th a t an im als  
treated w ith  p h e n o b a rb ito n e  have increased rates o f steroid h y d ro xy la tio n . This  e n h a n c e d  
rate o f d eac tiva tio n  leads to decreased phys io lo g ica l actio n  o f these e ndogenou s  substances. 
T h ere  are num erous in terre la ted , b io c h e m ic a l pa thw ays  th a t o c cu r on the  e n d o p la s m ic
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reticulum. These include the metabolism of androgens, oestrogens, progestagens, 
glucocorticoids, prostaglandins, porphyrins, glycoproteins, bilirubin, vitamins A, C, D, E, K, 
folates, fatty acids, thyroid hormones, glucuronic acids and haem. Any increase in P450- 
dependent monooxygenase activity (and hence metabolic capacity) due to the effects of 
microsomal enzyme induction is known to have a concomitant effect on many, or possibly all 
of these pathways. Such modification of primary metabolic processes can have subtle effects 
on cell structure, function, growth and rate of turnover due to modification of homeostasis. 
Whether such effects are beneficial or physiologically disruptive is dependent on the class 
and magnitude of the primary induction process.
1.2.3 The cytochrome P450 gene superfamilv
Over the past 25 years, it has been recognised that there are several distinct classes of 
mammalian cytochrome P450 inducing agents that trigger the transcription of multiple P450 
genes (For listings see Nebert et al., 1989). Recently, a system of nomenclature has been 
recommended to standardise the vast numbers of differing descriptions and codings used for 
the various genes and gene products. The nomenclature has been derived from the 
evolutionary similarity between amino acid sequences of gene products. The arbitrary 
difference between gene products of different families has been set at 40% amino acid 
sequence similarity. Thus a protein transcribed by a gene in one family w ill have an amino 
acid sequence more than 60% different when compared with a product from another family. 
(For review see Gonzalez and Nebert 1990.)
In the system of nomenclature, the cytochrome P450 genes have been given the root name 
GYP, families are designated by Arabic numerals, subfamilies by capital letters and the single 
gene by a number. For example, CYP2B1 is a cytochrome gene in the second family, B 
subfamily and as gene 1 in this family, transcribes one unique enzyme protein. In the same 
system of nomenclature, this protein is to be described with Roman numerals corresponding
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to the family, a letter corresponding to the subfamily and a number for the gene. Hence the 
gene product of CYP2B1 is - IIB1. At present, the cytochrome P450 superfamily consists of at 
least 20 gene families. Ten of these occur in mammals. With the known number of 
subfamilies, it is estimated that the total number of P450 genes is over 200.
Armed with the above system of nomenclature, various classes of inducing agents can now be 
given a standardised less vague description. For example, the historically named "P448 
inducers", include polycyclic aromatic hydrocarbons and certain benzoflavones, e.g. 
benzopyrene, G-napthaflavone and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). These 
induce the two genes in the CYP1 family by activating the aromatic hydrocarbon (Ah) 
receptor mechanism. These compounds cause little or no increase in smooth endoplasmic 
reticulum; induce cytochromes P450 IA1 and IA2 that exhibit a carbon monoxide binding 
complex at 448 nm. They increase a narrow range of oxidative pathways principally a 
characteristic rise in aryl hydrocarbon hydroxylation.
"P450 Inducers", such as phénobarbital and sodium barbitone, together with terpenoids and 
related compounds, increase the transcription rates of genes in the CYP2B and CYP2C as well 
as CYP3 and CYP6 families. These compounds cause marked proliferation of smooth 
endoplasmic reticulum; induce mainly cytochromes P450 IIB1 and IIB2 that have an 
absorption maximum of the carbon monoxide binding complex at 450 nm; and increase a 
number of oxidative pathways. These include p-nitroanisol déméthylation, benzphetamine n- 
demethylation, and aldrin epoxidation but typically no increase in aryl-hydrocarbon 
hydroxylase activity. At present, no receptor for phenobarbital-type P450 induction has been 
isolated.
Peroxisome proliferators (or "P452 inducers") activate transcription of genes in the CYP4 
family. Clofibrate and compounds typical of this class cause a moderate increase in smooth 
endoplasmic reticulum and induce a variety of cytochromes P450 in the IVA1-IVA7 groups.
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These have a carbon monoxide binding complex adsorption maximum at 452 nm and 
complement a very specific range of microsomal enzymes such as I auric acid hydroxylase and 
cyanide-insensitive palmityl CoA oxidase. Isseman and Green (1990) showed in vitro that 
peroxisome proliferators activate a nuclear receptor of the steroid hormone superfamily 
termed the Peroxisome proliferator Activated Receptor or PPAR.
New chemical induction groups are always being defined. Relatively recent examples 
include the glucocorticoids, which activate genes in CYP3 to produce proteins in the IIIA1- 
IIIA6 class; ethanol and acetone CYP2E (IIE1 and IIE2) and the macrolide antibiotics 
griseofulvin and erythromycin CYP3 (IIIA3).
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Table 4: Cytochromes P450 Observed in various Species
SYSTEMATIC
NAME
TRIVIAL NAME SPECIES INDUCING AGENT ARTIFICIAL SUBSTRATE
1A1 P448, c, pNF-B RAT POLYCYCLIC
AROMATIC
HYDROCARBONS
ETHOXYRESORUFIN O-DETHYLATION
METHYLCHOLANTHRENE
PI, c, form 6 HUMAN 2,4,6,8-TCDD
TETRACHLORO
DIBENZODIOXINE
BENZPYRENE HYDROXYLATION
form 6 RABBIT
PI MOUSE
1A2 P448, d RAT ISOSAFROLE METHOXYRESORUFIN O-DEMETHYLATION
P3, d, form 4 HUMAN PHENACETIN O-DETHYLATION
LM4, RABBIT
P3, P2 MOUSE
2A1 a1,a, 3, UT-F RAT ETHYLMORPHINE N-DEMETHYLATION
2A2 a2, RLM2 RAT COUMARIN 7a-HYDROXYLATION
2A6 P450(1) HUMAN
2B1 b, PB-4, PB-B RAT PHENOBARBITAL PENTOXYRESORUFIN O-DEPENTYLATION
2B2 e, PB-5, PB-D RAT BENZPHETAMINE N-DEMETHYLATION
2B4 LM RABBIT METHOXYCOUMARIN DEMETHYLATION
2B6 LM2 HUMAN
2C6 RAT PHENOBARBITAL
2C7 f RAT PHENOBARBITAL MEPHENYTOIN 4-HYDROXYLATION
2C8 1, mp-12, mp-20 HUMAN MEPHENYTOIN N-DEMETHYLATION
2C10 mp, mp-8 HUMAN
2C11 h, 16a, 2c, UT-A MALE RAT
2C12 1, 15P, 2d, UT-I FEMALE
RAT
2D6 dbl HUMAN DEBRISOQUINE 4-HYDROXYLATION
2E1 j HUMAN,
RAT
ETHANOL ACETONE ANILINE HYDROXYLATION
MOUSE ISONIAZID ACTIVATION OF NITROSAMINES
3a RABBIT
3A1 pcnl RAT GLUCOCORTICOIDS ERYTHROMYCIN N-DEMETHYLATION
3A2 pcn2 RAT MALE NIFEDIPINE OXIDASE
3A4 HPCN1 HUMAN CYCLOSPORIN OXIDASE
3A5 KPCN3 HUMAN
4A1 P452 RAT PEROXISOME
PROLIFERATORS
LAURATE 12-HYDROXLATION
4B1 lung p450 HUMAN
form 5 RAT,
RABBIT
Data derived from Nebert etal ,  1989, 1991
Many compounds that activate the transcription of specific, phase I cytochrome R450 
monooxygenases also simultaneously activate transcription of phase II conjugating enzymes 
such as the uridine diphosphoglucuronyltransferases (UDRGT), glutathione S-transferases and 
aldehyde dehydrogenases. Differences in induction profiles for both phase I and phase II 
enzymes have been noted across species as well as between sexes and between organ systems
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(Williams, 1974).
1.2.4 Sex differences in Microsomal Enzyme Activity
In the rat, clear sex differences in microsomal enzyme activity towards certain substrates have 
been observed. The rat appears to be unique in this respect, since these differences are not 
apparent in other experimental animals or humans (Kato, 1977). According to Kremers et a/., 
(1981), human liver microsomes metabolise various substrates at rates that are similar to the 
female rat. The male rat is considered so markedly different that Kato (1977) recommends 
that only females are used for the assessment of drug metabolism in pathological states.
Clear sex differences in substrate metabolism do not become apparent until rats reach sexual 
maturity at about 1 month of age and do not attain a maximum until animals are about two 
months old (Kato et al., 1962). The magnitude of the sex difference varies according to 
substrate but with certain enzymes can be 20 times higher in the male (Kamataki et al., 1980). 
It has been proposed that the sex difference in hepatic metabolism is due to neonatal 
"imprinting". In the newborn male rat, androgen exposure leads to an inhibition of a 
feminising factor secreted by the pituitary that results in a male pattern of hepatic metabolism. 
In the opposite sex, lack of neonatal androgen exposure results in a féminisation of the liver 
enzymes (Custaffson etal., 1980).
Sex-related differences in metabolic potential observed in rats appear to be under the 
influence of male sex hormones and thyroxine (Kato and Takahashi 1968) and are due to 
changes in the number and substrate capacity of the various cytochromes P450. For example, 
male rats metabolise hexobarbital more rapidly than females (Brodie etal., 1953). Thyroxine 
treatment causes a reduction in hexobarbital hydroxylation in male rats but increases the 
activity in females. Castration of male rats leads to a reduction in hepatic hexobarbital 
hydroxylation activity and P450 content (Kato and Onoda, 1969), which can be restored by 
administration of testosterone. Simultaneous administration of oestrogens appears to
counteract this androgenic activity.
Using two-dimensional gel electrophoresis, Vlasuk and Walz (1982) have shown that at least 
five distinct polypeptides present in adult male microsomes are absent in the female. Other 
studies, using sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS RAGE), have 
shown similar differences in the cytochrome R450 profiles between the sexes and also 
between immature rats and adults. Kamataki et a/., (1980), using antibodies against P450- 
male and P450-female showed that castration of male rats immediately after birth results in 
P450 female production whilst the male cytochrome was undetectable. Castrated animals 
treated with testosterone assume the male cytochrome P450 profile.
Some studies suggest that the pituitary plays an important role in the regulation of hepatic 
metabolism. Kramer et a/., (1975), noted that male castration reduced ethylmorphine 
metabolism by 54% whilst hypophysectomy had even greater effect (72%). Treatment with 
testosterone restored the ethylmorphine activity in the castrated group but not in the 
hypophysectomised group. In another study, Colby et a/., (1973) have shown that in 
hypophysectomised rats, sex hormones have no effect on hepatic steroid A - 4 - hydrogenase 
activity. Both these studies imply pituitary dependence for the action of testosterone on 
microsomal enzyme systems:-
In rats, sex-differences in metabolism are not restricted to artificial substrates such as 
hexobarbital, aminopyrene or hydroxycoumarin. Physiological substrates are also 
metabolised differently between sexes. Conney et a/., (1969) studied age-dependent sex- 
differences in testosterone metabolism and found independent activities for the 6(3-, 7a and 
16a-hydroxylases. The 16a-hydroxylase was also studied by Kremers et a/., (1981). Using 
progesterone, pregnenolone, testosterone and dehydroepiandrosterone, they showed that 
hydroxylation ratios between sexes were 1:1, 10:1, 12:1 and 7:1 for each respective substrate. 
In humans, on the other hand, hydroxylase levels were noticeably lower and no sex
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difference was observed. It could be calculated that the ratio between male rat enzyme 
activities and humans were 18:1, 5:1, 15:1 and 9:1 respectively. These results clearly 
demonstrate marked differences in the ability to hydroxyl ate various substrates between male 
and female rats and perhaps more importantly, between male rats and humans.
1.2.5 Adverse effects of enzyme induction
Microsomal enzyme induction is classically thought of as an adaptive, beneficial response 
that acts to minimise potential toxic effects of lipid soluble chemicals. This is not always the 
case. In addition to catalysing the oxidative metabolism of toxic substances cytochromes 
P450 may, under certain conditions, such as reduced oxygen tension (PO2 ), catalyse 
reductive metabolism.
The production of free radicals is one end-point of reductive metabolism by cytochrome 
P450. These chemical species that are highly reactive with cellular components such as 
proteins, lipids and DNA, cause cellular damage. As a result, reductive metabolism by 
cytochrome P450 has been described as a toxification rather than detoxification process 
(Slater, 1984). Carbon tetrachloride toxicity is a classic example of lipid peroxidation damage 
caused by free-radical interaction with fatty acids in membrane phospholipids. It is of interest 
to note, that the oxygen concentration gradients along the liver sinusoids between the 
periportal and centrilobular areas lead to selective toxicity. The lowest PO2  and the highest 
concentration of P450 activity are present in the centrilobular region where necrosis is the 
principal finding after treatment with carbon tetrachloride.
Free-radical damage due to reductive metabolism is not the only adverse effect of microsomal 
enzyme induction. In some instances, rather than being detoxified, certain xenobiotic 
chemicals can be converted to metabolites with higher toxicity than the parent compound .
A good example of this metabolic activation is the carcinogenicity of acetylaminofluorine 
(AAF). This compound, a very potent mutagenic, carcinogen in a number of animal species,
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causes tumours in the liver, bladder and kidney. Research has shown that the metabolism of 
AAF is a key issue in the development of the carcinogenicity. In the classic paper by M iller et 
a/., (1964), it was shown that the parent compound AAF produced tumours in mice but not 
in guinea pigs. This was because the latter species cannot metabolise AAF to the proximate 
carcinogen N-hydroxyacetylaminofluorine. The metabolite is a more potent mutagen than the 
parent compound; it binds specifically to the 8-position of guanine in the DNA molecule 
(Andrews etal., 1978).
Another example of increased toxicity due to metabolic activation occurs in the metabolism 
of benzopyrene, a potent carcinogen in a number of species. It is considered to be probably 
carcinogenic to humans although there is insufficient data (IARC Monographs, Supp 7, 1987). 
It has been demonstrated that this compound is metabolised through a variety of metabolic 
transformations catalysed by microsomal enzyme systems. These are primarily hydroxylations 
that occur at various sites on the aromatic rings that eventually result in conjugation of the 
hydroxyl groups with glucuronic acid or sulphate. A number of these hydroxylations proceed 
through the formation of an epoxide intermediate. It has been postulated that the ultimate 
carcinogen is the 7,8-dihydrodiol where the epoxide is next to the so called bay region (See 
Figure 1.5). In vitro studies have shown that benzopyrene reacts with nucleic acids to 
produce adducts only when microsomal enzyme systems necessary for the metabolic 
activation of the parent compound are present in the incubation mixture.
Figure 1.5: Structure of Benzpyrene 7,8, dihydrodiol 9,10 oxide.
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1.2.6 Summary
Enzyme induction is a term that denotes the ability of certain substrates to enhance the 
activity of microsomal and related enzyme systems principally by de novo synthesis but also 
by enhanced protein or mRNA stabilisation. It is a short-term, survival-promoting process that 
minimises potential toxic effects of endogenous substances and xenobiotics in a number of 
tissues. The induced enzymes appear to have a greater specificity for their natural, 
endogenous substrates than for the inducing agent involved. The administration of 
xenobiotics can lead to dose-dependent changes in microsomal enzyme levels. This in turn 
can result in associated interference with the normal metabolism of endogenous substances 
that may not be beneficial.
Microsomal enzyme inducing agents may be broadly classified as either CYP2 (P450), CYP1 
(P448) or CYP4 (P452) inducers according to the gene products or type of oxidative pathways 
that are induced. Qualitative and quantitative aspects of microsomal enzyme induction vary 
between species. In rats, an exaggerated induction profile is seen in males due inherently 
higher microsomal enzyme activities in this sex (Kamataki etal., 1980).
It seems logical to assume that if the male rat has a naturally higher inherent capacity for
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microsomal oxidation, then any tumourigenic finding, which is the result of this effect could 
be more apparent in this sex. If this reasoning applies to interference with thyroid function, it 
might, at least in part, account for a sex and species-related difference in thyroid tumour 
incidence observed in toxicity studies involving microsomal enzyme inducing agents.
Marked, sex-related differences in microsomal enzyme activities are not apparent in other 
species including man. For this reason, one must conclude that any averse effect of 
microsomal enzyme induction observed in male rats is unlikely to occur in man
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CHAPTER 2: MATERIALS AND METHODS
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2.1. INTRODUCTION
The following chapter summarises the methods and materials used in this thesis. It is subdivided 
into sections that describe the test compounds used, the animal husbandry procedures applied 
and finally, each laboratory method is covered in full detail.
Due to the large amount of information produced during the development of specific procedures, 
e.g., a rat-specific TSH method, this is presented separately in Appendix 1.
2.1.1 Health and Safety
Throughout the studies described, appropriate control measures were undertaken to ensure that 
chemicals were used safely. In particular, the Control of Substances Hazardous to Health 
regulations were applied. Similarly, the National Radiological Protection Board guidelines on the 
use and disposal of radiochemical substances were used for all procedures involving radioiodine.
2.2. MATERIALS
2.2.1 Phénobarbital
Phénobarbital (5-ethyl-5-phenyl-2,4,6-(1 H, 3H, 5H)-pyrimidinetrione) is a long-acting barbiturate 
used in human medicine. It is a white odourless, crystalline powder that does not occur naturally 
but was developed for use as a hypnotic, a sedative and for the control epilepsy. It was later 
found to be have substantial microsomal enzyme inducing properties. In the studies described 
batches of a single lot number 86F-0440, obtained from the Sigma Chemical Company, Fancy 
Road, Poole, Dorset, UK, were used. Purity was not defined but was assumed to be greater than 
9836.
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2.2.2 Propylthiouracil (PTU)
PTU (2-thio-4-hydroxy-6n-propyl-pyrimidine) is an anti hyperthyroid agent known to inhibit 
thyroid function by directly blocking of the enzymes involved in hormone synthetic pathway.
The material was obtained from the Sigma Chemical Company, Fancy Road, Poole, Dorset, UK. 
No purity data was provided but the compound was assumed to be greater than 98% pure.
2.2.3 Novel Plant Protection Products
Due to commercial confidentiality, developmental products used in this thesis are referred to by 
code numbers only. All developmental products were more than 98% pure.
2.2.3.1 Compound A12
This candidate, cereal herbicide was an azole containing a thioureylene grouping that may 
cause direct antithyroid activity.
2.2.3.2 Compound BIO
This fungicidal compound was a pyrimidine. The compound was a mild inducing agent of the 
phénobarbital class.
2.2.3.3 Compound C59
This fungicidal quinazolinone was a potent microsomal enzyme inducing agent of the 
phénobarbital class
2.2.3.4 Compound D21
This acaricide was a substituted tetrazine with moderate microsomal enzyme inducing properties 
of the phénobarbital class.
2.2.4 Other materials
All other chemicals used were of analytical grade and were obtained from the suppliers 
mentioned in the text. Test kits and other materials used in specific assays were obtained from 
the commercial suppliers indicated.
2.3. ANIMAL HUSBANDRY
Sprague-Dawley Crl:CD(SD)BR outbred albino rats, supplied by Charles River (UK) Ltd, Manston 
Road, Margate, Kent, UK, were used throughout. Animals were housed in Product Safety 
Laboratories 1 and 5 of the Toxicology Function, AgrEvo UK Ltd., Saffron Walden, Essex. Animal 
rooms were maintained at 21 °C  + 2°C with automatically controlled lighting (photoperiod 0700- 
1900 GMT) and humidity (50 + 20%). Room temperature and relative humidity were 
continuously recorded.
Modified SQC expanded ground rat and mouse diet No. 1 (Special Diet Services Ltd. Witham, 
Essex, UK) and tap water were offered ad libitum  throughout the studies except during urine 
collection periods, when animals were fasted overnight to prevent dietary contamination of 
samples.
Upon arrival from the suppliers, animals were weighed and examined for signs of ill-health. They 
were transferred to wire-mesh or polypropylene cages with wire bases, usually in groups of five. 
The animals were allocated to groups at random using a stratified method, based on bodyweight, 
so that group means at the start of the study, were as similar as possible.
Following allocation animals were individually identified with an ear-mark. The study number 
followed by the animal number constituted a unique identifier. W ithin the laboratory, blood and 
tissue samples were additionally identified with a unique laboratory number, allocated at
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random. This procedure was used to minimise potential analytical bias due to drift within 
batches of assays.
2.4. LABORATORY METHODS
2.4.1 Diet analysis
Prior to the start of the long-term study with phénobarbital, a procedure was developed to 
reliably prepare homogenous mixtures, at the required concentration, which were stable over the 
period of use. Weekly diet mixes were prepared. Excess supplies of previous mixes were 
incinerated. Samples of test diet were passed to the Dose Analysis Section, Toxicology Function, 
AgrEvo UK Ltd to monitor mean phénobarbital content and stability after 0, 4, 7 and 14 days 
storage at room temperature. Phénobarbital was extracted from diet by shaking w ith acetonitrile 
and methanol (90/10, v/v). The phénobarbital levels in these extracts were then measured by 
high performance liquid chromatography (HPLC) using UV detection.
Each sample was analysed four times and the mean result taken. Chromatographic conditions 
were generally those shown in Table 2.1.
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Table 2.1: Chromatographic Conditions For The HPLC of Phénobarbital
Column: Spherisorb 5 ODS, length 15 cm, I.D. 4.6 mm.
Pump: Perkin Elmer Series 10
Injector: Perkin Elmer ISS 100
Integrator: Beckman LIMS
Detector: Pye Unicam PU4020, wavelength 220 nm
Mobile phase: 350 ml/l acetonitrile in distilled water
Flow Rate: 1.5 ml/min
Injection volume: 20 pi
Retention time: Phénobarbital 2.3 min
2-napthol (marker) 5.9 min
2.4.2 Food consumption and test material intake
Food consumption was measured by weighing cage group food hoppers before and after the 
filling operation. Consumption was calculated by a computerised technique that took account of 
the number of animals per cage and the number of days in the collection period. From these 
data, the achieved chemical intake was calculated from the sum of the food consumption and 
dose level, divided by the cage group mean bodyweight.
2.4.3 Bodyweights
Bodyweights were collected weekly, from each animal, throughout the treatment period. In the 
long-term study, data were recorded on day 1, 29, 57, 99, 113,134, 169, 197, 225, 253, 281, 
309, 337, 365, 379 and 393.
2.4.4 Clinical signs and palpable masses
In the long-term study, clinical signs were bi-weekly during the first 12 months of the study and 
weekly from this time onwards. Animals were carefully examined and palpated for superficial,
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subcutaneous or internal tissue masses or swellings. Records included, as accurately as possible, 
the time of death; the nature, time of onset, severity and duration of clinical signs observed and 
the size, shape, consistency, location and extent of any tumours detected. Animals found dead 
or killed in a moribund condition were subjected to post-mortem examination with minimal 
delay.
2.4.5 Blood collection
Where feasible and in order to achieve greater between bleed-point comparisons, the first ten 
animals of each dose group were bled, via the orbital sinus, under ether anaesthesia. Samples, 
collected into tubes containing lithium heparin as an anticoagulant, were centrifuged as soon as 
possible after collection. The plasma was stored at -20°C until assayed. On completion of 
assays, remaining aliquots were stored deep frozen at -70°C as a contingency against further 
testing being required.
2.4.6 Thyroid Hormone Assays
Thyroxine (T4), triiodothyronine (T3), reverse T3 (RT3), free T4 (FT4) and free T3 (FT3) were 
measured by conventional 125-iodine, radioimmunoassay, using test kits purchased from 
Immunodiagnostic Systems (Boldon, Tyne and Wear). All assays were performed by strict 
adherence to manufacturer's instructions. Radioactivity counts and curve fitting were performed 
on a Packard (Pangbourne, Berks), Minaxi Gamma 5500 scintillation counter. Analytical quality 
control was maintained by using commercially available lyophilised, human serum; since rat 
serum controls are not obtainable.
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Plasma TSH
A radioimmunoassay method was developed by the author for rat specific TSH, using reagents 
supplied by Dr A Parlow, Pituitary Hormones and Antisera Center, Harbor-UCLA Medical Center, 
Torrance, California. The recommended assay procedure was changed to include a donkey anti­
rabbit, solid phase, second antibody coated, cellulose suspension, which was designed to speed 
the final separation step.
Plasma Phénobarbital
An EMIT® phénobarbital assay kit, supplied by the Syva Company, Palo Alto, CA was adapted 
for use on an Instrumentation Laboratory (Warrington, Cheshire) Multistat III microcentrifugal 
analyser. The assay was based on competition for antibody binding sites between unlabelled 
phénobarbital in the sample and phénobarbital labelled with glucose-6-phosphate 
dehydrogenase (C6PDH). On binding to the antibody, the activity of this enzyme becomes 
reduced. Measurement of G6PDH activity in the assay system is thus a measure of drug content. 
The coenzyme used in the system, functions only with the bacterial enzyme (Leuconostoc 
mesenteroides) employed in the assay, thus endogenous G6PDH does not interfere.
To confirm the analytical characteristics of the method, assay precision was measured at sample 
concentrations of approximately 30 and 65 p mo I/I. At these levels, the coefficients of analytical 
variation were 6.4% and 4.5% respectively.
Clinical chemistry
The following clinical chemistry parameters were performed to assess the health status of animals 
used in some studies:
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Total protein, Albumin, Total globulin, Albumin/Globulin (A/G) ratio, Calcium, Phosphate, 
Sodium, Potassium, Urea, Creatinine, Glucose, Total cholesterol, Total bilirubin, Chloride, 
Aspartate aminotransferase, Alanine aminotransferase, Alkaline phosphatase, y - glutamyl 
transpeptidase, Creatine kinase.
Analytical quality control was maintained using Beckman Decision; Multilevel 1 to 3 (High 
Wycome, Bucks) and by participation in the Wellcome National Quality Control Programme 
(Dartford, Kent) and the UK External Quality Assessment Scheme for Clinical Chemistry (Queen 
Elizabeth Medical Centre, Birmingham). The methods used were as follows:
2.4.9.1 Total protein
Modified biuret reaction - Gornall, A.G., Bardawill, C.J. and David, M.M.: 1949 J. Biol. Chem. 
177:751.
2.4.9.2 Albumin
Succinate buffered bromocresol green - Doumas, B.T., Watson, W.A. and Biggs, N.G.: 1971 Clin 
Chem. Acta. 31:87.
2.4.9.S Total globulin
Calculated by difference between total protein and albumin.
2.4.9.4 A/G ratio
Calculated as Albumin /G lobulin
2.4.9.5 Calcium
Cresolphthalein complexone - Connerty, H.V. and Briggs, A.R.: 1966 Am. J. Clin. Path. 
45(3):290.
2.4.9.6 Phosphate
UV phosphorus molybdate complex -Daly, J.A. and Ertingshausen, G.: 1972 Clin. Chem. 18:263
2.4.9.7 Urea
Urease method - Talke, H. and Schubert, G.E.: 1965 Klin. Wochenschr. 43:174.
2.4.9.8 Creatinine
Kinetic Jaffe method - Lustgarten, J.A. and Wenk, R.F.: 1972 Clin. Chem. 1_8(11):1419.
2.4.9.9 Glucose
Hexokinase/G-6-PDH method - US Department of Health, Education and Welfare.: 1976
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Publication N o. (CDC) 7 7 -8 3 3 0 .
2.4.9.10 Total cholesterol
Cholesterol esterase/oxidase - Allain, C.C. et al.: 1974 Clin. Chem. 20(4):470.
2.4.9.11 Total bilirubin
2,5-dichlorophenyl diazonium - Wahlefeld, A.W.: 1972 Scan. J. Clin. Lab. Invest. 29 (Suppl. 
126), Abstr. 1.1
2.4.9.12 Chloride
Mercuric thio cyan ate method -Schoenfeld, R.G. and Lewellen, L.J.: 1964 Clin. Chem. 10:533.
2.4.9.13 Aspartate aminotransferase
See 2.4.9.14
2.4.9.14 Alanine aminotransferase
Assays of AST and ALT were performed under optimised standard conditions conforming to the 
recommendations of the Deutsche Gesellschaft fur Klinische Chemie - Anon.: 1970 Z. klin. 
Chem. u. klin. Biochem. 8:658. Anon.: 1972 Ibid, 1_0:18
2.4.9.15 Alkaline phosphatase
PNR phosphate substrate/AMR buffer - Bowers, C.N. Jr. and McComb, R.B.: 1975 Clin. Chem. 
21:1988.
2.4.9.16 Gamma glutamyl transpeptidase
Modified Szasz method using L-gamma-glutamyl-p-nitroanilide substrate - Szasz, G.: 1969 Clin. 
Chem. 15:124.
2.4.9.17 Creatine kinase
CK-NAC - Oliver, I.T.: 1955 Biochem. J. 61:116. Rosalki, S.B.: 1967 J. Lab. Clin. Med. 69:696.
The above parameters were performed on a Coulter Dacos discrete analyser using test kits 
supplied by the same Company. (Luton, Beds).
2.4.9.18 Sodium and Potassium
Assayed by automated simultaneous flame photometry. Performed on an Instrumentation 
Laboratory 743 Flame Photometer (Warrington, Cheshire).
2.4.10 Urinary porphyrins
In the two year toxicity study with phénobarbital, urine samples were collected by placing the 
first ten animals individually in metabolism cages overnight. Water was available ad libitum  but
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animals were fasted to prevent dietary contamination of urine samples. On collection it was 
noticed that the treated male rat urines were distinctly red in colour. Control males and both 
treated and control female urines were a normal pale yellow colour. It is known that the presence 
of haemoglobin and excessive excretion of certain porphyrins in urine gives rise to a 
characteristic red colouration in pathological conditions.
Initially, samples were screened for haemoglobin content using BM-Test-7 strips. In this system 
haemoglobin (and myoglobin) catalyse the oxidation of an indicator impregnated in the strip. 
Although the abnormal red colouration slightly interfered with interpretation, it was concluded 
that no abnormal quantities of haemoglobin or myoglobin were being excreted by the male 
animals under test.
As a screening test for urinary porphyrins, 5 ml of each sample of urine was mixed with a mixture 
of 1 part glacial acetic acid and 4 parts ethyl acetate (HAc/EtAc) in a glass centrifuge tube. 
Samples were vortexed vigorously for two minutes and the phases were separated by a brief 
period of centrifugation. Samples of the organic upper layer (1 ml) were then aspirated into a set 
of clean glass centrifuge tubes containing 0.5 ml 3 molar hydrochloric acid. Samples were again 
vortexed and centrifuged. In this procedure the porphyrins were extracted into the lower, acid 
phase whilst most interfering-substances remained in the upper, organic phase. Samples were 
viewed under long-wavelength (397-408 nm) ultraviolet light (UV) since at this wavelength, in an 
acid medium, porphyrins exhibit an intense salmon pink fluorescence (620-639 nm).
When urinary porphyrins were found to be elevated it was considered prudent to confirm 
whether the increase was due to uro- or coproporphyrins. In the chromatographic technique 
described below, uroporphyrins remain at the origin whilst coproporphyrins move with the 
solvent front.
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A 10 pi of the upper HAc/EtAc phase described above was spotted onto a silica gel slide. This 
was placed into a tank containing the chromatographic solvent chloroform: methanol: 
ammonium hydroxide: water (ratio 12:12:3:2). Samples were run until the solvent front had 
moved 10 cm up the slide, which was then dried and viewed under UV, as described above.
2.4.11 Haematology
In view of the potential effect on haem biosynthesis and in order to measure the general health 
status of the animals, a full haematology profile was undertaken during month 20 of the two year 
phénobarbital study. Blood samples were collected under ether anaesthesia, via the retro-orbital 
sinus, into tubes containing EDTA. Data from treated animals were con pared with concurrent 
controls and pooled historical data derived from animals of the same age, sex and strain.
All assays were performed on the day of sampling using a Bayer Technicon H*1 (Basingstoke, 
Hants.). One exception to this was the reticulocyte count. For this assay, stained blood films 
were prepared on the day of sampling and examined later.
Analytical quality control for the Technicon H I was maintained using Alpha Laboratories Para- 
tech low, normal and high controls and by participation in the UK National External Quality 
Assessment Scheme for Haematology (Queen Elizabeth Medical Centre, Birmingham). The 
determinations performed and the methods used were as follows:
2.4.11.1 Haematocrit
Derived from the red cell count and mean cell volume in accordance with the Wintrobe 
formulae.
2.4.11.2 Haemoglobin
Modified manual cyanmethaemoglobin method - ICSH Standard EP 6/2:1977 and ICSH Standard 
EP 6/3:1977.
2.4.11.3 Red blood cells
Optical cytometry and isovo lu metric sphering - Kim, Y. R. and Ornstein, L.: 1983 Cytometry 
3(b):419. Sized by two angle laser light scatter - Tycko, D. H. et al.: 1985 App. Opt. 24(9).
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2.4.11.4 Mean cell volume
Obtained from the red blood cell/platelet channel as the mean of the red cell volume histogram.
2.4.11.5 Mean cell haemoglobin
Derived from the haemoglobin and the red cell count in accordance with the W introbe formulae.
2.4.11.6 Mean cell haemoglobin concentration
Derived from the haematocrit and the haemoglobin in accordance with the Wintrobe formulae.
2.4.11.7 Platelets
Optical cytometry - Kim, Y. R. and Ornstein, L : 1983 Cytometry 3(b):419. Sized by single angle
laser light scatter - Groner, W. and Tycko, D.: 1980 Blood Cells 6:141.
2.4.11.8 White blood cell and differential white cell count
Optical cytometry and cytochemical classification by preferential peroxidase staining - Advances 
in Automated Analysis, Technicon International Congress 1970.: Miami, Florida, Thurman 
Associates 1971 Vo I 1 : Saunders, A.M., Groner, W. and Kusnetz, J.: Page 453. Ansley, H. and 
Ornstein, L : Page 437. Basophils were counted by low angle laser signatures - Cremins, J. et al. 
(in preparation.)
2.4.11.9 Reticulocyte count
The percentage reticulocytes seen in 1000 consecutive erythrocytes was assessed in blood films, 
stained with brilliant cresyl blue
2.4.12 Preparation of Microsomes
Tris buffer: 2.42g TRIS, 85.6 sucrose, 2.0g Na2EDTA in 800 ml H20. pH adjusted to 7.4 with dil. 
HCI and made up to 11 with H20.
Three grams (+ 50 mg) of liver, obtained at necropsy were coarsely chopped and then 
homogenised, using a Ultra-Turrax T25, high-speed, ultra-fine homogeniser, in 9 ml of ice-cold, 
Tris buffer, pH 7.4, containing 250 mM sucrose and 5.4 mM EDTA. Tubes were balanced in 
pairs to within 100 mg and then homogenates were centrifuged at 19000 g (12610 rpm) for 15 
minutes at 4°C. The supernatant, containing the microsomal fraction was decanted into thick- 
walled polycarbonate tubes, were balanced and then further centrifuged at 4°C, under vaccuum, 
at 170,000 g (37500 rpm) for 45 minutes. The supernatant was removed and the volume noted.
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The pellet was gently washed and resuspended in the same volume of Tris buffer. The 
microsomal suspension was transferred to appropriately labelled tubes and was assayed 
immediately or was stored at -70° C.
2.4.13 Microsomal Uridine Diphosphoglucumnvl Transferase (UDPGT)
Hepatic, uridine diphosphoglucuronyl transferases (UDPGT) catalyse the transfer of glucuronyl 
groups from UDP-glucuronic acid to a number of exogenous and endogenous substrates. The 
assay used to monitor UDPGT activity takes advantage of this broad substrate specificity by 
utilising the glucuronidation of paranitrophenol. The procedure involved the addition of 250pl 
of microsomal suspension to 2200pl Tris HCI buffer pH 7.3, 250pl 60 mmol/l magnesium 
chloride, 250pl 18 mmol/l UDP-glucuronate, 50pl 10 pmol/ml p-nitrophenol. UDPGT activity 
was measured by monitoring the decrease in absorbance at 405 nm that was due to the 
glucuronidation of the p-nitrophenol.
UDPGT results were expressed as units per milligram of microsomal protein to account for the 
relative increase in liver mass observed in hepatic microsomal enzyme induction. The 
microsomal protein content was measured using the Pierce BCA® protein assay reagent 
(Rockford, IL, USA). This method is based on the interaction of two assay principles. The well- 
known, biuret reaction, in which protein reacts with the cupric ion (Cu2+) in alkaline medium to 
yield the cuprous ion (Cu^+), is coupled to the highly sensitive reaction between two molecules 
of bicinchonic acid and the cuprous ion (Cu^+). The purple reaction product that absorbs 
strongly at 562 nm is used to quantitate protein.
UDPGT is a family of isoenzymes known to be present in hepatic tissues. In these studies, p- 
nitrophenol was used as a surrogate substrate by which effects isoenzymes known to act on 
thyroid hormone metabolism was measured. Such colourimetric methods are easily automated
and large batches of samples can be analysed with relative accuracy. However, it is appreciated 
that if true measurements of if thyroid hormone disposal are to be obtained then radiochemical 
techniques using thyroxine or triiodothyronine as substrates must be substituted. Such 
procedures are not easily automated but do give a precise reflection of the metabolic capacity of 
the induced liver. It is suggested that the former assay using a surrogate substrate makes an ideal 
screening tool, whilst the latter method gives definitive proof that enzymes directly involved in 
thyroid hormone metabolism are affected.
2.4.14 INVESTIGATION OF ENZYME INDUCTION SUBCLASSES
Microsomal enzyme induction increases liver size and leads to a modification of the type and 
magnitude of certain biochemical processes within the hepatocyte. This occurs as a result of an 
increased number of detoxification enzymes. The discovery that there are multiple forms of 
Phase I (e.g. UDPGT) and Phase II isoenzymes (e.g. P450) and that cytochromes P450 are 
involved in the metabolism of many substrates (Cooper et al 1965) makes classification difficult. 
When defining the enzyme induction profile for a number of exogenous and endogenous 
substances it can be seen that compounds fall into groups that can be broadly classified. This has 
given great insight into mammalian physiology and mechanisms for toxicity of novel compounds. 
However, as more information is gathered it can be seen that there is great diversity of substrate 
specificities and a very large number of enzyme subfamilies involved. This can lead to confusion 
when trying to classify compounds according to enzyme induction type or when trying to link 
specific toxicity with a certain class of enzyme induction.
There are a number of different methods for evaluating the magnitude and sub-class of hepatic 
microsomal enzyme induction. In the following section includes a description of the different
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polypeptide that it effectively masks the natural charge on the molecule. It would appear that the 
polypeptides become organised into rod-like structures approximately 18Â in diameter with a 
length proportional to molecular weight (Pharmacia LKB Biotechnology 1992). Under 
electrophoretic conditions, the uniform charge on the molecule causes all SDS-polypeptides 
complexes to be driven towards the anode and to show different mobilities due to the sieving 
effect of the gel.
Polyacrylamide gels are a three dimensional lattice structure formed by the copolymerisation of 
acrylamide monomers with a cross-linking agent. Typically, NhT-methylene bisacrylamide (bis) 
is used and gels are polymerisation is catalysed by ammonium persulphate and initiated by 
TEMED (N,N,N%N'-tetramethylethylenediamine). The total acrylamide monomer (T%) and cross- 
linking agent, bis (C%) concentrations determine the pore size in the matrix. As T% increases, 
pore size decreases, thus by varying the amount of acrylamide (T%), bis (C%) or both in the gel 
different molecular weight (MW) ranges may be studied. As a guide, a T% : C% ratio of 37:1 has 
been used for the separation of proteins in the range 10,00 to 70,000 on 10% total acrylamide 
(T%) gels. Table 2.2, which follows serves as a guide to T% for proteins of differing MW ranges:
Table 2.2: Relationship of Polyacrylamide Gel Concentration to Molecular Weight Range
Molecular weight Range Percentage Gel
<50,000 15%
10,000 - 70,000 10%
25,000 - 200,000 5%
Up to 1,000,000 3.3%
The degree of electrophoretic separation achieved in a sample of mixed molecular weight
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proteins can be increased by varying the concentration of acrylamide across the gel. Gradient gel 
electrophoresis, as this is known, concentrates proteins into narrower bands by virtue of the ever 
decreasing pore size across the gel. During electrophoresis the proteins migrate until the 
decreasing pore size limits further movement. Since it is the pore size at the advancing edge that 
is restricting movement, the trailing edge migrates into the advancing edge thereby focusing the 
protein bands.
2.4.15.2 Materials
Polyacrylamide gels: The largest drawback with PAG electrophoresis is the potential health risks 
of handling acrylamide mixtures. Previous experience had shown that although more expensive, 
commercially available precast gels gave more consistent and reproducible results and were safer 
to use than the raw chemicals. For this reason, ExcelGel™SDS (Pharmacia LKB), gradient 8-18 
precast gels were used in these studies. These PAGs are supplied 0.5 mm thick on plastic support 
material to facilitate handling. On the cathodic side of the gel there is a T5% stacking zone that 
merges continuously into a T8-18% polyacrylamide gradient with C%= 3%, which makes the gel 
suitable for separations in the MW range 14,000 - 170,000.
Sample stock buffer (A) : 0.5 mo l/l Tris-Acetate, pH 7.5 (3g Tris/40 ml H20 was adjusted to pH
7.5 with approximately 1.4 ml acetic acid and made up to 50 ml with H20 . Sample buffer: (A) 
was diluted 1 + 9 with distilled water and 10 g/l SDS, 5 mmol/l dithiothreitol and 0.1 g/l 
bromophenol blue was added.
Fixing solution: 400 ml ethanol, 10 ml acetic acid made up to 1 litre with H20 .
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2.4.15.3 Method
Prior to electrophoresis all samples were diluted in SDS sample buffer such that they contained 
the same protein concentration. They were then heated to 95 °C for three minute to denature the 
proteins. Electrophoresis was performed using an LKB Multiphor 2117 electrophoresis tank 
containing a glass cooling plate and an LKB 2197 thermostatic circulator equilibrated to 15 °C. 
One m illilitre of light paraffin oil was placed on the cooling plate to maximise thermal 
conductivity and the gel was arranged so that the polarity of the gel corresponded to that of the 
plate and no air bubbles were trapped. Exgel™ SDS buffer strips were applied to the gel with the 
narrowest side on the surface to supply a discontinuous buffer system to the gel. The Anode strip 
contained 0.3 mol/L Tris, 0.3 mol/L acetate and 4 g/L SDS, pH 6.4 whilst the cathod strip 
contained 0.08 mo l/l Tris, 0.8 mol/L Tricine and 4 g/L SDS at pH 7.1.
Samples were applied to the gel as 3 pi droplets using a sample application template positioned 1 
cm from the cathode buffer strip. After application the template was removed and an 
electrofocusing lid was placed over the gel. Electrophoresis was conducted at a voltage of 600V, 
current 50 mA and 30W power for 75 minutes. Immediately after electrophoresis the buffer strips 
were removed and the gel was immersed in fixing solution for 30 minutes to precipitate the 
proteins and to allow the SD'S buffer to diffuse out. Protein bands were then visualised using a 
sensitive silver staining technique derived from that of Heukeshoven and Dernick (1985). The 
procedure used, which can be 100 times more sensitive than staining with Coomassie Blue R- 
250, was as follows.
After overnight incubation in a solution containing 17 g sodium acetate, 0.5 g sodium 
thiousulphate, 75 ml ethanol and 1.25 ml 25% w/v glutaraldehyde made up to 250 ml, the gel 
was washed three times in deionised water for a period of 15 minutes. The proteins were then
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stained for 20 minutes in a solution containing 0.25 g silver nitrate and 50pJ formaldehyde in 
250 ml deionised water.
The gel was developed for 10 minutes in a solution containing 6.25 g sodium carbonate and 
25pi formaldehyde in 250 ml before being placed in 14.6g/L EDTA in deionised water for 10 
minutes to stop the reaction. Gels were then washed in deionised water for three 15 minute 
periods before being placed in preserving solution containing 25 ml (87% w/w) glycerol in 250 
ml in deionised water for 30 minutes.
The plastic mounted gel was then placed gel side up onto a glass plate and was covered with 
cellophane that had been soaked in preserving solution and was allowed to slowly dry.
2.4.15.4 Determining molecular weights
For proteins in the 14,000 to 170,000 molecular weight (MW) range, Excel Gel SDS gradients give 
a linear relationship between the migration distance of an SDS denatured protein and the log of 
the MW. By running a molecular weight standard in a track alongside the unknown protein 
mixtures it is possible to calculate the approximate molecular weights of the unknown gel bands. 
The graph in Figure 2.1 summarises this principle.
Calculations of molecular weight given in the results section were derived by densitometry of the 
scanned gels. Each gel was run with a set of known molecular weight standards in the range 14 
to 100.000 Daltons. The particular standard used contained a lactalbumin (14,400), trypsin 
inhibitor (20,100), carbonic anhydrase (30,000), ovalbumin (43,000), albumin (67,000) and 
phosphorylase b (94,000). Gels were scanned using a Hewlett Packard scanner linked to 
Quantiscan © Microbial Systems Ltd. densitometric scanning software supplied by Biosoft, PO 
Box 10938, Ferguson, Mo 63135, USA. The relative peak positions defined were regarded as 
mobility figures and were used in the calculation of molecular weights .
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Figure 2.1 : Relationship between Mobility and Molecular weight
Molecular Weight
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2.4.16 Western Blotting and Immunological Staining Procedures
2.4.16.1 Introduction and principles
SDS polyacrylamide gel electrophoresis is an excellent technique for the separation and 
visualisation of proteins by molecular weight. However, it is not possible to positively identify 
individual proteins by such methods and there are a number of practical disadvantages to 
working with RAG gels. By using a technique known as electroblotting (Towbin and Gordon, 
1984), these problems can be overcome and the proteins can be visualised and identified 
specifically using immunological staining techniques.
The practical disadvantages of working with polyacrylamide gels include gel matrix effects, 
fragility and slow staining times. The matrix effects are particularly problematic when it comes to 
immunostaining. A nitrocellulose membrane is easier to handle; has the protein "concentrated" 
on the surface instead of diluted within the matrix of the gel; is a permanent record that w ill not 
dry out and is rapidly stained and destained by a number of methods including immunological 
techniques.
The electroblotting technique used involves the electrophoretic transfer of proteins from a PAG 
gel to the surface of a nitrocellulose membrane. The method is similar to that used by Professor 
E. Southern for the transfer of DNA from agarose gels. The PAG gel and the nitrocellulose 
membrane are subjected to an electrical potential, whilst sandwiched between filter papers and 
sponges soaked in suitable buffer solutions. The format of the gel sandwich shown in Figure 2.2 
below.
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Figure 2.2: Electroblotting: Format of Gel Sandwich
N eg at ive  pole
Sponge
Filter papers
Gel
M e m b ra n e
Filter papers
Sponge
Positive pole
A m ersham  International Pic. have d e ve loped  rat-specific  western b lo tt ing  reagents for the  
detection  o f  a variety  o f  cytochrom es P -4 5 0  using e n h a n c e d  ch em ilu m in e se n c e .  In this 
techn ique , proteins on nitrocellu lose  m em branes  are probed  using specific an tibod ies . O n c e  
b o u n d  these pr im ary  antibodies are located using a secondary  an tib o d y  labe lled  w ith  horse  
radish peroxidase. This is v isualised using pho tograp h ic  em uls ion  by  a l lo w in g  the horseradish  
peroxidase to catalyse the ox idat ion  of lum ino l (a cyc lic  diacyl hydraz ide) in the presence o f  
hydrogen perox ide .  T h e  energy from  the reaction is em it ted  as light at 4 2 8  nm . Certa in  
c o m p o u n d s  such as phenol derivatives e n h a n ce  the sensitivity o f  this reaction 1 0 0 0  fo ld , by  a 
m echan ism  that has yet to be defined. The  m etho d , w h ic h  is summ arised in Figure 2 .3 ,  is taken  
from  the A m ersham  W estern  Blotting Techn ica l M a n u a l .
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Figure 2.3: Principles of Enhanced Chemiluminescence Western Blotting
Protein on Membrane
Primary antibody
Secondary antibody 
with Horseradish label
Hydrogen peroxide OxididisedProduct
Oxidised enzyme  
+
Luminol
Enhancer
LIGHT
Enhanced c h em ilu m in e sc e n ce  offers a m e tho d  w ith  high sensitivity and lo w  b a c k g ro u n d  that has 
a s ignificant advantage over convent iona l staining techniques. T he  most im portan t b e in g  the  
ab il i ty  to stain and produce  hard copy  using o ne  a n tibod y  then to strip and subsequently  repro be  
using a different an tibody. This procedure  was used to systematically  probe m icrosom es w ith  
antibod ies  to GYP I A I , IA 2, IIB 1/2, II IA , I V A  and HE I .
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2.4.16.2 Materials and method
The reagents and method used to perform electrophoresis, blotting and immunostaining are 
exactly as described by the manufacturer's method sheets. The general procedure was as follows. 
Electrophoresis was performed on two gels containing the following samples; positive control 
microsomes from ethanol, phénobarbital, pregnenolone-16a-carbonitrile, pnapthaflavone, and 
isosafrole treated rats and the microsomal test samples used for SDS RAC electrophoresis 
described earlier taken from animals treated with A l 2 (750 ppm), B10 (5000 ppm), C59 (100 
ppm), D21 (400 ppm) and Propylthiouracil (2000 ppm). Sequential immunodetection of each 
cytochrome -R450 was performed. The gels being stripped between each detection process. 
Electrophoresis was performed using a Bio-Rad Mini-Protean™ system with Mini-protean 10-20% 
gradient gels. The reagents and microsomes were prepared as described in earlier sections of the 
thesis. Positive microsomes and molecular weight markers were reconstituted as described in the 
manufacturer's data sheets. Samples were applied to the gels in a 10 ul volume of microsomes 
diluted to a protein concentration of 5 ug. Electrophoresis was performed using a Bio-Rad 
PowerPac 300 set at 200v at 60 mA/gel for 45 minutes.
Western blotting onto Hybond-ECL nitrocellulose membranes was performed using a Bio-Rad 
Mini-Trans Blot module. A PowerPac 300 supply unit set to run overnight at 120V at 50 mA/gel 
was used.
Immunodetection was performed according to the following general procedure. Non-specific 
binding sites on the gel were blocked by incubating for one hour in Membrane Blocking reagent 
dissolved in Tris buffered saline. Details of this reagent are not provided by the manufacturer but 
solutions frequently contain non-fat dried milk and bovine serum albumin. Blots were then 
washed in Tris-buffered saline containing Tween-20™ (TBS-Tween) to minimise background
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staining. The membrane was then incubated in primary antibody before being washed again 
with TBS-Tween. The primary antibody was raised in either rabbit or sheep. The secondary 
antibody consisted of a species-specific, anti-rabbit or anti-sheep biotinylated IgC.
The membrane was incubated in second antibody for one hour, was washed carefully in TBS- 
Tween before being incubated for 20 minutes with a streptavidin-Horseradish peroxidase 
conjugate. Detection of the stained protein bands was performed using the ECL™ detection 
system, which generates light by the oxidation of luminol, as described earlier. The light was 
captured on Hyperfilm™-ECL that was developed and fixed using Kodak Developer (Sigma 
catalogue No P-7042) and Kodak fixer (Sigma catalogue No P-7176).
Membranes were reprobed after each detection by stripping with 62.5 mM Tris-HCl pH 6.7 
containing 2% SDS and 100 nM 2-mercaptoethanol for 30 minutes at 50°C. Assays were 
performed to identify the following cytochrome P-450 isoenzymes; CYPIA1, CYPIIB1/2, CYPIIIA, 
CYPIIE1 and CYPIVA.
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2.4.17 Measurement of Specific Microsomal Enzymes
2.4.17.1 Introduction
Historically, candidate microsomal enzymes have been used to classify compounds according to 
their enzyme induction subclass. Certain drugs and other xenobiotics have been selected for use 
in assays in which simple fluorometric or other easily measured end-points have been used. This 
section describes those enzymes used over the past several years by the Toxicokinetics 
Department at AgrEvo to categorise novel plant protection products according to enzyme 
induction subclass. Data on the compounds used in this thesis has been extracted from archived 
studies for comparison with the immunological methods described above.
2.4.17.2 Methods
2.4.17.2.1 Introduction
Hepatic microsomes used in the assays were prepared as described earlier and were used to 
measure the following enzymes. Due to the time interval between studies, different enzymes 
were measured although each is a surrogate for a particular sub-class of cytochrome P-450 
activity. As a positive control for each sub-class, male, Charles River rats (strain Crl: CD(SD)BR) 
were dosed with the following compounds in each study.
CYP1A1 - |3-Napthaflavone (80 mg/kg) suspended in corn oil at 100 mg/ml and dosed I. P. at a 
rate of 0.8 ml/kg bodyweight for 4 days.
CYP2B1/2 - Phenobarbitone (80 mg/kg) dosed in water at 100 mg/ml and dosed I. P. at a rate of 
0.8 ml/kg bodyweight for 4 days.
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CYP4A1 - Clofibrate (400 mg/kg) suspended in corn oil at 500 mg/ml and dosed I. P. at a rate of 
0.8 ml/kg bodyweight for 4 days.
2.4.17.2.2 Microsomal Protein Measurement
Microsomal protein measurements were conducted either using the Pierce BCA® protein assay 
reagent described earlier or by the Lowry method (Lowry et al., 1951).
2.4.17.2.3 Determination of Cytochrome P450 and b5
These assays were performed on the same microsomal sample on the day of sample collection. 
The microsomal samples were diluted 1:9 with Tris: Sucrose: EDTA buffer and were homogenised 
and scanned using a Shimadzu U. V. 240 spectrophotometer calibrated with a holmium filter at
453.3 and set to scan the range 390 to 500 nm.
Cytochrome bs was assayed by difference spectrum between the peak maximum (approx. 423 
nm) and 500 nm of a control sample and a sample that has been reduced by adding 25 pi of 3% 
(w/v) NADH in 1% NaHC03. The molar extinction coefficient of cytochrome b5 was taken to be 
171.
Total cytochrome P450 values were obtained by difference spectrum. A few milligrams of 
sodium dithionite were added to test and blank microsome solutions and carbon monoxide was 
bubbled through the test sample for 20 seconds. The cytochrome levels were determined by 
measuring the difference between peaks at the peak maximum (approximately 448 to 452) and 
that at 480 nm. The molar extinction coefficient of cytochrome P450 was taken to be 91. 
Cytochrome levels were calculated either as nmoles/mg protein or as nmols/g of liver according 
to the following formula:
Absorbance X 1 CP X 40 
Extinction X (protein concentration)
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2 .4 .1 7 .2 .4  Determ ination of Laurie Acid Hydroxylase (LAH)
The activity of this enzyme was determined by the method of Parker and Orton. The assay 
produces two metabolites the 11-OH metabolite is produced by enzyme of the 2B1/B2 
phénobarbital subclass whilst the 12-OH metabolite is specific for peroxisome proliferating 
compounds in the CYP4A1 or cytochrome P452 subclass.
The assays were performed in triplicate and each sample contained 1 mg microsomal protein 
suspension, 200pl (0.2pmol) "cold" lauric acid (40.06 mg/ml methanol), 10 pi (0.1 pCi) [14C- 
lauric acid (10 pCi/ml in methanol) and 1.96 ml deionised water.
Samples were incubated in a shaking water bath at 37°C for 5 minutes prior to initiating the 
reaction by adding 40 pi NADPH (33.3 mg/ml in 1% NaHC03). After further incubation for 5-10 
minutes the reaction is stopped by adding 200 pi 3M HCI. Ten millilitres of diethyl ether are was 
then added and tubes were mixed for 10 minute before being allowed to stand whilst the phases 
separated. Eight millilitres of the ether phases were then removed and transferred to a test tube to 
be evaporated to dryness under a stream of nitrogen. The residues were redissolved in 100 pi 
acetonitryl and were subjected to HPLC analysis using a Technicol Spherisorb % ODS 2 250 X
4.6 column. The analytical conditions used are presented in Table 2.3. Results were calculated 
from the fractional conversion of substrate to total hydroxyl products.
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Table 2.3: HPLC Conditions for the Measurement of Lauric Acid Hydroxylase Metabolites
Column: Spherisorb 5 ODS, length 25 cm, I.D.
4.6 mm.
Mobile
phase:
A: Water/0.1 % Acetic acid B 
Methanol
Flow Rate: 1.0 ml/min /0.9 ml/min
Gradient: Time %B Flow
0 55 0.9
25 55 0.9
50 100 1.0
60 100 1.0
65 55 0.9
Retention
time:
11 -OH I au rate 
12-OH I au rate 
Lauric acid
44 
min
45 
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2.4.17.2.5 Determination of Ethoxycoumarin Deethylase (ECD)
This enzyme was measured using the highly fluorescent endpoint 7-hydroxycoumarin, which is 
generated by some enzymes in the phénobarbital (2B1/B2 R450) subclass but principally by 
enzymes in the P-napthaflavone (CYR1A1/1A2 P448) subclass.
The procedure followed is described in Table 2.4.
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Table 2.4: Procedure for the Measurement of Ethoxycoumarin Deethylase Activity
REAGENT STEP
BLANK
1
BLANK
2
W
TEST
W
STD
W
Tris HCL Buffer (66 mM; pH 7.4; 8 g/l) 200 120 100 200
G-6-R (121.6 mg/ 100 ml buffer) + 
G-6-R-DH (200 units)
100 100 100 100
7-ethoxycoumarin (1 nM 19 mg/100 ml buffer) 700 700 700 -
7-hydroxycoumarin (0.5 mM 8.1 mg/100 ml buffer) 
For standard curve 0-360
Microsomes (1 mg/ tube) - 100 100 -
Incubate for 3 minutes at 37°C
NADPH (31.1 mM 26 mg/ml buffer) 20 20 20
Incubate for 10 minutes at 37°C
Acetone 1000 1000 1000 1000
7-ethoxycoumarin (1 nM 19 mg/100 ml buffer) 700
Deionised water 5000 5000 5000 5000
Centrifuge to remove protein. Excite at 385 and read fluorescence at 460 nm
A standard curve was prepared by adding 7-hydroxycoumarin to water in the proportions shown 
in Table 2.5.
Table 2.5: Standard Curve for the Measurement of Ethoxy Coumarin Deethylase Activity
7-Hydroxycoumarin
(nmoles)
0 7.5 15 30 60 90 120 150 180
|il 7-hydroxycoumarin 
added
0 15 30 60 120 180 240 300 360
ml Water added 5.00 4.985 4.97 4.94 4.88 4.82 4.76 4.7 4.64
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2.4.17.2.6 Determination of Aldrin Epoxidase (AE)
This assay is based on the enzymatic conversion of aldrin to dieldrin. It is catalysed by enzymes 
of the phénobarbital (CYP 2B1/2B2; P450) subclass.
Assays were performed in triplicate in tubes containing 100 pi G-6-P (40 nM; 11.25 mg/ml in 
buffer), 600 pi Tris/HCl buffer (66 mM; pH 7.4; 8 g/l), 100 pi NADPH (5 mM; 4.17 mg/ml buffer), 
100 pi G-6-P-DH (10 units/ml buffer), 100 pi microsomes (to give assay concentration of 5 
mg/ml). These were incubated at 37°C for 3 minutes and the reaction was started by the addition 
of 2 pi of aldrin (100 mM; 36.5 mg/ml).
The incubation mixture was then incubated for a further 5 minutes. Then 5 ml hexane was 
added and the mixture shaken for 20 minutes. A 50 pi aliquot was then removed and was further 
diluted with 1.25 ml of hexane. One pi of this diluted sample was then passed through a gas 
chromatograph using a 3% Dexil column at 220°C.
The conversion of aldrin to dieldrin was then calculated by ratio of the peak areas.
2.4.17.2.7 Determination of Ethoxyresorufin O-Deethylase (EROD)
This assay was used to determine the activity of enzymes in the P-napthaflavone (CYP 1 A l/1  A2; 
P448) subclass. Unlike Ethoxycoumarin deethylase (ECD), induction by phénobarbital is very 
minimal. The assay is based on the fluorescent end-point resorufin, which is excited at 510 and 
measured at 586 nm.
Microsomes were added to pre-warmed Tris HCI buffer (0.05 M; pH 7.5; 3.025 g/500 ml) at 37°C 
such that the final volume of 2 ml contains 1 mg of protein. To this 10 pi of ethoxyresorufin (50 
mM; 11.95 mg/l in methanol) was added and the mixture was equilibrated whilst a base-line was
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measured.
Ten micro litres of NADPH (416.5 mg/ml) were then added and the rate of conversion was 
monitored until the gradient of the decay line could be accurately measured. This linear gradient 
was compared with that derived from a set of resorufin standards. These were prepared from a 
100 pM solution of resorufin (21.32 mg/10 ml methanol). This was diluted progressively in 
methanol. First 1 ml was diluted in 100 ml. Then 5 ml of this dilution in 100 ml to give a 5 pM 
solution Then this was further diluted according to Table 2.6.
Table 2.6: Method for the Measurement of Ethoxyresorufin O-deethylase Activity
nmoles
Resorufin
pi
Standard Microsomes Buffer
5 50
4 40 Control microsomes To make volume up to
3 30 added to give 1 mg/ml 2 ml
2 20 protein
1 10
0.5 5
0.25 2.5
2.4.17.2.8 Determination of Pentoxyresorufin O-Dealkylation (PROD)
This assay was used to determine the activity of enzymes in the phénobarbital (CYP 2B1/B2; 
P450) subclass. The assay is based on the fluorescent end-point resorufin, which is excited at 
510 and measured at 586 nm.
Microsomes were added to pre-warmed Tris HCI buffer (0.05 M; pH 7.5; 3.025 g/500 ml) at 25°C 
such that the final volume of 2 ml contains 1 mg of protein. To this 40 pi of pentoxyresorufin (5 
mM; 1.14 mg/ml in methanol) was added and the mixture was equilibrated whilst a base-line was 
measured.
Ten |il of NADPH (416.5 mg/ml) was then added and the rate of conversion was monitored until 
the gradient of the decay line could be accurately measured. This linear gradient was compared 
with that derived from the same set of standards used in the Ethoxyresorufin O-Deethylase assay 
described above. Results are recorded as nmoles resorufin formed per minute per milligram of 
microsomal protein.
2.4.18 Statistical analyses
The range of statistical analyses used to evaluate plasma hormone and other clinical pathology 
data are documented below. In some instances, as a guide to the magnitude and clinical 
significance of any statistically significant change, the Standard Deviation Index was used. In this 
test, the magnitude of difference between treated and control mean data was compared with the 
natural variation (standard deviation) seen in the control group. Results are expressed in standard 
deviation units (SDI). In this simplistic test no account is taken of skewed distributions.
Detailed statistical evaluation of data such as the clinical pathology results, was undertaken by 
applying the follow ing tests. Bartlett's Test was used to determine homogeneity of variance 
between groups; if significant at the 5% level, a log transformation was applied to the data to 
attempt to remove any heterogeneity observed. If the data was considered to be homogenous, 
i.e., homogeneity of variance was demonstrated on either the untransformed or transformed data, 
parametric tests to detect significant difference between control and test groups at the 5, 1 or 
0.1 % level were applied. These comprised one-way analysis of variance to establish the 
significance of variability among all groups and Student's Y  Test, based on a pooled variance 
estimate, for intergroup comparisons, i.e. control versus each test group.
If significant heterogeneity of variance was observed after logarithmic transformation, then non- 
parametric analysis was performed using the Kruskal-Wallis Rank Test to detect any significant
group differences at the 5 , 1 or 0.1 %  level.
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CHAPTER 3: PREDICTING THE POTENTIAL TO CAUSE 
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3.1. INTRODUCTION
Hepatic microsomal enzyme induction (MEI) is believed to be indirectly goitrogenic in rats. 
This is due to enhanced peripheral metabolism of thyroid hormones (Oppenheimer et al.,
1968) by the enzymes T4-UDPGT and a monodeiodinase, which are located in the smooth 
endoplasmic reticulum. The resultant increased turnover of these hormones leads to relative 
hypothyroidism, which triggers the pituitary to secrete TSH into the plasma. This in turn 
activates the thyroid gland, which produces hormones to make up the apparent metabolic 
deficit. Prolonged TSH stimulation of the thyroid to meet continuous peripheral demand for 
thyroid hormones leads to thyroid hypertrophy, hyperplasia and thence neoplasia (Hill et a i,
1989). For this reason, it can be hypothesised that thyroid follicular cell neoplasia is a 
general and chronic consequence of chemicals causing hepatic microsomal enzyme 
induction.
A number of different classes of microsomal enzyme inducing agents are known to exist. The 
most frequently observed types of enzyme inducing agents are those in the 2BI/2B2 or 
phénobarbital (PB) class. Studies in our laboratory involving hepatic microsomal enzyme 
inducing agents have shown varying magnitudes of effects on thyroid function. Some potent 
inducing agents have shown no treatment related changes at high doses whilst administration 
of other compounds with a limited induction capacity at relatively low doses have lead to 
thyroid follicular cell tumours in two year carcinogenicity studies. From this it was 
hypothesised that the mechanism of such effects must be related to the class of enzyme 
inducing agent.
Several papers refer to phénobarbital as a thyroid tumour promoter (Hiasa et el., 1982 and 
1983). However, no report could be found in the literature, which showed conclusively that 
rat thyroid neoplasia was the direct consequence of long-term treatment with this classical 
enzyme inducing agent. In order to prove the hypothesis that microsomal enzyme induction
per se can lead to thyroid follicular cell neoplasia, a two year toxicity study was initiated with 
rats treated with phénobarbital at a maximally tolerated dose. Full details of the results of this 
study can be found later in this Chapter.
In the first study described, a validation of certain methods was undertaken to prove the 
diagnostic efficiency of assays that were to be used in the two year carcinogenicity and other 
studies.
3.2. EFFECTS OF CHEMICAL AND SURGICAL THYROIDECTOMY
3.2.1 Rationale
In a number of the studies planned, serum radioimmunoassays, using commercially available 
human test kits, were to be used in the assessment of rat thyroid function. W ith the exception 
of the TSH assay, no attempt to optimise these test kits for use in the rat was considered 
necessary. Plasma hormone ranges in rats and humans are similar and a number of 
publications refer to the use of such kits in rat investigative pathology (Depaolo and Masoro, 
1989).
The peptide sequence of TSH varies between species and antibodies raised against TSH from 
one species do not cross-react with those of another. Hence, it is not appropriate to use 
immunodiagnostic test kits designed for use in one species to evaluate pathological effects in 
another. To overcome this problem, a solid-phase rat-TSH assay was developed using 
antibodies and other rat-specific materials available from Dr A Parlow, Pituitary Hormones 
and Antisera Center (Torrance, California, USA).
The following study was used to validate the planned range of analytical methods, which had 
not been fully evaluated for use in the rat. The study compared the effects of surgical 
thyroidectomy and treatment with the direct, peroxidase-inhibiting goitrogen propylthiouracil 
(PTU) with normal, untreated control animals.
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3.2.2 Design
Groups of 10 male rats were used. Group 1 was untreated and served as a control. Group 2
was surgically thyroidectomised by the supplier whilst Group 3 animals were treated with diet
FTU
containing a daily equivalent of 100 mg/kg/a dose known to inhibit thyroid function. Group 
2 animals were given a 1.5% calcium lactate supplement in their drinking water, to 
compensate for the effects of thyroidectomy on calcium homeostasis.
Two days after receipt, animals were subjected to stratified allocation according to 
bodyweight and were allowed a further three days to acclimatise to the environmental 
conditions before treatment commenced. Previous experience had shown that the effects of 
surgical thyroidectomy and chemical blockage were apparent after two weeks. After 17 days 
of treatment all animals were killed and blood samples were collected into lithium heparin. 
Samples were centrifuged for 10 minutes at 4°C to allow removal of plasma for analysis. All 
assays were performed in duplicate. The parameters listed below were measured or derived. 
Thyroxine (T4), triiodothyronine (T3), thyrotropin (TSH rat-specific), free T4 (FT4), free T3 
(FT3), reverse triiodothyronine (RT3). Additionally, samples of liver were obtained at 
necropsy for the measurement of microsomal uridine diphosphoglucuronyl transferase 
(UDPGT: EC 2.4.1.17) using p-nitrophenol as a substrate.
3.2.3 Results (Table 3. land Photomicrographs 3.1 and 3.2)
A severe reduction in all of the plasma thyroid hormones, with a corresponding increase in 
circulating TSH was observed in both surgical and chemical thyroidectomy. As might be 
expected, the magnitude of the effect was slightly less in the chemically "thyroidectomised" 
group. An interesting effect on UDPGT values was also recorded. In the surgically 
thyroidectomised group UDPGT activity had fallen by more than 50% whilst in the 
chemically "thyroidectomised" group the activity increased by 50%. UDPGT activity is
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thyroid hormone dependent and is influenced by thyroid status. Hypothyroid animals have 
lower levels of this enzyme. This was assumed to account for the former result and probably 
reflects a biological attempt to conserve hormones. Propylthiouracil is known to be excreted 
as an S-glucuronide in vivo and in vitro (Lindsay et al., 1977), hence the latter effect is 
presumed to be the result of induction of this enzyme in an attempt by the animal to rapidly 
metabolise and excrete the toxic compound.
In order to visually demonstrate the marked effect of treatment with propylthiouracil a 
separate experiment was set up. Groups of male rats were treated with propylthiouracil in the 
diet at 100 mg/kg per day for seven days. At necropsy the thyroid glands were removed, fixed 
in formalin and stained with haematoxylin and eosin. The thyroid gland from a control 
animal and from an animal after treatment with PTU are shown Photomicrographs 3.1 and 
3.2.
Table 3.1: Effect of Chemical and Surgical Thyroidectomy
PARAMETER Control Thymic ectomy
Surgical Chemical (PTU)
MEAN SD MEAN SD MEAN SD
TSH ng/ml 8.1 1.1 23.7 *** 9.7 19.3 * 8.0
T4 nmol/L 91 9 16 *** 3 2 i *** 4
FT4 pmol/l 16.2 2.3 <2.3 *** - <2.3 *** -
T3 n mo I/I 2.3 0.2 0.8 *** 0.2 1.0 *** 0.2
FT3 pmol/l 2.7 0.3 <1.1 *** - 1.2 *** 0.1
RT3 pg/ml 196 42 <21 *** - <22 *** -
UDPGT U/mg 36 18 16 * 10 54 * 25
*** = p <0.001 ** = p <0.01 * = p <0.05
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Photom icrograph 3.1 - Thyroid Control (M agnification X I 80)
V
;i y \
I A; A *\  v V .*c > '
C ontro l m a le  rat th yro id  g land stained w ith  h aem a to xy lin  and eosin . 
C yst-like  fo llic les  (F) com prised  o f rings o f squam ous ep ith e lia l cells  
c o n ta in  h o m o gen ous , p in k -s ta in in g  c o llo id . In the centre, ab ove  a b lo o d  
vessel (B), an u ltirn o b ra n c h ia l cyst (U ) can be seen. These are freq u en tly  
seen in rat th yro id  tissue and are derived  e m b ry o lo g ic a lly  from  the 
u ltirn o b ra n c h ia l g land (Russfield, I 9 6 7 ). In fish, am p h ib ian s  and birds  
this g land  secretes c a lc ito n in  w h ic h  is secreted by C -cells  in the 
m a m m a lia n  thyro id .
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Photom icrograph 3.2 - Thyroid, 7 days PTU 1 00 m g/kg (M agnification X I 80)
M a le  rat th yro id  g land stained w ith  h a em a to xy lin  and eosin and  
s h o w in g  the effect o f the thyro id  b lo c k in g  agent p ro p y lth io u rac il 
ad m in is tere d  at I 0 0  m g/kg per day. T he  th yro id  g land has irregular 
fo llic le s  (A) c o n ta in in g  m u c h -red u ce d  am ounts  o f very pa le -s ta in ing  
c o llo id . Th e  e p ith e liu m  (C ) has b e co m e  c o lu m n a r or h ig h -cu bo ida! 
and w ith in  the fo llic u la r  cells m an y  o f the n u c le i (N ) have beco m e  
p o la rised  to the side distal to the fo llic u la r lu m en .
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3.2.4 Summary
This study was primarily set up to monitor the efficiency of radioimmunoassay methods 
designed for use in humans and to test a newly developed rat TSH method. As expected, 
thyroid hormone levels fell dramatically and there was a marked compensatory increase in 
TSH. It was concluded that human-based assay kits and the new TSH method were suitable 
for monitoring normal and clinically abnormal, circulating hormone levels in rats.
3.3. PHENOBARBITAL - TWO YEAR RAT CARCINOGENICITY STUDY
3.3.1 Rationale
The classic cytochrome P-450 inducing agent, Phénobarbital was the first organic anti­
epileptic agent used (Hauptmann 1912). It has been the most safe, effective and w idely used 
anti-epileptic agent and has been used in human therapeutic medicine for the past 80 years 
without evidence of thyroid carcinogenicity.
In the following study, phénobarbital was used to study the relationship between thyroid 
function and induced hepatic metabolism in rats. Previous studies designed to show the 
promoting effect of phénobarbital used an initiator such as diethylnitrosamine (DEN) to 
induce thyroid tumours. It was anticipated that no additional initiating chemical was required 
to demonstrate neoplasia if phénobarbital was administered at a sufficiently high dose level.
3.3.2 Design
Sixty animals of each sex per group were used in this study. Phénobarbital was continuously 
administered to test groups by dietary administration. Control groups received untreated diet. 
A 25 mg/kg per day dose level was selected since it was known to result in potent enzyme 
induction (Oppenheimer et al., 1969). However, analysis of blood samples in the early stages 
of the study showed that hormone levels were affected only to a limited amount. For this
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reason, and to account for the relative reduction in test material intake that occurs as animals 
age, the dose level was increased to 50 mg/kg per day on study day 120. It was hoped that 
this would achieve the effect seen by Lees et a/., (1977) who had shown a doubling of TSH in 
rats treated with a lower dose level of 37.5 mg/kg.
The health and well being of each animal was monitored prior to the start of treatment and at 
two weekly intervals throughout the study. Bodyweights were recorded at approximately four 
week intervals in the first year and two weekly thereafter. Food consumption measurements 
were conducted at intervals throughout the treatment period. Water consumption was not 
measured. Blood samples were collected via the retroobrital sinus under ether anaesthesia in 
months 3, 5, 6, 12, 13 ,20 and 24. At necropsy animals were killed by exsanguination via the 
abdominal aorta, under deep ether anaesthesia. The following organs were removed and 
weighed on each occasion: brain, pituitary, heart, spleen, kidneys, adrenals, testes, 
ovaries, liver, thyroid and uterus. A bone marrow smear was also prepared. Due to the 
delicate nature of the thyroid gland, this organ was fixed in 10% neutral buffered formalin, for 
a 4 day period, prior to being trimmed and weighed. These tissues, together with the 
parathyroid and any other abnormal tissues observed at post mortem, were fixed in 10% 
neutral buffered formalin pending future histopathological examination.
The primary purpose of this study was to assess any changes in thyroid pathology that might 
occur secondarily to the effects of liver microsomal enzyme induction. For this reason, 
histopathological examination was restricted to the thyroid and liver at the 12 month stage, 
whilst after 24 months of treatment the pituitary, thyroid, liver and testes were examined. The 
testes were selected because of the known male susceptibility to thyroid effects and for a 
secondary investigation into the effects of MEI on testicular pathology. This is documented in 
Chapter 4.
Following fixation, these tissues were routinely processed, sectioned (4 pm) and stained with
haematoxylin and eosin. Slides were examined by Mr I R. Major, Pathologist, AgrEvo UK Ltd, 
using standard light microscopy. For observed lesions, the severity was graded on a semi- 
quantitative scale. Results were collated, processed and reported using a computerised 
pathology system (ROELEE 84).
3.3.3 Results
3.3.3.1 Diet analyses
Each diet sample was measured four times and the mean of these analyses are presented in 
Table 3. 2.
Table 3. 2: Stability of Phénobarbital in Test Diets
WEEK STORAGE
INTERVAL
PHENOBARBIT/ 
PERCENT NOM
<L
INAL
DAYS AT 
ROOM TEMP
MEAN SD
4 0 102.9 1.4
8 0 100.1 1.5
8 4 94.2 1.1
8 7 93.6 0.5
8 14 98.1 2.1
It was concluded that the procedures used to store, prepare and dispense homogenous 
mixtures of phénobarbital in the diet gave suitable accuracy of concentration. The analyses 
also showed that the prepared diets were stable at room temperature for up to 14 days.
3.3.3.2 Food consumption and test material intake
A significant reduction in food intake was seen in both sexes throughout the treatment period. 
This data is presented in Figure 3 .1 , as can be seen, the effect was greater and reached a 
level of statistical significance in females only. The mean reduction in food consumption for
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the study was 3.8% in males and 9.7% in females.
The achieved chemical intake in mg/kg per day was calculated from the product of the dose 
level and the cage group mean food consumption divided by the cage group mean 
bodyweight. The mean test material intake, at the initial dietary concentration 26.1 mg/kg 
and 34.2 mg/kg day in males and female respectively. When the dose level was increased on 
day 120, the mean achieved intake for the rest of the study period, rose to 37.7 mg/kg day, in 
males and 53.7 mg/kg day, in females. The mean of the sexes combined, 45.7 mg/kg day, 
equated favourably with the planned test material intake of 50 mg/kg per day. These data are 
presented in Figure 3. 2.
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Figure 3. 1: Average food consumption
Control males Treated males
Control females Treated females
27
25
23
g/d 21
Day 7 Day 98 Day 133 Day 182 Day 364 Day 399
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Figure 3. 2: Achieved Intake of Test Material
mg/kg day
o
OCN
□  Male □  Female
500 ppm 1000 ppm
Day 7 Day 98 Day 133 Day 182 Day 364 Day 399
3.3.3.3 Bodyweights (Figures 3.3 and 3.4)
Th e  statistica lly  s ig n ifican t re duc tion  in b o d y w e ig h t and b o d y w e ig h t gain seen th ro u g h o u t the  
trea tm en t period  in fem ales  d id  no t b e co m e  ap p a ren t in m ales until d ay  1 6 9 . A t the end  o f the  
trea tm en t period  b o d yw eig h ts  w e re  a p p ro x im a te ly  1 0 %  lo w e r in treated  m ales and 3 0 %  
lo w e r in treated fem ales  w h e n  c o m p ared  w ith  the corresp o n d in g  contro l an im als . For this  
reason, the study m et c o n te m p o rary  M T D  crite ria  in m ales and far e xc eed ed  the M T D  in 
fem ales.
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Figure 3. 3: Graph of Group Mean Bodyweights
800
700
600
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400
300
200
100
1 57 113 169 225 281 337 379 407 435 463 491 519 547 575 603 631 659 687 715
DAY OF STUDY
Control Male 1000 ppm Male Control Female 1000 ppm Female
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INCIDENCE OF PALPABLE MASSES
MALES FEMALES
Dose ppm)
0 1000 0 1000
Number of animals 60 60 60 60
No. with masses 25 30 31 11
Mean time of onset 63 54 80 76
Mean masses/animal 0.6 0.6 0.6 0.18
Mass 1
Cutaneous 6 2 2 1
Subcutaneous 4 9 23 7
Miscellaneous 0 1
Not found but site taken 15 17 5 2
Cannibalised 1 0
Mass 2
Cutaneous 2 1 2 1
Subcutaneous 0 2 8 0
Not found but site taken 9 10 0 1
Mass 3
Cutaneous 1 6
Subcutaneous 2 0 1 1
Not found but site taken 4 3
Mass 4
Cutaneous 0 1
Subcutaneous 1 0
Not found but site 4 5
Mass 5
Cutaneous 1 1
Subcutaneous 1 1
Miscellaneous 0 1
Not found but site taken 2 1
Mass 6
Subcutaneous 1 1
Not found but site taken 2 0
Mass 7
Subcutaneous 1 1
Subcutaneous 1 0
Mass 8
Subcutaneous 2 0
Figure 3. 4: Graph of Cumulative Bodyweight Gain
300 t
250 --
200 - -
</)
|  1 5 0 -  
O
100 - -
50 --
1 57 113 169 225 281 337 379 407 435 463 491 519 547 575 603 631 659 687 715
DAY OF STUDY
—♦—Control Male 1000 ppm Male A Control Female 1000 ppm Female
3.3.3.4 Clinical signs and palpable masses
Few  c lin ic a l signs w ere  seen in the  e a rly  stages o f the  study. A n im a ls  w e re  c le a rly  sedated; 
e sp e c ia lly  in the early  m orn in g . As the study progressed a d d itio n a l trea tm e n t-re la ted  signs 
w ere  observed. These in c lu d ed  h yp o a c tiv ity , lethargy, unsteady ga it and  reduced  m uscle  
to ne. O th e r occasional signs w e re  no t considered  to be re lated  to trea tm en t since  
observations w ere  s im ila r across contro l and treated  groups.
In all m ales and in control fem ales  there w as no s ig n ifican t d iffe ren ce  in the  n u m b e r or 
lo catio n  o f p a lp a b le  masses observed. T h e  m ean n u m b er o f masses per an im al b e in g  0 .6 .  
Th e  tim e  o f onset o f spontaneous masses w as e arlie r in m ales (control 6 3  w eeks , treated  5 4  
w eeks) than in fem ales  (control 8 0  w eeks, treated 7 6  w eeks). T rea ted  fe m a le  a n im als  had  
fe w e r masses (m ean n u m b er per an im al 0 .1 8 ) b u t as seen ab o ve, the tim e  o f onset fo r those  
observed w as s im ilar to the treated  group.
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3.3.3.5 Thyroid hormone assays (Figures 3.5 and 3.6)
N o  consistent b io lo g ic a lly  s ig n ifican t e ffec t on p lasm a Total T 4  or Total T3  w as observed in 
e ith er sex at any  tim e  p o in t m easured. W ith  the exc ep tio n  o f the  3 m onth  results in m ales, 
the m a jo rity  o f the  T 4  results w e re  lo w e r in the treated  groups in both sexes. This d id  not, 
h o w e ve r, reach a level o f statistical s ign ificance  exc ep t at m onth  1 3 in m ales.
Figure 3.5: Total T4 Results
90 i nmol/L 
80 
70 - 
60 -1
50 I
40
30 -
20 -
Control male »  Treated male -e™ Control female Treated female
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Figure 3. 6: Total T3 Results
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A lth o u g h  Free T 4  and  Free T3  had a p p a ren tly  been successfully m easured in the C h e m ic a l 
and Surgical T h y ro id e c to m y  study described  earlie r, results o b ta in e d  in this study w e re  no t 
considered  to be v a lid . T h e  in itia l study had suggested norm al values in the range 1 1 .6  - 2 0 .8  
p m o l/l fo r Free T 4  and  2.1 - 3 .3  p m o l/l Free T 3 . In this study, a high degree o f v a ria b ility  w as  
fo u n d  w ith  both param eters at each b leed  p o in t in this study. A t the extrem es, contro l an im al 
values fo r Free T 4  varied  b e tw ee n  b leed  points by  as m uch  as 1 .2  - 8 .8  on  o n e  occas io n  to  
2 1 .0  to 6 9 .6  on ano th er. S im ila r w id e  varia tions w ere  seen w ith  Free T 3  w ith  contro l an im al 
results b e tw ee n  0  - 1 .5  and 0  - 1 7 .7  p m o l/l b e tw ee n  the b e g in n in g  and  en d  o f the study. 
Results appeared  to be consistent at each  tim e  p o in t b u t w ere  sub ject to w id e  flu c tu atio n s  
across occasions. D esp ite  attem pts to standardise the m e th o d o lo g y  no consistency w as  
o b ta in e d .
Free T 4  and Free T 3  m ethods fo r hum an  diagnosis are based on the c o m p le x  in te rre la tio n s h ip  
b e tw ee n  horm ones th at are b o u n d  to th e ir b in d in g  prote ins (in the case o f hum ans to 
h o rm o n e  b in d in g  g lobu lins) and the free horm ones w h ic h  c ircu la te  in p lasm a. S ince the  rat 
has no c o m p a ra b le  high a ffin ity  b in d in g  p ro te in , it is assum ed that m in o r varia tio n  in b lo o d
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sampling techniques, time taking to separate plasma from red blood cells, storage conditions 
and time of storage all have varying degrees of effect on this parameter. Similarly, slight 
differences in the different manufacturers kit constituents also contribute to the variability 
observed. Unfortunately, due to the limited amount of plasma available insufficient sample 
remained for a more detailed investigation of the factors contributory to these effects.
3.3.3.6 Plasma Thyrotropin (Figure 3.7)
After 3 months of treatment with phénobarbital at 25 mg/kg, a moderate increase in TSH was 
observed in rats of both sexes when compared with concurrent controls. In males, the 
magnitude of the effect was seen to be greater (5/10 abnormal when compared to historical 
controls).
In females, the mild but statistically significant increase in TSH was seen also in months 5, 6,
13 and 24 although on each occasion very few animals had values outside background 
control limits.
In males after 12 and 13 months of treatment with phénobarbital a very marked, statistically 
significant increase in TSH was observed. Group mean values were 2.5 times those observed 
in corresponding controls. Five out of 7 treated males had values that were above the normal 
historical control range.
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Figure 3.7: Thyrotrophin Results
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3.3.3.7 Plasma Phénobarbital (Figure 3.8)
After three months treatment with phénobarbital at 25 mg/kg per day, the mean plasma 
concentration in females was almost 3-fold higher than that observed in males (124 pmol/l 
females, 44 pmol/l males). When the dose was increased to 50 mg/kg per day, a 
corresponding rise in circulating plasma level was seen (272 pmol/l females, 100 pmol/l 
males). The mean plasma phénobarbital remained at these orders of magnitude until month 
24 when a significant increase was observed in both sexes, presumably as a consequence of 
decreasing metabolic competence.
As described previously, a significant reduction in food consumption was observed in both 
sexes. Males ate 96.4% and females 90.3% of the food consumed by the corresponding 
control animals. However, due to the difference in bodyweight between the sexes the mean 
achieved chemical intake in mg/kg per day was approximately 1.4-fold higher in females. On 
average, rats have a blood volume of approximately 62 ml/kg which when expressed as total 
blood volume equates to 31 ml in males and 18 ml in females (derived from Wolfensohn and 
Lloyd 1994). Due to this fact and hence the lower volume of distribution in the females, this 
presumably would have resulted in a higher plasma phénobarbital concentration in this sex. 
However, since the achieved intake is only 1.4-fold higher this is unlikely to have resulted in 
a 3-fold higher circulating plasma phénobarbital level. The large difference between sexes is 
almost certainly due to a higher rate of excretion in males due to greater P450 induction. 
Paradoxically, the higher phénobarbital level in females does not result in higher long-term 
toxicity. Females were clearly more sedated than males but other effects such as the general 
incidence of masses and the specific incidence of thyroid follicular cell neoplasia was much 
lower in this sex.
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Figure 3.8: Graph of Plasma Phénobarbital Concentration
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3.3.3.8 Clinical chemistry
In the c lin ical chem istry  data  there w e re  no b io lo g ic a l ly  s ignificant effects o f  treatm ent.  
Statistically s ignificant observations w ere  w e re  w ith in  norm al limits w h e n  c o m p a re d  to 
c oncurrent and  historical controls.
3.3.3.9 Urine analysis
U rin e  samples co llec ted  from  m a le  an im als  after I 2 m onth  o f  trea tm ent w e re  dis tinctly  red in 
colour. T h e  cause o f  this abnorm al co loura tion  was investigated. After the use o f  a s im p le
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dip-stick test to exclude haemoglobin and myoglobin as a potential cause for the red 
colouration, prior knowledge suggested that excessive porphyrin excretion was the likely 
cause. This theory proved to be correct. Acid organic extracts from male animals examined 
under UV light exhibited a characteristic, intense salmon-pink fluorescence. This 
colouration, which is due to the high degree of saturation present in the tetrapyrroll ring, is a 
highly characteristic feature of the porphyrins. No corresponding fluorescence was observed 
in treated or control females or control males. A chromatographic screen of an organic 
extract of urine samples showed that the porphyrins present in treated males were 
uroporphyrins, since they did not move from the sample origin under prescribed 
chromatographic conditions.
A number of drugs and chemicals are known to cause porphyria. Barbiturates in general and 
many other microsomal enzyme inducing agents are believed to lead to increased porphyrin 
production by the induction of 5 ALA Synthetase. This enzyme acts on glycine and succinyl 
coenzyme A to produce 5 Aminolaevulinic acid (ALA) a precursor of porphobilinogen and 
hence the porphyrinogens and ultimately the porphyrins. This observation, although 
significant, was not considered to have any relevance to the main purpose of this thesis and 
was not considered further. •
3.3.3.10 Organ Weights (Tables 3.3 and 3.4)
Absolute and relative organ weights for the interim and final kill are presented in the tables on 
the following pages.
3.3.3.10.1 Interim Kill (12 months)
A statistically significant increase in thyroid and liver weights (expressed as an absolute and 
relative to body and brain weight) was observed in male animals only. The absolute thyroid 
and liver weights were approximately 30% greater than controls. The testes weight was 20%
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higher than corresponding controls although this did not reach a level of statistical 
significance unless expressed as a ratio to body or brain weights.
In females, although the absolute liver weight was lower in treated animals, an increased 
relative liver weight was seen when expressed relative to bodyweight. This and other 
statistically significant changes in organ weights were considered to be due to bodyweight 
effects and were therefore considered to be of limited biological significance.
3.3.3.10.2 Final Kill (24 months)
In males, mean absolute thyroid and liver weights were approximately 30% larger than 
controls but for the thyroid gland the effect did not reach a level of statistical significance.
The lack of statistical significance on the thyroid was due to a large variation in gland weight 
in the control animals.
In females, a number of statistically significant reductions in organ weight were seen, which 
included heart, spleen, adrenal and thyroid gland. These and the other statistically significant 
effects seen in this sex were attributed to the large effect on bodyweight seen in treated 
females at this stage of the study.
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Table 3. 3: B o d y w e ig h t , Organ Weight and Brain to Organ Weight Ratio (12 Months)
PARAMETER CONTROL MALE TREATED MALE CONTROL FEMALE TREATED FEMALE
Terminal BW 671.1 (91.66) 613.8 (43.12) 416.8 (91.77) 315.0(34.25)
Brain Wt 2.17 (0.052) 2.05 (0.151)* 1.95 (0.101) 1.84 (0.057)**
Ratio BW 0.33 (0.042) 0.33 (0.019) 0.49 (0.108) 0.59 (0.058)*
Ratio BR 1 0 0 1 0 0 1 0 0 1 0 0
Pituitary Wt 0.017 (0.0061) 0 . 0 1 2  (0.0026) 0.044 (0.0721) 0.014 (0.0030)
Ratio BW 0.002 (0.007) 0.002 (0.005) 0.012 (0.023) 0.005 (0.0011)
Ratio BR 0.77 (0.286) 0.60 (0.143) 2.21 (3.577) 0.78 (0.164)
Heart Wt 1.82 (0.46) 1.47 (0.109)* 1 .2 1  (0.172) 0.98 (0.142)**
Ratio BW 0.027 (0.046) 0.24 (.025) 0.30 (0.044) 0.32 (0.059)
Ratio BR 83.8 (19.81) 72 (7.2) 62.2 (9.47) 53.7 (8.44)*
Spleen Wt 1.01 (0.278) 0.84 (0.112) 0.53 (0.089) 0.48 (0.067)
Ratio BW 0.15 (.040) 0.14 (0.024) 0.13 (0.023) 0.15 (0.034)
Ratio BR 46.5 (11.82) 41.2 (6.43) 27.0 (4.49) 26.0 (4.06)
Kidneys Wt 3.12 (0.239) 3.09 (0.202) 2.29 (0.417) 2 .0 1  (0.206)
Ratio BW 0.47 (0.053) 0.51 (0.050) 0.56 (0.082) 0.64 (0.084)*
Ratio BR 143.8 (11.09) 151.4(11.48) 118.0 (22.49) 109.8 (11.25)
Adrenals Wt 0.048 (0.0099) 0.047 (0.0090) 0.062 (0.0138) 0.068 (0.0154)
Ratio BW 0.007 (0.0013) 0.008 (0.0016) 0.016 (0.0043) 0.022 (0.0051)**
Ratio BR 2.20 (0.459) 2.29 (0.509) 3.24 (0.716) 3.70 (0.866)
Gonads Wt 4.91 (0.991) 5.77 (h im ) 0.118 (0.0293) 0.108 (0.0157)
Ratio BW 0.74 (0.184) 0S$ (0.238)* 0.030 (0.0103) 0.035 (0.0068)
Ratio BR 225.9 (45.34) 283*6 (5937)* 6.11 (1.583) 5.89 (0.967)
Liver Wt 17.62 (2.642) 2333 (2375)** 11.88 (2.670) 11.11 (1.470)
Ratio BW 2.64 (0.299) 3,79 (0.467)** 2.86 (0.397) 3.53 (0.379)**
Ratio BR 811.7 (120.41) 1139,2 {164,2)*» 613.4 (147.11) 605.1 (77.41)
Thyroids Wt 0.046 (0.0067) 0.060 (0 ,0 1 8 2 )* 0.046 (0.0124) 0.041 (0.0099)
Ratio BW 0.007 (0.0011) 0,010 (.0027)* 0.011 (0.0036) 0.013 (0.0028)
Ratio BR 2.12 (0.295) 2.94 (0.767)* 2.38 (0.665) 2.22 (0.517)
Uterus Wt - - 0.82 (0 .2 0 0 ) 0.61 (0.155)*
Ratio BW - - 0.20 (0.0063) 0.19 (0.052)
Ratio BR - - 42.4(10.55) 33.1 (8.21)
Key: W t = weight BW = bodyweight BR = Brain
All weights in grams. (Standard deviation bracketed.) N = >17<27
* p <= 0.05 ** p<= 0.01. Shaded area = treatment related significance.
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Table 3. 4: Bodyweight, Organ Weight and Brain to Organ Weight Ratio (24 Months)
PARAMETER CONTROL MALE TREATED MALE CONTROL FEMALE TREATED FEMALE
Terminal BW 673.5 (84.31) 614.0 (63.52) 480.5 (96.59) 320.5 (47.40)
Brain Wt 2.24 (0.096) 2.21 (0.141) 1.95 (0.067) 1.90 (0.095)
Ratio BW 0.34 (0.045) 0.36 (0.045) 0.42 (0.087) 0.60 (0.075)**
Ratio BR 1 0 0 1 0 0 1 0 0 1 0 0
Pituitary Wt 0.047 (0.0927) 0.022 (0.0138) 0.055 (0.0640) 0.019 (0.0239)
Ratio BW 0.007 ((0.0121) 0.004 (0.0029) 0.012 (0.0157) 0.006 (0.0063)
Ratio BR 2.06 (3.936) 0.98 (0.620) 2.79 (3.255) 0.99 (1.341)
Heart Wt 2.08 (0.502) 1.78 (0.218)* 1.61 (0.190) 1.22 (0.217)*
Ratio BW 0.31 (0.0066) 0.29 (0.037) 0.34 (0.051) 0.39 (0.054)*
Ratio BR 92.4 (22.29) 80.8 (1 1 .6 8 ) 82.6 (10.05) 64.2 (11.42)**
Spleen Wt 1.09 (0.254) 1.06 (0.224) 0.63 (0.126) 0.52 (0.084)**
Ratio BW 0.16 (0.034) 0.17(0.030) 0.14 (0.030) 0.16 (0.027)**
Ratio BR 48.8 (11.64) 48.3 (9.84) 32.6 (6.97) 27.1 (4.68)**
Kidneys Wt 3.90 (0.723) 3.80 (0.654) 2.66 (0.355) 2.41 (0.689)
Ratio BW 0.58 (0.113) 0.63 (0.165) 0.57 (0.091) 0.76 (0.218)**
Ratio BR 173.2 (29.08) 172.4 (28.70) 136.7 (19.70) 127.3 (39.44)
Adrenals Wt 0.098 (0.1230) 0.116(0.1278) 0.098 (0.0237) 0.077 (0.0237)*
Ratio BW 0.014 (0.0159) 0.021 (0.0276) 0.021 (0.0054) 0.024 (0.0072)
Ratio BR 4.35 (5.329) 5.3 (5.872) 5.03 (1.234) 4.09 (1.306)*
Gonads Wt 4.91 (1.094) 4.80(1.065) 0.217 (0.1146) 0.184 (0.1401)
Ratio BW 0.74 (0.187) 0.79 (0.184) 0.045 (0.0191) 0.051 (0.0185)
Ratio BR 219.4 (50.17) 218.3 (51.29) 11.13 (5.873) 9.66 (7.431)
Liver Wt 17.77 (3.013) 22<49 (4+431M 13.76 (2.938) 12.99 (2.847)
Ratio BW 2.65 (0.411) ; 3.67 (0.639$* 2.87 (0.278) 4.13 (0.953)**
Ratio BR 792.5 (137.68) 1023.21212.71)** 706.8 (155.31) 682.4 (146.64)
Thyroids Wt 0.067 (0.0724) 0.035 (0.035) 0.026 (0.0055)*
Ratio BW 0.010 (0.0104) 0,014 (0,0082)*...... 0.008 (0.008) 0.008 (0.0016)
Ratio BR 2.98 (3.241) : 3.87(2-19)* 1.80 (0.781) 1.35 (0.283)*
Uterus Wt _ - 0.73 (0.0156) 0.69 (0.371)
Ratio BW _ - 0.15 (0.0049) 0.20 (0.063)*
Ratio BR - - 37.7 (7.95) 36.2 (19.98)
Key: W t = weight BW = bodyweight BR = Brain
All weights in grams. (Standard deviation bracketed.) N = >17<27
* p <= 0.05 ** p<= 0.01. Shaded area = treatment related significance.
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3.3.3.11 Histopathology (Photomicrographs 3.3 to 3.16)
Photographs of remarkable histopathological findings are included at the end of the section.
3.3.3.11.1 Interim kill (12 months)
3.3.3.11.1.1 Thyroid Gland
The incidence of colloid depletion, follicular cell hypertrophy and agglomeration of colloid 
was slightly higher in treated males than the corresponding controls. No equivalent effect 
was observed in females.
3.3.3.11.1.2 Thyroid tumour incidence
A single, benign, follicular cell adenoma, was observed in a control male, and a parafollicular 
cell adenoma was seen in a treated male. No tumours were observed in females.
3.3.3.11.1.3 Liver
Slight to severe, centrilobular hepatocyte enlargement and vacuolation (minimal) was seen in 
animals of both sexes dosed with phénobarbital. In males, this was accompanied by 
treatment-related, minimal to moderate, ground-glass degeneration, minimal to slight 
pigmentation of hepatocytes-and eosinophilic cytoplasmic inclusion bodies.
3.3.3.11.2 Terminal kill (24 months)
3.3.3.11.2.1 Thyroid gland
The incidence of colloid depletion and follicular cell hypertrophy observed in treated males 
was less than that observed at 1 2  months.
The incidence of minimal to severe colloid agglomeration was significantly higher than that 
observed at 12 months. Although this lesion occurred in almost 50% of the control animals 
of both sexes, treatment appeared to amplify the incidence to over 70% in both sexes.
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3.3.3.11.2.2 Thyroid tumour incidence
In males, twice the normal incidence of benign and malignant follicular cell tumours was 
observed. The total number of males with benign tumours was 13/50 (26%) whilst the total 
with malignant tumours was 5/50 (10%). The incidence in control males was 10% and 4%, 
for benign and malignant respectively. No effect was observed in females where the total 
tumour incidence in control and treated animals was 4% and 6 % respectively.
3.3.3.11.2.3 Pituitary
Benign (34%) and malignant (2-6%) anterior lobe tumours were observed in treated and 
control males. In control females, benign tumour incidence (72%) was almost twice that of 
males (34%), whilst in treated females (2 0 %) incidence was almost halved. Other 
histopathological findings in this tissue were not treatment related.
3.3.3.11.2.4 Liver
Treatment-related, slight to severe, centrilobular hepatocyte enlargement and with 
vacuolation (minimal) was seen in animals of both sexes dosed with phénobarbital. In males 
(predominantly), this was accompanied by minimal to moderate, ground-glass degeneration; 
minimal to moderate pigmentation of hepatocytes and focal cystic degeneration.
Bile duct hyperplasia was seen in approximately 40-50% of control males and treated animals 
of both sexes In control females, only 13% showed this effect.
3.3.3.12 Photomicrographs of Histopathological Findings
On the following pages photographs of the principal pathological observation are presented.
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Photom icrograph 3.3 -  Thyroid C ontro l H&E (M agnification X250)
Control m a le  thyroid  g land stained w ith  h a em ato xy lin  and eosin. 
Large fo llic les  con ta in in g  h om o gen ous  p ink  staining co llo id  are 
present (F). Follicles are l ined by fla ttened squam ous e p ith e l iu m .
This section was taken from a two year old animal. By this 
age thyroid follicles are usually smaller in size. This section 
shows an area with a number of large follicles. It should be 
noted that this is not typical.
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Photom icrograph 3.4 Thyroid, 2 year Phénobarbital 50 m g/kg per day H&E (X200)
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M a le  rat thyroid g land stained w ith  h a em ato xy lin  and eosin and  
s h o w in g  the effect o f  phénob arb ita l  treatment for two years at 5 0  m g/kg  
per day by d ietary  adm ix tu re .  T he  gland contains irregular fo llicles  
c o n ta in in g  small am ounts  o f c o l lo id .  The  c o llo id  is poorly  stained and is 
s how ing  signs of c o l lo id  agg lom eration  (C). The  fo ll icu lar cells are 
cubo ida l  and the nucle i have polarised to the basal side of the cell (N).  
There  are also signs o f slight fo ll ic u la r  cell hypertrophy  (H)
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Photom icrograph 3.5 - Thyroid Collo id  Agglom eration H&E (X250)
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T h e  intensity o f  staining, the density and the physical structure o f  
c o l lo id  w ith in  thyro id  fo llic les is often very variab le . Sometim es there 
are even differences b e tw e e n  fo llicles in the same thyroid lobe. W ith  
age and treatm ent w ith  certain chem ica ls  this effect becom es very  
p ro n o u n c e d  and is k n o w n  as c o llo id  agglom eration . In the  
pho to m ic ro g rap h  dense staining c lum ps of co l lo id  (A) can be seen. 
X-ray crystallography has show n that these are frequen tly  associated  
w ith  increased am ounts  o f  sulphur, z inc, m agnesium  and ca lc iu m .  
Som etim es c lear rings o f  pale-sta in ing  co llo id  a round m ore dense  
material can be observed (R).
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Photom icrograph 3.6  Thyroid Collo id  Agglom eration PAS (X250)
T h e  per iod ic  ac id -Schiff  stain is typ ica lly  used to stain tissue 
carbohydrates  such as g lycogen a lthough the techn ique  also 
dem onstrates m ucoprote ins  such as c o llo id  in the thyroid gland. The  
pr in c ip le  is based on period ic  acid  ox idat ive  c leavage of carbon bonds  
in 1, 2 , -glycols to fo rm  aldehydes. These react w ith  S c h if f  s reagent to 
fo rm  an insoluble  alkyl su lphonate  that is m agenta  in colour.
The  pho tom icrograph  shows PAS positive material in the fo ll icu la r  
lum en  (E). The  te c hn ique  also highlights the basem ent m em branes (B).
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Photom icrograph 3 .7  Thyroid Follicular Cell Adenom a (X50)
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P hotom icrograph  shows extrem e variab il ity  in size of fo ll icu lar structure. 
W h e n  a norm al sized fo ll ic le  (T) is com p a re d  w ith  that observed in the  
fo ll ic u la r  cell a d e n o m a  (F) a massive difference can be seen. 
C o m pariso n  o f  the very densely  packed nuclei (N) in the a d e n o m a  w ith  
those o f the norm al fo ll ic le  shows the m arked  ce l lu lar  proliferation  
present.
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Photom icrograph 3.8  Thyroid Follicular Cell Carcinom a (X250)
ÊA
All ev id e n c e  o f  fo ll ic u la r  structure has been lost in this e xa m p le  o f a 
fo ll icu la r  cell ca rc in o m a . T h e  nuclei are larger than norm al and contain  
occasional m ito t ic  figures (M)
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Photom icrograph 3 .9  Liver C entrilobu lar Hepatocyte Enlargement (X75)
? >
In this section o f  m a le  rat liver, cells a round  the central vein (C ) have  
h y p e rtroph ied  due to the effects of treatm ent w ith  phénobarb ita l at 5 0  
m g/kg  per day.
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Photom icrograph 3.1 0 Liver Ground Glass D egeneration (X200)
Functional adap ta tion  to hepatic  m icrosom al e n z y m e  induc ing  agents 
occurs at three levels, e n h a ncem ents  o f certain enzym es, proliferat ion of  
organelles, eg. smooth e n d o p la sm ic  re ticu lum  and proliferation of  
w h o le  cells. In this pho tograph , enlarged centr i lobu lar hepatocytes (E) 
can be seen. T h e  nuclei are also en larged and have p rom inen t nuc leo li  
(N). The  no rm a lly  basophil ic  c lum ps of rough e n d o p lasm ic  re ticu lum  
are dispersed and the cytoplasm  has a fine grannular eos ino ph il ic  
a ppe ara nc e  (G). This is k n o w n  as ground glass degenerat ion.
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Photom icrograph 3.11 Liver Portal Triad (X 200  )
In the classic description o f  the liver lobule , the anatom ica l re lationship  
b e tw e e n  hepatocytes, the b lo o d  supply  and the b il ia ry  tree are 
considered to form  a hexagon . In this structure the central vein is in the  
m id d le  and the portal triads o f hepatic  portal vein, hepatic  artery and  
the b i le  duct are at the corners. This pho tom icrograph  shows a portal 
triad (T) at the perim eter o f one  cell th ick plates (R) o f hepatocytes  
w h ic h  radiate  from  the central vein.
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Photom icrograph 3 .12  Liver Bile D uct Hyperplasia (X 200  )
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Pro longed treatments w ith  hepa to tox ic  agents frequently  lead to 
hyperp las ia  o f  the b ile  ducts. This pho tom icrograph  shows this effect 
(H ).
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Photom icrograph 3.1 3 Liver Focal Cystic Degeneration (X200)
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This photograph  is o f  a section o f  liver stained w ith  haem ato xy lin  and  
eosin. It shows a focus o f cyst-like form ations (C) that are thought to
Ifco cells
arise from  degenerat ing  hepatocytes. Som e cysts contain  e o s ino ph il ic  
material (E) w h ils t others conta in  red b lo o d  cells (R).
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Photom icrograph 3 .14  Pituitary C ontro l (X200)
?
b #  « 
m m  0 ê  * - - tg»T#
% *  ** # ‘ -m *  mrlrW. s
^  m s
#'
*.. 
r i  I
%
*, .  •■■■
4/** "* I K
’
*m v  TlEnv W >
,
B
This pho tograph  shows the n u m b e r  o f  different types of cell that 
constitute the norm al pituitary. A lthough  these have historically  been  
identif ied  as a c id o p h i l ,  basophil and c h ro m o p h o b e ,  this categorisation  
does not p rov ide  precise de fin it ion  of funct ion . Im m u n o h is to h em ic a l  
staining is required  to accurate ly  differentiate  each cell type accord ing  
to function .
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Photom icrograph 3 .15  Pituitary Adenom a (X200)
•  ï
This p itu itary  a d e n o m a  can be seen to be com prised of p r inc ipa lly  o ne  
cell type. M i to t ic  figures (M ) are present and the nuclei (N) are large  
and  have fine  a chrom atin  ne tw o rk  ( leptochrom atic) .
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Photom icrograph 3 .16  Pituitary A denocarcinom a (X350)
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In this a d en o c a rc in o m a  o f the pituitary, the cells are p le o m o rp h ic  and  
have a w id e  variety  o f  b izarre  (B) and different sized nuclei (A).
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3.3.4 Summary
Groups of 60 rats of both sexes received dietary phénobarbital at approximately 50 mg/kg 
bodyweight per day. Control animals received untreated diet. Diets were stable for up to 14 
days and were prepared at this interval. A significant reduction in food intake was seen in 
both sexes. The mean reduction in food consumption for the study was 3.8% in males and 
9.7% in females. A significant reduction in bodyweight and bodyweight gain was seen 
throughout the treatment period in females and from day 169 in males. Achieved test 
material intakes were 26.1 mg/kg and 34.2 mg/kg in male and females respectively. This led 
to signs of sedation in both sexes. Throughout the treatment period, plasma phénobarbital 
levels observed in females were 2  to 3-fold higher than those observed in males. This was 
thought to be caused by higher metabolic turnover in males.
No consistent biologically significant effect on plasma thyroxine or triiodothyronine was 
observed. A significant increase in TSH was observed in both sexes after 3 months of 
treatment with males the most affected. After 12 and 13 months of treatment, an elevated 
TSH was observed in male animals only. Group mean levels were 2.5 times control values 
with 5 of the 7 males having values that exceeded the historical control range. In females, a 
mild but statistically significant increase in TSH was seen in months 5, 6 , 13 and 24. On 
each occasion very few animals had values outside historical control limits.
Animals appeared to be healthy throughout the treatment period and no significant effect on a 
battery of clinical chemistry and haematological parameters was observed. Overnight, urine 
samples collected from treated males were distinctly red in colour. Investigations into the 
cause of this effect showed that males were excreting significant amounts of uroporphyrins. 
Higher thyroid and liver weights were seen in treated males at 12 and 24 months. An 
increase in testes weight was seen at the 12 month but not at the two year stage. No 
significant effect on organ weights was seen in females. Other statistically significant changes
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in organ weights were considered to be the result of a reduction in body weight rather than a 
true effect on the organs themselves.
After 1 2  months of treatment, the male thyroid glands showed signs of colloid depletion, 
follicular cell hypertrophy and agglomeration of colloid. No corresponding effect was seen in 
females and no follicular cell tumours were observed in either sex. Centrilobular hepatocyte 
enlargement was seen in rats of both sexes. In males, ground glass degeneration, 
pigmentation of hepatocytes and eosinophilic cytoplasmic inclusion bodies were also 
observed.
After 24 months of treatment, the incidence of colloid depletion and thyroid follicular cell 
hypertrophy was lower than that observed at 1 2  months but the incidence of severe 
agglomeration of colloid was significantly higher. In males, twice the normal incidence of 
follicular cell neoplasia was observed in treated animals. In females, no treatment related 
change in follicular cell tumour incidence was observed.
Centrilobular hepatocyte enlargement was observed in both sexes. Ground glass 
degeneration, pigmentation of hepatocytes and eosinophilic cytoplasmic inclusion bodies 
were observed In females, no treatment related change in follicular cell tumour incidence was 
observed. Bile duct hyperplasia was significantly lower in control females than in the other 
groups.
A similar incidence of benign and malignant pituitary cell tumours was observed in control 
and treated males. In treated females the incidence was half that seen in males, whilst in 
control females the incidence was doubled.
The results presented above clearly show that phénobarbital is a complete thyroid carcinogen 
in male but not female rats when administered at 50 mg/kg per day. The cause of this effect is 
believed to be due to enhanced TSH levels which are the result of enhanced thyroid hormone 
metabolism. This in turn is thought to be due to the significant microsomal enzyme induction
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observed in males. Based on the data presented in this study, effects on higher neural centres 
a n d /o r the thyroid gland cannot be excluded. However, the absence of thyroid follicular 
cell tumours in females, in the presence of significantly higher circulating plasma 
phénobarbital levels, would suggest that such effects are unlikley.
A significant increase in circulating TSH would appear to be implicated in the mechanism for 
thyroid follicular neoplasia observed. The histopathology data shows that the thyroid gland is 
functioning at an increased level of activity. However, the gland appears to be able to 
maintain normal circulating levels of the principal thyroid hormones. This tends to suggest 
that phénobarbital is not directly goitrogenic. It is presumed to act on the thyroid gland by an 
indirect mechanism that is linked to enhanced peripheral metabolism of thyroid hormones 
due to microsomal enzyme induction.
Prompted by the observation that a number of chemicals with microsomal enzyme inducing 
properties have caused thyroid follicular cell neoplasia in lifetime toxicity studies, it was 
hypothesised that in rats, this is a generic effect of this class of chemicals (Hill et a/, 1988). It 
was believed that all chemicals with cytochrome P-450 IIB1/2 inducing properties have the 
potential to cause thyroid follicular cell neoplasia if administered to rats at a maximally 
tolerated dose. This study supports this hypothesis. It shows that the classic enzyme inducing 
agent, phénobarbital administered to rats at 50 mg/kg per day causes thyroid follicular cell 
neoplasia in males.
3.4. PERCHLORATE DISCHARGE STUDIES
3.4.1 Rationale
Two basic mechanisms account for thyroid follicular cell neoplasia in most species. In 
examples of the first, thyroid tumours have been produced by a number of direct acting, 
genotoxic carcinogens such as 2-acetylaminofluorine (Cox et al 1947) and dichlorobenzidine
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(Pliss 1959). The other mechanism involves interference with normal thyroid function leading 
to hormone imbalance.
Many chemicals are capable of affecting thyroid function. Antithyroid compounds can be 
broadly divided into two classes. Direct acting goitrogens interfere with one or more steps in 
the synthesis and secretion of thyroid hormones. Indirect acting goitrogens affect the 
peripheral metabolism and disposition of the thyroid hormones by modifying rates of disposal 
or interfering with peripheral deiodination or act as thyroid hormone analogues.
When considering possible causes of chemically induced thyroid follicular cell neoplasia, 
direct goitrogenesis needs to be excluded. It is essential to have proven that compounds 
under investigation are indeed indirect acting and not direct thyroid blocking agents. The two 
classes of goitrogen, direct and indirect acting can be differentiated by one simple experiment 
- the perchlorate discharge test (Barnes and Bledsoe 1972). In human medicine the test is 
conducted as follows. A patient is given a tracer dose of 2-15 fiCi 131 iodine. One hour 
later, thyroid radioactivity is measured to determine the basal iodine uptake rate. An oral 
dose of 0.25 - 1.0 grams of potassium perchlorate is then given and the 131 iodine uptake is 
then repeated one hour later. Perchlorate selectively inhibits iodine trapping and leads to the 
discharge of any radioiodine ihat has been accumulated by the thyroid gland but which has 
not been stabilised by incorporation into intracellular, iodinated organic compounds. A 
normal thyroid gland discharges less than 1 0 - 1 5 %  of the 1 hour iodine uptake. In other 
words, more than 85 % of the absorbed dose of radioiodine is normally organified w ithin one 
hour of the dose and therefore is not selectively discharged by the perchlorate. In 1987, 
Atterwill and his colleagues published an adaption of this technique for use in rats. The 
following section describes the use of this assay.
3.4.2 Study design
For convenience of description and presentation a number of studies conducted over a twelve
month period have been grouped together. Positive and negative control groups were used 
on each occasion although for convenience only one set of data is presented. Nine groups of 
twelve, five week old Sprague-Dawley rats were used in these studies. Control animals 
received untreated diet throughout. For a seven day period, the other animals were fed diet 
containing a daily equivalent of either: Propylthiouracil (PTU) at 100 mg/kg, Phénobarbital 
(PB) at 50 mg/kg, Compound A12  at 125 mg/kg, Compound B10  at 250 mg/kg and 
Compound C59 at 5 mg/kg. All dose levels were selected on the basis of proposed maximally 
tolerated dose levels that were to be used or had been used in chronic toxicity studies 
conducted by AgrEvo UK Ltd. Compound D21 was not tested.
On study day eight, all animals were injected intraperitoneally (IP) with a 100 |d dose of Ip, 
Curie 125lodine according to a very strict time schedule. Six hours later, six of the animals 
(the even numbered test groups) were injected (IP) with potassium perchlorate dissolved in 
0.9 % w /  v physiological saline and dosed at 10  mg/kg. The six odd numbered test groups 
were given physiological saline (10 ml /  kg IP) to act as a concurrent control. Precisely 2.5 
minutes later, animals were killed by cervical dislocation and a blood sample was taken from 
the abdominal aorta. Simultaneously the thyroid glands were removed, trimmed and 
weighed. Thyroid glands for histopathology processing are fixed in formalin prior to trimming 
to minimise trauma. In this method fresh tissue is used and great care is required to 
standardise the weights obtained. Full details of the perchlorate discharge test are 
summarised in Table 3. 5.
In the laboratory, a measured blood volume and the weighed thyroid glands were counted in 
a Packard Minaxi y 5500 gamma counter. The amount of radioactivity present per gram of 
thyroid and per m illilitre of blood was derived. From these values the thyroid: blood 
radioiodine ratios were calculated. Results for each saline control and perchlorate treated 
group are presented in Figure 3. 9
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Table 3. 5: Procedure for Perchlorate Discharge Studies.
Period Control Phénobarbital Propylthiouracil
Day 1 -7 0  mg/kg 50 mg/kg 1E00
Day 8 : 
time Oh 1 pcurie radioiodine /  animal I.P.
Day 8 : 
time 6  h
Saline KCLO4 Saline KCLO4 Saline KCLO4
1 0  ml/kg 
I.P.
1 0
mg/kg
I.P.
1 0  ml/kg 
I.P.
1 0
mg/kg
I.P.
1 0  ml/kg 
I.P.
1 0
mg/kg
I.P.
Day 8 : 
time 6  h 
+ 2.5 m
'Count' blood and thyroids
Saline = 0.9% w/v sodium chloride in water
3.4.3 Results
3.4.3.1 Interpretation of Perchlorate Discharge Studies
There are two aspects to the interpretation of a perchlorate discharge test (PDT). The first 
significant component is the 125lodine uptake test, which in otherwise healthy animals is 
proportional to the activity or hormone excretion rate of the thyroid gland. When the iodine 
uptake is low, the thyroid requirement for iodine is similarly low and the animal is not 
producing thyroid hormones and is likely to be hypothyroid. Conversely, if the animal is 
hyperthyroid, there is increased production of thyroid hormones, therefore the rate of iodine 
utilisation is high, the turnover of iodine is increased and therefore the iodine uptake is 
elevated. The second component of the PDT involves comparison between the saline and 
perchlorate treated animals. If the animals are hypothyroid due to thyroid block e.g. 
inhibition of peroxidase enzymes then iodine that is accumulated in the thyroid gland does 
not become organified. Hence, treatment with perchlorate, which competes with iodine for 
binding space in the thyroid, leads to a discharge of this unbound, non-organified iodine.
142
Control animals treated with saline w ill not display a similar discharge and so comparison can 
be made. The conclusion is that the higher the discharge the more likely the compound 
under test is a direct thyroid blocking agent.
3.4.3.2 Propylthiouracil treatment
Animals treated with this directly acting goitrogenic agent showed obvious signs of reduced 
activity that were presumed to relate to the hypothyroid status. The animals ate less than half 
the amount consumed by corresponding controls (41%) which led to a significantly lower 
bodyweight gain (75%). The thyroid gland was chemically blocked and showed a very low 
125|odine uptake (44 %). As a result, the thyroid had begun to compensate for the direct 
thyroid block and was 1 . 8  times larger than controls
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Figure 3. 9 : Results of Perchlorate Discharge Studies
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KEY: C M  - C O N TR O L MALE CF - C O N TR O L FEMALE
PTM - PROPYLTHIOURACIL MALE PTE - PROPYLTHIOURACIL FEMALE 
PBM - PHENOBARBITAL MALE PBF - PHENOBARBITAL FEMALE
A 1 2 M ,  B 10M  and C 59 M  - TEST C O M P O U N D S  MALES O N LY
SUMMARY OF TEST:
G roups  o f tw e lv e  an im als  w e re  treated w ith  e ither (P TU), (PB), a novel test c o m p o u n d  or 
rece ived untreated control diets for a period  o f  seven days. O n  study da y  e ight, all an im als  
w ere  in jected  w ith  a 1 0 0  jal in traperitoneal (IP) dose o f Ip G u r ie  , 2 5 lod ine  . Six hours later, 
six o f  the an im als  w e re  in jected w ith  potassium perchlora te  dissolved in 0 .9  %  w  /  v 
physio logical saline (1 0  m g / k g  IP) w h ils t  the o ther  six w ere  given physio log ica l saline (1 0  ml 
/  kg IP) to act as concurren t controls. Precisely 2 .5  m inutes  later, an im als  w e re  k il led  by  
dis location  o f  the neck  vertebrae and  a b lo o d  sam ple  w as taken from  the a b d o m in a l  aorta.  
S im ultaneous ly  the thyro id  glands w e re  rem oved , tr im m e d  and  w e ig h e d .  T h e  a m o u n t  o f  
rad ioactiv ity  present per gram o f thyro id  and per m il li l i tre  o f  b lo o d  was derived . From these  
values the thyroid: b lo o d  ra d io io d in e  ratios w e re  c a lcu la ted  and are presented in the  a b o v e  
graph.
D Saline 
El Perchlorate
A12M B10M C59M
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3.4.3.3 Phénobarbital treatment
Bodyweight gain and food consumption figures were comparable to controls in this test 
group. However, the animals were obviously sedated and exhibited signs of hypoactivity, 
lethargy, unsteady gait and reduced muscle tone. These effects are consistent w ith the 
pharmacological effect of barbiturates. The 1 ^ Io d in e  uptake was almost double that of 
corresponding controls. This suggests that the thyroid gland was fully competent and was 
producing hormones at a significantly higher rate. There was no significant discharge of 
iodine on treatment with perchlorate. This suggests that the thyroid gland of rats treated with 
phénobarbital contained no free iodine and were therefore fully competent and able to 
organify iodine. Both observations are consistent with the proposed indirect goitrogenic 
action of phénobarbital.
3.4.3.4 Treatment with novel compounds A12, BIO and C59
W ith two of the compounds tested (A12 and C59) there was no significant difference between 
treated groups and corresponding controls. Thyroid weights were normal, 1 ^ Io d in e  uptake 
was some 20 - 30 % higher than controls but did not reach a level of statistical significance 
and there was no significant perchlorate discharge. Animals treated with compound BIO had 
a significantly higher 1 ^^lodine uptake but there was no increase in thyroid weight or 
perchlorate discharge. It was concluded that none of the compounds studied are direct acting 
goitrogens since iodine uptake was higher in each case than corresponding control values. It 
was also concluded that the rate of thyroid hormone synthesis for each compound studied 
was higher than corresponding controls. Compounds could be graded with A12 and C59 
having less effect on the thyroid gland than compound B10.
3.4.3.5 Sex differences
No significant difference between control males and females was observed for any parameter
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measured. The thyroid count to blood count ratio appeared to be higher in females but the 
significance of the observation could not be determined from the limited amount of data 
available. Females responded to treatment with PTU in a similar manner to males. The 
response to phénobarbital was also similar between the sexes although the higher blood to 
thyroid ratio in this sex was noted.
3.4.4 Summary
The above studies were designed to evaluate whether or not compounds were direct or 
indirect acting goitrogens. Propylthiouracil used as a positive, direct acting control material 
showed an expected reduced radioiodine uptake and enhanced perchlorate discharge. 
Phénobarbital was considered to be a indirectly goitrogenic agent thought to act by increasing 
thyroid hormone turnover by enhanced peripheral disposal The results of the perchlorate 
discharge test supported this theory. Radioiodine uptake was increased and an insignificant 
amount of discharge occurred after perchlorate treatment. Evaluation of novel test materials 
showed that they too were not directly goitrogenic.
In a direct comparison between the sexes using phénobarbital and PTU, no sex difference was 
found that could account for the male biased tumour incidence observed in the long-term 
study described in Section 3.3.11.2.2. Retrospective consideration of these data highlight a 
significant observation which is that these animals started treatment at four weeks of age.
Since rats do not reach sexual maturity until 8  weeks of age (Kato et a/., 1962), the animals 
used in these studies could be considered sexually immature. Hence, they may not have 
exhibited the full sexual differentiation of metabolism that is known to exist. (See previous 
Chapter).
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3.5. INVESTIGATION OF TIME COURSE OF HORMONE EFFECTS
3.5.1 Rationale
Phénobarbital has been known to affect thyroid function in rats since Oppenheimer's 
pioneering work in the 1960's. However, speculation still exists about the multiple sites of 
interference and what impact such effects (and similar observations seen after treatment with 
novel pharmaceuticals and pesticides) has on man. One key element that must be evaluated 
is whether such effects can be attributed to direct action on higher neural centres, or to 
hypothalamic stimulation, or to pituitary stimulation or perhaps by post pituitary interference 
with hormone synthesis or site of action. One means of monitoring this is to determine 
whether a rise in TSH seen after treatment with such compounds, occurs after a reduction in 
circulating triiodothyronine or thyroxine. In other words, is the elevated TSH due to a normal 
pituitary feedback response or due to direct pre thyroidal stimulation? The follow ing study 
was designed to investigate this.
In the risk assessment of novel chemical products it is assumed that no significant effect on 
thyroid and hepatic function w ill occur at low dose levels. Hence, no thyroid tumours w ill be 
induced by such dose levels because the effect w ill be below a dose response threshold. 
Although thyroid follicular cell neoplasia caused by microsomal enzyme inducing agents is 
believed to be a rat specific phenomenon, this study was used to monitor the effects of a 
human therapeutic dose of phénobarbital over a six week period. No human thyroid 
follicular cell neoplasia has been reported in the eighty years of human therapy with 
barbiturates.
3.5.2 Study design
Animals were purchased at 12 weeks of age to ensure that during the study they would be at
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sexual maturity. Weights on arrival ranged between 225 and 450 grams. Thirty animals per 
sex were allocated to two treatment groups. One group received phénobarbital in the diet at 
50 mg/kg per day. This dose level was chosen because it had been seen to cause thyroid 
follicular cell tumours in the earlier two year study. The second group were treated by gavage 
at a human dose level (0.25 mg/kg per day) and was designed to simulate a repetitive 
therapeutic dose.
Subsets of animals were bled for hormone analysis on days 2, 3,4, 6 , 20 and 44. They were 
subsequently necropsied and the livers were removed weighed and assayed for uridine 
diphosphoglucuronyl transferase (UDPGT) activity using p-nitrophenol as a substrate. This 
enzyme is known to be the rate lim iting step in thyroid hormone metabolism.
3.5.3 Results
Animals treated with 50 mg/kg per day phénobarbital in the diet were sedated each morning. 
No clinical signs of treatment were noted in the animals dosed at the lower (0.25 mg/kg) dose 
level.
The effects of phénobarbital treatment on triiodothyronine (T3), thyroxine (T4), thyrotropin 
(TSH) and UDPGT are presented in Table 3. 6  and Table 3. 7.
In the 0.25 mg/kg groups no significant effect of treatment was seen on any parameter 
measured.
In animals treated with 50 mg/kg phénobarbital, no significant effect on plasma T3 was 
observed in either sex. In males, plasma T4 was lower than controls throughout the treatment 
period; although this achieved a level of statistical significance only on days 2 and 6 . In 
females no significant effect on T4 was observed. The fact that plasma T4 was statistically 
significantly lower than controls in this sex on day 4 was considered to be an artefact; the 
control values being higher than normal rather than the test samples being lower.
No significant effect on plasma TSH was seen in females. UDPGT values in this sex were also
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not a ffected  by  trea tm en t a lthoug h  a very m ild  b u t s tatistica lly  s ig n ifican t e le v a tio n  o f this  
param eter w as noted on d ay  6.
In m ales, m ean  TSH  values w e re  seen to g rad u a lly  increase across the trea tm e n t perio d . By 
day 3 3  this e ffec t w as h ig h ly  s ig n ifican t and a n u m b e r o f an im als  had a bnorm al TS H  levels. 
U D P G T  values fo llo w e d  a s im ila r b u t e a rlie r trend w ith  s ig n ifican tly  h igher values seen by  
day 4 . Th e  graph in Figure 3 . 1 0 , sum m arises the in terre la tionsh ips  b e tw ee n  T 4 , TS H  and  
U D P G T  a c tiv ity  seen in m a le  rats treated w ith  p h é n o b arb ita l in the d ie t at a dose  
c o n cen tra tio n  o f 5 0  m g/kg per day.
Figure 3.10: Endocrine Changes in Male Rats Following 45 days of Phénobarbital at 50
mg/kg
25 t
20
TSH
15
UDPGT
Û 1 0 . .
5
45
Day o f treatment
SDI = Standard deviation index - calculated as the difference between treated and control mean divided by the standard deviation of 
the control data. UDPGT values were not measured beyond day 6.
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Table 3. 6: T3, T4, TSH and UDPGT Values in Males.
Parameter Day Dose level (Phénobarbital)
Omg/kg 50mg/kg 0.25 mg/kg
Mean +/- SD Mean +/- SD Mean +/- SD
T3 2 0.9+/-0.16 1.0+/-0.19 1.0+/- 0.13
nmol/l 3 1.3+/- 0.43 1.1+/-0.46 1.2+/-0.37
4 1.3+/-0.19 1 .2 +/- 0.08 1.4+/- 0.49
6 1.5+/- 0.35 1.3+/- 0.24 1.6+/-0.50
33 1.7+/- 0.35 1.2+/- 0.46 -
45 1.4+/- 0.2 1 .0 +/- 0 . 2 0 -
T4 2 91+/- 11.5 74+/-8.2 ** 83+/-5.2
nmol/l 3 84+/- 11. 8 6 6 +/- 10.4 8 8 +/- 17.6
4 72+/- 11 . 8 67+/- 11.9 87+/- 15.4
6 79+/- 13.1 63+/- 10.1 * 92+/- 7.2
33 83+/- 12.0 55+/- 3.3 -
45 72+/- 7.3 62+/- 9.0 -
TSH 2 12.2+/- 1.58 14.7+/-2.83 13.3+/-2.67
ng/ml 3 13.0+/-2.47 12.3+/-3.35 14.9+/-2.72
4 14.4+/-2.70 15.1+/-4.84 14.9+/- 2.29
6 14.1+/-3.42 17.0+/-3.04 15.3+/-5.01
33 12.1+/-0.72 29.5+/- 14.6 *** -
45 16.1+/-2.71 35.4+/- 15.0 *** -
UDPGT 2 13.2+/-3.14 12.1+/-4.04 10.4+/- 6.16
U/g 3 15.8+/-3.26 16.9+/-4.67 13.1+/-5.28
4 14.6+/-3.03 23.7+/- 3.63 * 15.7+/-9.72
6 10.1+/-0.67 24.5+/- 1.97 ** 13.6+/-3.69
* p<= 0.05 ** p <= 0.01 ***p <= 0.001
- = not assayed
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Table 3. 7: T3, T4, TSH and UDPGT Values in Females.
Parameter Day Dose level (Phénobarbital)
0  mg/kg 50 mg/kg 0.25 mg/kg
Mean +/- SD Mean +/- SD Mean +/- SD
T3 2 1.6 +/- 0.33 1.2+/-0.16 1.4+/- 0.29
nmol/l 3 1.2+/- 0.29 1.5+/- 0.49 1.4+/- 0.43
4 1.8+/-0.17 1.5+/- 0.46 1.7+/-0.19
6 2 .0 +/- 0 .2 1 1.9+/- 0.27 1.6 +/- 0.38
33 1.1+/-0.18 1.6+/-0.31 -
45 1 .6 +/- 0.06 2.4+/- 0.57 -
T4 2 52+/-5.3 53+/- 8.0 6 6 +/- 8.7
nmol/l 3 54+/- 11.5 48+/-5.4 65+/- 19.4
4 75+/- 8.5 48+/- 4.0 ** 69+/- 12.3
6 53+/-24.1 41+/-9.1 54+/- 6.7
33 56+/-5.9 40+/- 2.4 -
45 42+/- 3.0 40+/- 6.5 -
TSH 2 11.3+/-2.33 11.4+/- 2.07 17.0+/- 1.49
ng/ml 3 10.9+/- 1.36 13.5+/-3.59 12.7+/-2.45
4 15.3+/- 7.99 11.7+/- 1.00 11.8+/- 1.53
6 11.1+/- 1.48 12.7+/- 1.82 11.6+/- 1.57
33 10.4+/- 1.45 16.8+/-4.85 -
45 14.4+/, 4 . 5 5 19.6+/-7.13 -
UDPGT 2 6.2+/- 2.85 4.7+/- 1.75 6.1+/- 1.65
U/g 3 9.6+/- 3.59 11.3+/- 1.22 8.2+/- 1.98
4 10.6+/-2.49 10.0+/-4.97 6 .6 +/- 1.42
6 8.14/-3.54 12.1+/-2.50 * 6.4+/- 0.8
* p<= 0.05 ** p <= 0.01 ***p <= 0.001
- = not assayed
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3.5.4 Summary
This study was set up in sexually mature rats to investigate the early phase endocrine response 
to treatment with a human therapeutic dose of phénobarbital and a dose level known to 
induce thyroid follicular cell tumours in males.
Results clearly show that at the lower 0.25 mg/kg dose level there is no significant effect on 
thyroid hormones, TSH or liver UDPGT activities in either sex.
At the higher dose level (50 mg/kg), no significant effect of treatment was seen in females. In 
males, T4 levels were lower than controls throughout the treatment period. This led to a 
marked increase in TSH by day 33. Coincidental with these endocrine changes an 
approximate doubling of liver microsomal UDPGT was observed.
Current theory on the significance of these observations concerns the extrathyroidal 
mechanisms involved. It is thought that the reduction in T4 is due to increased peripheral 
metabolism due to enhanced conjugation by UDPGT. Reductions in T4 levels are associated 
with an earlier increase in this enzyme and lead to an increase in circulating TSH levels by 
day 33 of treatment.
Since T4 values fall before TSH levels rise, this is good evidence that phénobarbital affects 
thyroid hormone metabolism at a level below higher neural centres and that hypothalamic 
and or pituitary stimulation are caused by normal negative feedback and not by direct 
pharmacological or chemical action. The fact that plasma hormone levels are held at or near 
normal physiological limits when phénobarbital is administered at significant dose levels also 
supports this assumption. It seems very likely based on this evidence tha t, phénobarbital is 
likely to reduce thyroid hormone levels by mechanisms outside the thyroid pituitary axis.
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3.6. COMPARISON OF EARLY PHASE HORMONE CHANGES
3.6.1 Rationale
As previously discussed, some novel compounds tested in our laboratories have shown effects 
on thyroid function. A number of these are known microsomal enzyme inducing agents of 
the phénobarbital type. If as hypothesised, the observed thyroid effects are due to enhanced 
peripheral metabolism of thyroid hormones a consistent pattern of events might be seen if the 
effect of these compounds on T4, T3, TSH and UDPGT levels were studied and compared. 
The purpose of this study was to compare the effects of phénobarbital, propylthiouracil and 
novel compounds A12, BIO, C59 and D21 on the above parameters.
3.6.2 Study design
Groups of 10  male rats were treated with dietary doses of A12 (125 mg/kg), B10  (250 mg/kg), 
C59 (5 mg/kg), D21 ( 2 0  mg/kg), phénobarbital (50 mg/kg) and propylthiouracil (10 0  mg/kg) 
for a period of 8  days. Five animals were necropsied after being bled for hormone assays on 
days 3 and 8 . Samples of liver taken at necropsy were homogenised and microsomal 
preparations were made. These were assayed for UDPGT activity using p-nitrophenol as a 
substrate.
3.6.3 Results
For reference the following table summarises the findings observed in regulatory toxicology 
studies with the novel test materials.
3.6.3.1 Compound A12
No significant effect of treatment was observed. On day 8 , one of the animals had high
153
U D P G T  and microsomal protein levels.
3.63.2 Compound BIO
On day 3, a mild but statistically significant increase in mean UDPGT levels was observed.
No other significant effects were seen, although one animal had a low thyroxine and another 
a markedly elevated TSH. The apparent rise in T3 seen on day 8  did not reach a level of 
statistical sugnificance and was w ithin the limits of normal biological variation.
3.6.33 Compound C59
On day 3, a mild but statistically significant increase in TSH was observed. No other effect of 
treatment was seen. By day 8 , a moderate increase in UDPGT and mild increase in micro 
protein levels was observed. No effect on TSH or thyroid hormone levels was seen.
3.63.4 Compound D21
On day 3 a slight increase in UDPGT expressed per litre of liver homogenate but no effects on 
other parameters were seen. By day 8 , UDPGT was markedly increased but no effect on 
hormone levels was observed.
3.63.5 Phénobarbital
On days 3 and 8 , a mild but statistically significant reduction in T4 was observed. A marked 
increased in UDPGT and micro protein levels was also seen on day 8 .
3.63.6 Propylthiouracil
On day 3, a mild reduction in T3 was observed. By day 8  this was accompanied by a 
reduction in T4 and a marked increase in TSH and UDPGT. No effect on microsomal protein 
levels was observed.
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Figure 3.11: Early Phase Effects on Plasma T4 Values
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□  C o n t r o l
□  D a y  3
D a y  8
Treatm ent
Groups of 10 male rats were treated with dietary doses of Compounds A 1 2 (125 mg/kg), B10 (250  
mg/kg), C59 (5 mg/kg), D 21, (20 mg/kg), phénobarbital (50 mg/kg) or propylthiouracil (100 mg/kg) for 
8 days. Five animals from each dose group were bled for hormone assay on days 3 and 8. The above 
graph shows the relative effect of each compound on plasma thyroxine compared to pretest control
values
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Figure 3.12: Early Phase effects on Plasma T3 Values
T3 Values
= 0.8
j
T L x  _
B I O  C 5 9 A 12 D 2 I  PB
C o m p o u n d
P T U
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Groups of 10 male rats were treated with dietary doses of Compounds A12 (125 mg/kg), B IO (250  
mg/kg), C59 (5 mg/kg), D 21 , (20 mg/kg), phénobarbital (50 mg/kg) or propylthiouracil (100 mg/kg) for 
8 days. Five animals from each dose group were bled for hormone assay on days 3 and 8. The above 
graph shows the relative effect of each compound on plasma triiodothyronine compared to pretest
contro l values
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Figure 3.13: Early Phase Effects on Plasma Thyrotropin Values
T S H  V a l u e s
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Groups of 10 male rats were treated with dietary doses of Compounds A 12 (125 mg/kg), B IO  (250  
mg/kg), C59 (5 mg/kg), D 21, (20 mg/kg), phénobarbital (50 mg/kg) or propylthiouracil (100 mg/kg) for 
8 days. Five animals from each dose group were bled for hormone assay on days 3 and 8. The above 
graph shows the relative effect of each compound on plasma thyrotropin compared to pretest control
values.
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Figure 3.14: Early Phase Effect on Hepatic Microsomal UDPGT Values (U/g)
□  Control
T reatment
Groups of 10 male rats were treated w ith dietary doses of Compounds A12 (125 mg/kg), B IO  (250  
mg/kg), C59 (5 mg/kg), D 21, (20 mg/kg), phénobarbital (50 mg/kg) or propylthiouracil (100 mg/kg) for 
8 days. Five animals from each dose group were bled for hormone assay on days 3 and 8. Five  
an im als  from  each  dose group w e re  necropsied  on days 3 and 8 . sam ples o f live r w e re  
rem o ved , h o m o gen ised , m icrosom al pellets w e re  p ro d u ced  and w ere  assayed fo r U D P G T  
activ ity  using p -n itro p h e n o l as a substrate. T h e  ab o ve  graph show s the re la tive  e ffec t o f  each  
c o m p o u n d  on the activ ity  o f this e n zy m e  expressed as units per gram  o f live r
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3.6.4 Summary
PTU, the direct thyroid blocker showed a clear reduction in T4 and a concomitant increase in 
plasma TSH after treatment for the 8  day period. Figure 3.11 shows the effect that this 
compound has on the total T4 level. In this study, no other compound has a biologically 
significant effect on T4. Phénobarbital showed a statistical reduction in this parameter but the 
magnitude was considered of limited biological significance. A review of the TSH data in 
Figure 3.13 supports this hypothesis since only PTU showed evidence of increased TSH in the 
8  day period.
No effect on T3 levels was seen in this study (Figure
Most compounds affected UDPGT levels and could be graded according to the magnitude of 
the response (Figure 3.14). If it is assumed that such levels are maintained throughout periods 
of longer term treatment, it could be that compounds with higher levels would excrete thyroid 
hormones at a higher rate. Compound B10 had by far the most severe effect on this 
parameter. Others, could be classed as either having a marked effect ( phénobarbital, 
propylthiouracil and D 21 ), a moderate effect (C59) or no effect at all (A12). These data are 
summarised in the six graphs of Figure 3.15. All data are presented on the same scale so that 
data can be compared as a visual "fingerprint".
In conclusion, measurements of plasma thyroid hormones, TSH and hepatic microsomal 
UDPGT does not appear to be useful predictive markers of thyroid changes seen in long term 
toxicity studies. Although compounds could be ranked according to the magnitude of the 
UDPGT response, this appears to correlate with their known microsomal enzyme inducing 
properties rather than with any thyroid effect observed. The fact that the direct acting 
goitrogen, propylthiouracil also increases UDPGT activity restricts the usefulness of this 
enzyme as a predictive marker of abnormal thyroid pathology caused by microsomal enzyme 
inducing agents. However, thought must be given to two key points. Firstly , UDPGT is a
family of enzymes with multi substrate capacity. Although the use of p-nitrophenol as a 
substrate is thought to correlate with that of thyroxine metabolism, this is not the only UDPGT 
isoenzyme that might be affected. Secondly, the microsomal enzyme activities of all the 
compounds studied have been measured using surrogates such as ethoxyresorufin, as 
candidate substrates for a particular class of enzyme inducting agent. This approach is 
problematic when considering metabolic effects on specific substrates such as thyroxine or 
triiodothyronine. Careful consideration of the actual enzyme induction class or combination 
of one or more classes must be made.
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Figure 3 . 15 :  Comparative Effect of D ifferent Test Materials on Early Phase Endocrine 
Response
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3.7. INVESTIGATION OF ENZYME INDUCTION SUBCLASSES
3.7.1 Rationale
In the previous study designed to test the early stage effects of microsomal enzyme induction 
on endocrine parameters, hepatic microsomes were prepared for the assessment of UDPGT 
activities. These were derived from animals that had been dosed at a maximally tolerated 
level with compounds A12, BIO, C59, D21, Phénobarbital and propylthiouracil. These 
microsomes were further investigated using three principal methods of classifying compounds 
according to electrophoretic profile or enzyme induction subclass.
In the first section, sodium dodecylsulphate (SDS) electrophoresis and densitometry were used 
to determine the incidence, magnitude and molecular weight of the principal proteins 
induced by each compound.
In the second section, SDS gels were electroblotted onto nitrocellulose. These were then 
subjected to enhanced chemiluminescence to systematically probe and classify the 
compounds according to type of enzyme induction observed. Specific antibodies to CYPIA1 
IA2, IIB1/IIB2, I HA, I VA AND IIE1 were used.
Finally, the results of attempts to classify each compound according to enzyme induction 
subclass using classical surrogate substrates is presented. The enzymes measured include 
total cytochrome P450, cytochrome b5, lauric acid hydroxlase, ethoxycoumarin deethylase, 
aldrin epoxidase, ethoxyresorufin deethylase and pentoxyresorufin dealkylase.
3.7.2 Results
3.7.2.1 SDS electrophoresis
A typical electrophoretogram of microsomal proteins separated by sodium dodecylsulphate 
electrophoresis is shown in Figure 3. 16. Eight bands of protein that were visualised by silver
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sta in ing can c le a rly  be seen. Lane 1 con ta ins  a series o f m o le c u la r w e ig h t m arkers ranging  
from  1 4 .4  to 9 4  D a lto n s  these w ere  used to c a lib ra te  the subsequent m o le c u la r w e ig h t  
d ete rm in a tio n s . Lane tw o  w as a contro l sam ple  taken from  an untreated  rat. T h e  o th er lanes  
(3 -8 ) c o n ta in e d  sam ples from  rats treated  w ith  C o m p o u n d s  A 1 2  (1 2 5  m g/kg), B IO  (2 5 0  
m g/kg), C 5 9  (5 m g/kg), D 21 (2 0  m g/kg), p h é n o b arb ita l (5 0  m g/kg) and p ro p y lth io u ra c il (1 0 0  
m g/kg).
Figure 3. 16: SDS Electrophoresis of Hepatic Microsomal Proteins
"Mr
:o
67'
MW C B10 C59 A12 D21 PB PTU
LANE 1 2 3 4 5 6 7 8
It is not possib le to spec ific a lly  id en tify  proteins by  e lectrophores is  and d en s ito m etry . T h e  
o n ly  in fo rm atio n  that can g leaned  w ith  som e degree  o f c o n fid e n c e  are th e  m o le c u la r w eigh ts  
o f the  separated proteins. This w as perform ed as described  in Section 3 .7 .2 .2 .
C lose scru tiny o f the prote in  bands in seen in treated  an im als  s how ed  a s ig n ifican t increase  
p a rtic u la r ly  in those proteins averag ing  4 3  to 5 5  D a lto n s . These are h ig h lig h ted  b y  the  use o f  
a red b ox  in the ab ove  e lec tro p h o re to g ram . T h e  observation  is in accord  w ith  the  various
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different forms of cytochromes P450 that in rodents, are known to have molecular weights in 
the range 48 to 55 Daltons (Welton et a i 1975 and Haugen and Coon 1976). The relative 
density and hence approximate concentration of each protein band was determined by 
densitometry
3.7.2.2 Calculation of molecular weights
As described in an earlier Chapter, sodium dodecyl sulphate (SDS) electrophoresis provides a 
linear separation of proteins in the range 14 to 10 0  Daltons. This means that mobilities, 
measured in terms of migration distance, are proportional to molecular weight. Since each 
electrophoretic run included marker proteins of defined molecular weights, a standard curve 
could be drawn. This was then be used to determine the molecular weight of each unknown 
protein band.
The results of the densitometry and molecular weight determination are presented in Figure 3. 
17. From this it can clearly be seen that each compound has a similar but slightly different 
protein profile. A number of peaks concur and are present in both test and control samples. 
For example, consideration of the protein band presumed to be albumin at 67 Daltons 
showed the phénobarbital sample had the highest level whilst the PTU sample had the 
lowest.
In order to highlight the specific bands affected by treatment with the test compounds, the 
peak height value obtained for the control sample was subtracted from that obtained for each 
test material. These results are presented in Figure 3. 18.
3.7.2.2.1 Compound A12
Significant peaks for this compound occurred at 27 and 30 where most of the other 
compounds have values that are lower than control. Other peaks occurred at 37, 42, 43, 63, 
94, 111,137,and there was a large increase in proteins in the molecular weight range from
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149-179. There was a significant reduction at peak 39.
3.7.2.2.2 Compound BIO
This was the most atypical compound of the group. Close examination of Figure 3 . 18 shows 
the effect to be due to a phase shift in peaks at these positions i.e. the peaks are present but 
have migrated to a greater or lesser extent than the corresponding control.
3.7.2.2.3 Compound C59
This test material showed the least effect with peak heights and positions that were very 
similar to control. Exceptions to this were an increase at 42, 43 and a decrease at 30 and 39.
3.7.2 .2.4 Compound D21
Compound D21 also had a similar pattern to the control. The major differences can be seen 
at 37, 43, 94, 96, 137 and in the range 149-179
3.7.2.2.5 Propylthiouracil
Propylthiouracil also had a protein pattern that was similar to control. The exception to this 
rule was the peak that is unique to PTU and the control which occurred at 125. Peaks that 
were higher than control occurred at 21, 42-43, 94 and in the range 149-165. Peaks that 
were lower than control occurred at 14, 30, 34, 39 and 67
3.7.2.2 .6  Phénobarbital
This compound showed peaks that were in a similar position to the control but that were 
much higher in some areas. Significantly higher values occur at 21, 26,37, 42, 43, 50, 55,
67, 94, 96, and in the range 148-179. A lower result was seen at 39 Daltons.
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3.7.2.3 Western Blotting and Immunological Staining
As stated previously, SDS electrophoresis is an excellent separation technique but is limited 
by the inability to identify the proteins concerned. Also, the acrylamide matrix prevents the 
further identification of proteins by specific staining techniques because the sample is 
embedded in an insoluble matrix. By extracting the sample from the matrix by Western 
blotting and applying immunologically linked stains, individual proteins can be identified. 
Amersham International has developed specific methods for the detection of a variety of 
specific cytochromes P450 by enhanced chemiluminescence.
Microsomes prepared from animals treated with Compounds A12, BIO, C59, D21 and 
propylthiouracil together with positive control microsomes from animals treated with ethanol 
(IIE1), (3- napthaflavone (IA1), phénobarbital (IIB1/2), clofibrate (IVA), pregnenolone - 16a- 
carbonitrile (111 A) and isosafrole were subjected to SDS electrophoresis. The separated 
proteins were electroblotted onto nitrocellulose membranes and were probed w ith a selection 
of antibodies to the cytochrome P450 subclasses (shown in brackets in previous paragraph). 
The results for each compound are shown in Table 3. 8 .
Each isoenzyme measured, occurred either as a constituative protein, present in normal 
microsomes but that could be induced to a higher concentration by chemical treatment, or a 
protein that was not present in control microsomes but was induced to detectable levels by 
the effects of enzyme induction
The results obtained for the positive control materials clearly show the anticipated induction 
of IA1/2 by p-napthaflavone and isosafrole, IIB1/2 and IIIA by phénobarbital, IIIA by 
pregnenolone-16a-carbonitrile and IVA by clofibrate.
The results obtained for the novel pesticidal products were as follows:
Compound A12 induced IA1 and had the normal constituative levels of NIA, IE1 and IVA.
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C o m p o u n d  B1 0  and C 59  in d u c e d  IIB 1 /2  and had norm al constitua tive  levels o f the o th er  
isozym es.
C o m p o u n d  D 21 in d u ced  IIB 1 /2  and IIIA  and had constitua tive  levels o f the o th er isozym es. 
An e x a m p le  o f a p h o to g rap h ic  film  p ro d u ced  using e n h a n ce d  c h em ilu m in e sc e n ce  is 
presented in Figure 3 . 19 . T h e  film  shows a serial d ilu tio n  o f p h én o b arb ita l in d u ced  
m icrosom es probed  w ith  an a n tib o d y  to C YP IIB 1 /2 . T h e  m u ltip le  prote in  track show n in the  
rig h t-h an d  lane  is a m o le c u la r w e ig h t m arker c o n ta in in g  Phosphorylase b (9 7 4 0 0  D a lto n s ), 
C atalase (581 0 0 ), A lco h o l dehydrogenase (3 9 8 0 0 ) , C arb o n ic  anhydrase (2 9 0 0 0 ) ,  Trypsin  
in h ib ito r (2 0 1 0 0 ) and Lysozym e (1 4 3 0 0 ) . It can be seen th at the C YP IIB 1 /2  has a m o le c u la r  
w e ig h t s ligh tly  less than 5 8 1 0 0 . This  is consistent w ith  o th er p u b lications .
Figure 3. 19: Serial d ilu tio n  o f C YP IIB 1 /2
-m m
Table 3. 8: Western Blotting Results
CYTOCHROME P450
Treatment IA1 IIB1/2 IIIA IIE1 IVA
A1 2 (1 25 m g/kg) + - + + +
B1 0  (2 5 0  m g/kg) - + + t +
C 5 9  (5 m g/kg) - + + + + I
D 21  (2 0  m g/kg) - + + + |
P ro p y lth io u rac il (1 0 0  m g/kg) - - + + +
Ethanol (IIE1 ) - - + +
P -n ap th a fla vo n e  (IA1 ) 'M * - + + +
P h énobarb ita l (IIB 1 /2 ) - + +
C lo fib ra te  (IV A ) - - + +
P regneno lone-1  6 a -c a rb o n itr ile  (IIIA ) - - ■H- - +
Isosafrole (IA 2) + - + + +
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Positive control materials were used as supplied. Dose information was not supplied.
3.7.3 Measurement of Specific Microsomal Enzymes
As described in the materials and methods section, data was extracted from archived studies 
for comparison with the immunological assays described above. The enzymes described are 
those conducted by the Toxicokinetics Section of AgrEvo UK Ltd as the routine toxicological 
profile. Since the studies conducted span several years the choice of assays performed has 
changed with time and similar assays are not available for each of the compounds studied. 
No data is available for Compound A12.
The data recorded for each compound studied are presented in p.fc:.0.
1 7 0
Table 3.9. These included liver weight (g/100 g bodyweight), microsomal protein (mg/g liver), 
total cytochrome P450 and cytochrome b5 (nmol/mg protein), ethoxyresorufin-O-deethylase, 
EROD., lauric acid hydroxylase, LAH. and pentoxyresorufin-O-dealkylase PROD., 
ethoxycoumarin deethyl ase ECD., and aldrin epoxidase AE., (nmol/min per mg protein).
For the positive control materials results clearly showed the induction class of each 
compound. Clofibrate increased liver weight, microsomal protein, cytochrome P450 and 
LAH. The latter enzyme being increased 3.4 times control values. 
p-Napthaflavone increased liver weight, cytochrome b5 and EROD. The latter increased 
almost 17 times control.
Phénobarbital increased all parameters except LAH. PROD being increased by 177 times 
control values.
Compound BIO showed very mild effects in comparison with positive control materials. 
Statistically significantly increased liver weight, EROD and PROD activities suggested very 
mild induction of enzymes in the IA1/2 and IIB1/2 sub classes.
Compound C59 was seen to show a similar magnitude and profile of induction as 
phénobarbital. It increased all parameters except LAH and cytochrome b5 and PROD was 
increased by 158 times control levels.
Both sexes were tested in the study involving Compound D21. This was fortuitous since clear 
sex differences control values and in response to test materials can be seen. Ethoxycoumarin 
deethyl ase and aldrin epoxidase activities were clearly lower in females by 40% and 80% 
respectively. The response to test material administration was more marked in males. All 
parameters measured were statistically significantly higher in this sex. In females, liver 
weights were unaffected by treatment but microsomal protein, cytochrome P450, EROD and 
LAH were all slightly higher than corresponding controls.
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3.7.4 Summary
The effects of the variety of chemical treatments used can clearly be seen using SDS gel 
electrophoresis and densitometry. Similar protein patterns but significant quantitative 
differences in certain molecular weights were observed. Specific consideration of 
cytochrome P450 activities by examination of proteins in the range 43 to 55 Daltons showed 
five principal peaks at approximately 43, 50, 52, 55 and 57 Daltons.
At the dose levels selected, phénobarbital was generally the most potent microsomal enzyme 
inducing agent of this group of chemicals. It induced significantly more proteins at a higher 
level than the others.
The isoenzymes measured by Western Blotting followed by antibody detection using 
enhanced chemiluminescence are CYP IA1/2, IIB1/2, IIIA, IIE1 and I VA. Positive results were 
obtained for IA1/2 by (3-napthaflavone and isosafrole, IIB1/2 and IIIA by phénobarbital, IIIA 
by pregnenolone-16a-carbonitrile and IVA by clofibrate.
Normal constituative levels of IIIA, IE1 and IVA were seen with the majority of the novel 
pesticide! products tested. Cytochrome 11 El is present in the microsomes of normal untreated 
animals but is enhanced by the administration of compounds such as ethanol and isoniazid. 
Cytochrome 4A is present in significant quantities in microsomes derived from untreated 
animals. Biochemically, this family of isoenzymes are involved in the co-hydroxylation of 
I au rate, the first step in the oxidation pathway of fatty acids. Certain hypolipaemic drugs such 
as clofibrate and fluorinated fatty acid derivatives such as perfluorodecanoic acid are potent 
peroxisome proliferators which induce this family of cytochromes.
From the above results it can be concluded that at the dose levels selected, none of the novel 
pesticide! products are peroxisome proliferators. However, significant levels of induction 
were seen for the following. Compound A12 induced IA1/2 to a similar amount as isosafrole 
but less than (3-napthaflavone. Cytochromes IA1 are unique in their affinity for planar
molecules and frequently metabolise these compounds to carcinogenic metabolites. There 
are two IA subfamilies, cytochrome IA1 and IA2  that are not differentiated by this assay, . 
which cross-reacts with IA1 and IA2  isoenzymes and which are not detectable in microsomes 
derived from untreated control animals. Cytochromes IA1 are principally induced by 
polycylic aromatic hydrocarbons such as benzpyrene and whilst IA2  is induced by amides 
and amines such as arylamines. The result obtained for Compound A12 is somewhat 
surprising since it is a non-planar azole with no amide or amine sub-grouping.
The classic cytochrome P450 IIB1 and IIB2 family of isoenzymes are induced by the 
administration of barbiturates and steroids. They are not detectable in microsomes derived 
from untreated control animals but are strongly induced by treatment with compounds such 
as phénobarbital. The amino acid sequence in each isoenzyme is very similar hence the 
antibody used in the assay detects both forms. Compound BIO and C59 were inducers of 
IIB1/2 but to a lesser amount than phénobarbital (PB). Unlike PB, these compounds did not 
induce IIIA.
Compound D21 had a very similar profile to PB. It induced IIB1/2 and IIIA but the former 
was not as significantly induced as it was with PB. Cytochrome IIIA is induced by steroids 
such as pregnenolone-16a-carbonitrile and dexamethasone as well as by phénobarbital and 
some antibiotics. The enzymes are sexually differentiated and levels decline after sexual 
maturation in female but not male rats. The enzymes concerned have physiological roles and 
as such are particularly involved with androstenedione and testosterone hydroxylation. 
Propylthiouracil did not show any evidence of microsomal enzyme induction.
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CHAPTER 4: A STUDY OF PROLIFERATIVE LESIONS IN RAT
LEYDIG CELLS
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4.1. Introduction
In previous Chapters, the physiological processes that link microsomal enzyme induction and thyroid 
hormone metabolism were discussed. In a study designed to monitor the consequence of 
microsomal enzyme induction, proliferative lesions in male but not female thyroid follicular cells was 
seen in a two year dietary phénobarbital study in rats. An unexpected, significant effect on the testis 
was also seen in this study, which was not considered to be linked directly to the main theme of this 
thesis. After 12  months of phénobarbital treatment, animals had heavier testes than corresponding 
controls. In view of the sex-related difference in tumour incidence, it was decided retrospectively to 
study the significance of this observation.
The purpose of this Chapter is to describe the testicular pathology, summarise the results of some 
additional hormone assays that were performed and to discuss the possible significance and 
relevance of these observations. To orientate the reader, the discussion opens with a review of 
testicular biology.
4.1.1 Testicular structure and Function.
4.1.1.1 Embryology
Embryologically the testis develops from the undifferentiated tissue of the gonadal ridge, a 
condensation of tissue near the adrenal gland. During the third week of gestation, the germ cells 
migrate to this ridge from the yolk sac endoderm. The gonad develops a cortex and a medulla; the 
former differentiates into the ovary in females whilst the latter, during the weeks 7  to 8  of gestation 
develop into the testis.
The testis contains interstitial cells, which consist of Leydig cells (1950), connective tissue, blood and 
lymphatic vessels, fibroblasts and macrophages. The origin of the Leydig cells and the Sertoli cells 
(Sertoli, 1965) of the seminiferous tubules is much debated. Some researchers assume that these are
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derived from a common stromal precursor cell, whilst others believe that the sex cords arise from a 
down growth of the surface epithelium into the gonad. In genetically male embryos, testosterone 
from Leydig cell, drives the germ cells in the sex cords to aggregate and differentiate into the 
seminiferous tubules.
Throughout gestation there is a progressive transition from sex cord to seminiferous tubules and these 
ultimately connect to the excretory duct system, derived from the mesonephric duct. Seminiferous 
tubules converge and integrate with the rete testis tubules to link with the efferent ducts of the 
proximal epididymides. These efferent ducts then continue as the vas deferens and seminal vesicles. 
From this stage onwards, an embryo containing functional testes w ill derive male characteristics that 
are solely due to testosterone. In rats a brief exposure to testosterone at this stage of development 
leads to male patterns of; sexual behaviour, hypothalamic control of gonadotropin secretion and 
hepatic metabolism.
4.1.1.2 Structure
A dense connective tissue capsule, the tunica albugenea, surrounds the adult testis. This consists of 
loops of convoluted seminiferous tubules. Non-motile spermatozoa (sperm) are produced in these 
loops and drain from both ends into the epididymides and in to the vas deferens. At the time of 
ejaculation, seminal fluid enters the urethra through ejaculatory ducts in the body of the prostate. On 
contact with the seminal fluid sperm are prompted to become motile.
The anatomy of the seminiferous tubule is complex and forms an essential blood-testis barrier. 
Characteristics of the basal lamina supporting the Sertoli cells, plus the tight junctions between these 
cells are the basis of the barrier. It provides optimum conditions for the development of sperm. The 
barrier limits diffusion of chemicals into the tubules and provides a protective physiological barrier 
against toxins.
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4.1.1.3 Function
At birth, the testes contain small, closely packed tubules without lumina. Germ cells are present and 
the interstitial tissue contains Leydig cells. Gonadal development in all mammals becomes quiescent 
at this stage and the Leydig cells disappear w ithin a few weeks.
The testes do not achieve adult size and function until the pituitary is triggered to release 
gonadotrophins at puberty. Although gonadotrophins are present prior to puberty, this sudden 
change in circulating concentration activate the dormant Leydig cells and stimulates spermatogenesis 
(Odell, 1979). In mature rats Leydig cells comprise almost 3% of the testicular volume (Mori and 
Christensen 1980) and produce large quantities of testosterone. Once mature, an animal is wholly 
reliant on the pituitary to maintain the gonads. In the male, hypophysectomy leads to testicular 
atrophy. This is because the gonadotrophins lutropin (LH) and follitropin (FSH) maintain the 
principal functions of the testis, which are to produce sperm and androgens.
4.1.1.3.1 Spermatogenesis
In the Sertoli cells, interaction of FSH with a receptor stimulates a number of second messengers 
including cAMP and Ca++ (Bardin et al., 1988). This leads to cell division, protein secretion and 
energy production. Lactate is the principal energy source. At puberty, spermatogenesis is initiated 
under the control of FSH. In the seminiferous tubules the spermatogonia on the basal lamina, mature 
into primary spermatocytes, which undergo meiosis. This is a two-stage process, during which they 
divide into secondary spermatocytes and then into spermatids with a haploid number of 
chromosomes. These mature into spermatozoa in deep folds of cytoplasm within Sertoli cells.
4.1.1.3.2 Testicular steroidogenesis
The second principal function of the testis is to synthesise the male sex hormone, testosterone. The 
enzymes of the testosterone synthesis pathway are complex and compartmentalised and unlike the
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adrenal cortex, where 1 1  and 2 1  hydroxylases are present, the testis contains only 17a-hydroxylase. 
This distribution of steroidogenic enzymes means that testosterone is only secreted in significant 
amounts by the testis. Castration or destruction of Leydig cells reduces plasma testosterone to very 
low levels. The small residual amount is presumed due to a negligible contribution from the adrenal. 
As rats mature, testosterone levels decline (Chan et a i, 1977) due to a reduction in circulating LH 
values.
The Leydig cells in the interstitial spaces of the testis synthesise testosterone from cholesterol via 
pregnenolone. Cholesterol is produced locally by synthesis from acetate in the smooth endoplasmic 
reticulum or is derived from circulating low density lipoproteins. The first step, the side-chain 
cleavage of cholesterol, occurs via a cytochrome R-450 mediated reaction involving a yellow 
flavoprotein (diaphorase), a non-haem iron protein (adrenodoxin) and reduced nicotinamide adenine 
dinucleotide phosphate (NADRH). It is believed that this limited electron transport system transfers 
two electrons from NADRH to the terminal oxidase P-450. This process is located on the inner 
mitochondrial membrane (Yago, 1970) and it is proposed that the transfer of cholesterol to this 
location is the rate lim iting step. The biochemical process is believed to include the stepwise 
conversion of cholesterol to 2 0 a-hydroxycholesterol to 2 0 a, 2 2 -dihydroxycholesterol and then to 
pregnenolone.
Pregnenolone synthesised by the above route is transferred out of the mitochondrion and into the 
smooth endoplasmic reticulum. Here, there are two main pathways for testosterone production one 
via dehydroepiandrosterone and the other via progesterone; the so called A5 or A4 pathways 
respectively. In the rat both occur in the microsomal fraction. As can be seen in the Figure 4.1, it is 
possible for the pathways to interconnect by the enzymatic action of 3p-hydroxysteroid hydro gen ase 
(3bOHSD) and A4'5-3 ketosteroid isomerase (iso). Essentially, pregnenolone and progesterone are 
hydroxylated at the 17 position (by the 17a hydroxylase present in testis but not adrenal) yielding 
17a-hydroxpregnenolone and 17a-hydroxyprogesterone. Desmolase (17-20 lyase) then acts on each
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product to produce dehydroepiandrosterone (DHEA) and androstendione respectively.
In addition to the action of 3(3-hydoxysteroid hydrogen ase (3bOHSD) to convert DHEA to 
androstenedione, DHEA can also be converted to A5-androstenediol (d5-androstenediol).
Testosterone is formed at the terminal step in each pathway either by the effect of (3bOHSD) on A5- 
androstenediol or by the action of 17p-hydroxysteroid dehydrogenase (1 ZbOHSD) on 
androstendione.
The testosterone pathway is complex and branching. It is conceivable that the route selected for the 
synthesis of testosterone is dependent on the species, the substrate available and the interaction of 
other biochemical processes w ithin the cell, e.g., availability of substrate and the selective induction 
of enzymes. The substrates available do not appear to be uniformly distributed. For example, 17a 
hydroxyprogesterone appears to be free to diffuse throughout the cell whereas progesterone is 
selectively concentrated w ithin the smooth endoplasmic reticulum (Matsumoto and Samuels. 1974). 
Hence, provided the supply of progesterone is constant, this would presumably be the preferred and 
less regulated route; the other route being limited by the rate of diffusion of 17a hydroxyprogesterone 
from other parts of the cell.
In primates and in the rat, testosterone is not secreted continuously but is released in a pulsatile 
manner over each 24 hour period. Some other animals, which are seasonal breeders, produce 
testosterone cyclically in breeding seasons. The regulation of testicular steroid synthesis is driven by 
the pituitary via LH (Creep and Fevold, 1937). This has been demonstrated in vitro by Catt et al., 
(1972), who demonstrated that testosterone was produced from endogenous precursors when LH was 
added to a rat testicular preparation. The mechanism by which this process occurs has not been 
defined although it is known that it is dependent on FSH for the induction and maintenance of Leydig 
cell LH receptors.
In man plasma LH values tend to increase with age. However, in the rat LH tends to decline as the 
animal gets older (Rubens, R. et al., 1974). This effect is probably due to the age related decline in
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LH production observed in this species (Prentice and Meikle 1995).
Figure 4.1 : Biosynthesis and Metabolism of Testosterone
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4 .1 .1 .3 .3  Role o f Testosterone
Testosterone, a n d ro sten ed io n e  and d eh yd ro e p ian d ro s te ro n e  are the p rin c ip a l a n d ro g e n ic  horm ones  
in m ost m a m m a lia n  species. Testosterone is a p ro h o rm o n e  since it is con verted  to the  m ore  ac tive  
dihydroxytestosterone  and  to oestrad io l in periphera l tissues by  5 a -re d u c ta s e  and  arom atase  
respectively . T h e  latter ac tiv ity , w h ic h  can o ccu r in the Leydig cell acts to in h ib it testosterone  
p ro d u c tio n . In the liver, testosterone is m etabo lised  to the less p o ten t andro stero ne  and  
d ehydro an d ro stero n e , both o f w h ic h  are fo u n d  in u rine  as in active , su lphate  and  g lu c u ro n id e
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Testosterone is both a paracrine and endocrine hormone. In the latter role it is considered to have a 
number of functions. It is essential for the development of the accessory sex glands and external 
genitalia leading to penile and scrotal development and growth as well as prostate, seminal vesicle 
and bulbourethral gland growth and secretion. It affects skeletal muscle by enhancing protein 
synthesis and hence nitrogen retention. It initiates epiphysial closure and hence affects bone 
structure. It has mineralocorticoid activity, which leads to sodium, potassium, calcium, sulphate, 
phosphate and water retention. It affects hair growth, e.g., beard and hair loss, e.g., male pattern 
baldness. It increases sexual libido, Sertoli cell maturation and androgen-binding protein synthesis. 
Testosterone is also the principal paracrine hormone of the testis and as such is responsible for 
maintaining spermatogenesis (Parvinen and Ruokonen, 1982). There are a number of other 
substances in the testis that have paracrine activities. A number affect the Leydig cells and include 
LHRH-like peptide, transforming growth factor-p, insulin-like growth factor -1, inhibin, and activin 
(Lin et al. 1989). The whole endocrine paracrine process is interactive and principally controlled by 
the hypothalamic-pituitary-testicular axis. A diagrammatic representation of testicular control is 
presented in Figure 4.2.
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Figure 4.2: Hypothalamic-Pituitary-Testicular Axis
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Testosterone and LH form a classic metabolic feedback loop between the testis and the pituitary. As 
testosterone is metabolised and the plasma level decreases, so the hypothalamus is prompted to produce LH 
releasing hormone (LHRH) to activate the pituitary to release LH. This in turn activates the testis via LH 
receptors on the surface of the Leydig cell. W hen compared to man, the rat has a disproportionate number of 
LH receptors. There are 1500/cell and 20,000/cell in the respective species. The significance of this 
observation is not known but in each species occupation of the LH receptor leads to activation the classic cyclic 
AM P second messenger system and testosterone is produced. In rats, the number of LH receptors increases with  
age although due to decreasing LH concentrations the amount of testosterone secreted declines (Chan et al., 
1977).
Interestingly, in addition to LH receptors the rat Leydig cell also has LHRH receptors w hich when activated by a 
paracrine hormone (LHR H -like factor) secreted by the Sertoli cell w ill initiate testosterone production. The rat 
appears to be unique in this respect (Prentice and M eikle  1995).
FSH acts on the Sertoli cells, where it stimulates spermatogenesis, again via cAM P as a second messenger. The 
Sertoli cells also produce Inhibin, a polypeptide that is thought to close the feedback loop by an effect on the 
pituitary gonadotrophs or directly on the hypothalamus. There is evidence that FSH, and perhaps prolactin 
increase and maintain the number of LH receptors on Leydig cells (Z ipf et ah, 1978).
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4.1.2 Leydig cell neoplasia
Differentiation of Leydig cell hyperplasia and neoplasia is not possible in morphometric terms. Size 
of lesion is the accepted discriminator with proliferative lesions greater than the diameter of a 
seminiferous tubule being classed as a tumour (Boorman et a i, 1990). In toxicological terms, since 
hyperplasia and neoplasia are considered on a continuum, they are usually presented as pooled 
incidences.
Leydig cell tumours are the most frequently observed testicular neoplasm in rats irrespective of 
method of induction. Spontaneous neoplasia is an age-related phenomenon some strains of rats, 
notably Fischer 344, which may show an incidence approaching 100% in lifespan studies (Boorman, 
et a i, 1990). Leydig cell proliferation in other species is not common.
A number of different agents are known to cause Leydig cell neoplasia. These include irradiation, 
carcinogenic hydrocarbons, hormones alone or in combination with other agents, subtotal castration, 
mechanical trauma, zinc or copper salts, cadmium, acetoaminofluorene and nitrosopyrrolidine 
(Mostofi et al., 1990). According to these authors, the affinity and specificity of LH and PRL receptors 
on such tumours are similar to that found in non tumourous tissues. However, the quantity of 
receptors is greatly altered. They found the numbers of LH receptors in tumours were almost 10 0  fold 
lower than normal control tissues and these were further decreased (XV*) if tumours were transplanted 
into hypophysectomised rats. Prolactin (PRL) receptors in tumours were only slightly lower than 
normal rats but were 2 0 % lower in tumours grown in hypophysectomised rats. LH and PRL 
receptors varied greatly between tumours but were always in the same ratio and were responsive to 
pituitary hormones. However, the cAMP response to LH, in Leydig cell tumours, was half that found 
in normal testis.
4.2. Materials and methods
The samples used were obtained from the two studies described earlier but summarised below:
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Study 1 : A two-year carcinogenicity study conducted in Sprague Dawley rats details can be found in 
Chapter 2. Sixty animals of each sex per group were given phénobarbital by dietary admixture (50 
mg/kg per day). Control groups received untreated diet.
Study 2: In the study designed to investigate early phase hormone changes described in Chapter 3, 
sexually mature animals were treated with phénobarbital at a maximally tolerated dose level (50 
mg/kg).
4.2.1 Histopathology
In the two year study (Study 1), animals were killed by exsanguination via the abdominal aorta, under 
deep ether anaesthesia. The testes were removed and weighed after 12 and 24 months of treatment 
and were fixed in 10 % neutral buffered formalin. Following fixation, the testes were routinely 
processed, sectioned (4 pm) and stained with haematoxylin and eosin. Slides were examined by Mr I 
R. Major, Pathologist, AgrEvo UK Ltd, using standard light microscopy. For observed lesions, the 
severity was graded on a semi-quantitative scale. Results were collated, processed and reported using 
a computerised pathology system (ROELEE 84).
No samples were taken in Study 2
4.2.2 Hormone assays ■
In both studies, the limited amount of plasma that remained from previous work had been stored 
deep-frozen at minus 7CPC. This was used to investigate the mechanism of the effect seen on Leydig 
cells. Relatively large volumes of sample are required for radioimmunoassay and an insufficient 
amount was available for detailed study. The results presented are therefore limited to: 
a: measurements of certain pituitary hormones during month 12 of the two year study (Study 1 ) 
b: testosterone, measured (in sing!icate) prior to dosing and 24, 48 and 96 hours after the start of 
treatment with 50 mg/kg phénobarbital in Study 2.
Rat specific lutropin, somatotropin and prolactin were measured using radioimmunoassay kits
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supplied by Amersham, Aylesbury. Assays were calibrated against reference standard preparation 
(NIH-RP2) provided by the National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK), Baltimore, USA.
Testosterone was measured using an Immunochem Testosterone kit supplied by ICN Biomedicals, 
Ltd, Thame, Oxfordshire.
4.3. Results
4.3.1 Histopathology
Phénobarbital fed to rats at a dietary dose level 1000 ppm led to an increased incidence of 
hyperplastic foci and Leydig cell tumours in treated animals after two years of treatment. The 
combined incidence of hyperplastic foci and benign tumours was 8 %. No foci or tumours were seen 
in control animals.
No effects were seen in testes sampled at the 12 month stage.
Photomicrographs of principal finding are presented on the following pages.
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Photom icrograph 4.1 Testis C ontrol ( X I50)
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Portions o f three sem in iferous tubules (S) can be seen in this 
p h o to m ic ro g rap h  o f a section o f rat testis. In the centre  a group o f 
in terstitia l cells (I) can be seen.
Photom icrograph 4 .2  Testis Leydig Cell Focal Hyperplasia (X1 50)
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This section also shows portions o f three sem in iferous tubules (S). 
H y p e rp la s ia  o f the Leydig cells in the in terstitium  (I) can c learly  be  seen.
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Photom icrograph 4 .3  Leydig Cell Benign Tum our (X I 50)
This section o f rat testis, show n at the same m ag n ifica tio n  as the  
prev ious tw o , has no e v id e n c e  o f sem in iferous tubules due to the  
presence o f a ben ign  tu m our.
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4.3.2 Hormone Assays
4.3.2.1 Testosterone
Radioimmunoassays are by nature, less reproducible than other clinical pathology parameters. For 
this reason, assays are traditionally run in duplicate. When dealing with small laboratory animals this 
is not always possible or practical. It is often considered more appropriate to get some (less precise) 
data than to have no data at all. This is the case with the follow ing set of testosterone values. A 
small volume of residual sample had been saved from previous assays and had been stored deep- 
frozen at -70°C. This was used in a testosterone assay where samples (but not standards or controls) 
were run in "singlicate". Results are presented in Figure 4.3. Testosterone values were very variable. 
Control values ranged from 1.3 - 17.5 nmol/l and treated animals had results in the range 1.7 - 12.3 
nmol/l. Predose means were similar in both groups. After 24 hours of treatment testosterone values 
in treated animals were higher (132%) than corresponding controls. In the period 24 to 48 hours 
after the start of dosing, testosterone values were lower than corresponding controls by 4 9 % and 32% 
respectively. None of these observations reached a level of statistical significance.
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Figure 4.3: Testosterone Results in Rats Dosed with Phénobarbital (50mg/kg)
18 T
16
14
12
10o
Ec 8
6
4
2
0
o
%
CL
Time
B Control b  Phénobarbital (100 mg/kg)
4.3.2.2 Pituitary Hormones
In o rder to e va lu a te  effects o f p h én o b arb ita l ad m in is tra tio n  on the  p itu ita ry  the fo llo w in g  assays w ere  
perfo rm ed . Plasm a sam ples, o b ta in e d  at necropsy by  e x a n g u in a tio n  from  the  a b d o m in a l aorta  un d er 
ether anaesthesia, w ere  assayed for lu tro p in , som ato trop in  and p ro lac tin . Results are presented in 
T a b le  4 .1 . N o  s tatistica lly  s ig n ifican t effects o f trea tm e n t w e re  observed fo r any  p a ra m eter m easured. 
Lutrop in (LH ) values seen in treated  and control an im als  o f both sexes w e re  very  s im ila r.
G ro u p  m ean  som atotrop in  (G H ) values seen in fe m a le  contro l an im als  w e re  h ig h er than  those  
observed in m ales. H o w e v e r , the an a ly tica l varia tio n  w as high and  the observed  ranges w e re  s im ilar; 
1 2 .9  - 7 9 .8  ng/m l and 6 .9  - 8 2 .4  ng/m l in fem ales  and  m ales respectively . P h én o b arb ita l trea tm e n t 
lead to a very  slight decrease in G H  in both sexes.
P ro lactin  results w e re  also d iffe ren t b e tw ee n  sexes; fe m a le  controls  group m ean w as th ree  tim es  
higher than the m ale . T rea tm e n t w ith  P hénobarb ita l lead  to a reduction  in group m ean  PRL values.
In both  sexes, values w e re  a p p ro x im a te ly  h a lf those seen in the  controls.
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Table 4.1: Pituitary Hormone Results in Rats treated with Phénobarbital (50mg/kg)
Parameter Control Phénobarbital 
50 mg/kg
Male Female Male Female
Lutropin (LH) 2 . 6 2.7 2.4 2 . 8
ng/ml (2.4) (0.5) (0.3) (0.5)
Somatotropin (GH) 17.1 34.9 13.7 26.9
ng/ml (23.1) (23.1) (7.1) (8.3)
Prolactin (PRL) 26 91 13 49
ng/ml (17) (48) (8 ) (49)
4.4. Discussion
In a two year feeding study, phénobarbital administered at 50 mg/kg caused Leydig cell hyperplasia 
and adenomas. Phénobarbital administered to rats has not previously been reported to cause Leydig 
cell proliferation and so a mechanism has not been defined. Phénobarbital is not thought to be 
genotoxic and has not caused increased incidence of testicular tumours in humans treated for 
epilepsy (Olsen et a/., 1989) and has not caused testicular tumours in other species tested (IARC 
1977, 1978). For this reason, it was considered likely that an indirect non-genotoxic mechanism was 
the cause of the Leydig cell adenomas seen in rats.
A number of mechanisms could account for Leydig cell tumourigenesis. Disruption of the 
hypothalamic-pituitary-Leydig cell axis may lead to testicular neoplasia in a manner similar to the 
way disruption of the hypothalamic-pituitary-thyroid axis causes thyroid follicular cell neoplasia. The 
latter mechanism is linked to constant TSH stimulation of the thyroid due to enhanced excretion of 
thyroid hormones.
Phénobarbital is known to lead to enhanced peripheral metabolism of testosterone and other steroids 
in rats (Kuntzman, 1969). This is believed to be due to the enhancement of P-450 mediated 
metabolism of androgens. The principal metabolites of androgens are glucuronide and sulphate
conjugates of multiple forms of hydroxyl ated testosterone, 5a and 5f3-androsterone and 5 a and 5(3- 
androstanediol (Baulieu and Robel, 1970). Perhaps the mechanism of Leydig cell hyperplasia and 
tumour formation is linked to the enhancement of this route of metabolism in rats treated with 
phénobarbital.
To test this hypothesis, testosterone levels were measured in samples taken from a study (Study 2) of 
the early phase endocrine effects of treatment with phénobarbital at a dose level of 50 mg/kg. 
Individual results showed a lot of variation, but group mean values indicated that after twenty four 
hours of treatment, testosterone values were raised and subsequently fell to below control levels 48 
and 96 hours after treatment commenced. This is good evidence of an effect on this parameter but is 
subject to the following shortcoming.
The relevance of a single sampling point in the measurement of gonadal function has accepted 
limitations and can only be used as guidance in any diagnosis. Plasma LH, FSH and testosterone are 
known in men, to be subject to wide and markedly irregular fluctuations with time. Samples 
collected at 1 0  minute intervals over an 8  hour period have been shown to oscillate between 2 0 0  
and 400 ng/100ml for testosterone, 1.5 and 14.5 mlU/ml for LH and 1.5 and 4.5 mlU/ml for FSH 
(Smith et a/., 1974). In some instances samples adjacent in time (i.e. 10 minutes apart) varied by as 
much as 50% of the range. A similar study in rats (Ellis and Desjardin 1982), showed that 
testosterone and LH are secreted in a similar manner with pulses occurring every 1 to 2 hours. The 
cause has been ascribed to LHRH pulses released by the hypothalamus (Ellis et a i,  1983). Such 
wide variations in clinical pathology parameters makes diagnosis difficult.
To overcome the above problem in humans, some investigators have recommended assaying a 
plasma pool of equal volumes of three samples taken 20 minutes apart (Coldzieher et a i, 1976). In 
toxicity studies, the use of a number of animals to derive group mean data overcomes this problem to 
a certain extent. However, it must be recognised that the smaller the group size, the more bias a 
single value, subject to wide natural oscillation, w ill have on the mean result observed.
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Testosterone is known to be metabolised to a variety of compounds by the different cytochromes 
P450. A paper on testosterone hydroxylation (Chapman et al.,) showed differences in the profile of 
testosterone metabolites for each rat cytochrome P450 (Table 4.2).
Table 4.2: Testosterone Metabolites For Various Cytochrome P450.Isozymes
CYTOCHROME P450 MAJOR METABOLITE MINOR METABOLITE
IA1 6 a 2P
IA2 . 6 a
IIA1 7a, 6 a 6 DHT
IIA2 1 5a, 18, 6(3, 7a A, 15p
IIB1 16a, 16(3, A -
IIB2 A 16a, 16P
IIC5 - -
IIC7 - 16a
IIC11 2 a, 16a, A 16P
MCI 2 - la ,  15a
MCI 3 6 P 15a, 16a,
ME1 - -
MIA1 2P, 6 P, 15p, 6 DHT 18, IP, 16P, A
MIA2 2P, 6 P, 2a, 16P, A
Key to table: A = Androstendione, 6 DHT = 6 -dihydrotestosterone, other numbers and characters refer 
to the ring position and isomer, e.g., 15(3 = p isomer of testosterone hydroxyl ated at position 15.
It can be seen from the Table that compounds of the Phénobarbital class, which induce principally 
cytochromes IIB1 and IIB2 metabolise testosterone to a mixture of 16a, 16(3-OH testosterone and 
androstendione. Increased metabolism of testosterone via such pathways as a result of significant 
microsomal enzyme induction, would increase the rate of disposal of testosterone. As a result, the 
hypothalamic-pituitary feedback mechanism would be activated and lutropin would be released. 
Sustained metabolism of testosterone would theoretically lead to a requirement for compensatory 
sustained LH release.
To test this hypothesis, plasma LH values were measured in animals treated with dietary 
phénobarbital at 50 mg/kg for 12 months. No effect was observed but for a number of reasons this 
does not rule out the hypothesis. Firstly, samples were not collected with the assay of LH in mind.
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They were collected from the aorta of ether anaesthetised animals at terminal necropsy. Such 
anaesthesia is known to significantly elevate LH levels (Roberts et al., 1989a). If such elevations were 
to have occurred this may have obscured a significant treatment related effect. Such effects are 
known to be minimal. In an investigation of Leydig cell tumours caused by a calcium channel 
blocker, SDZ 200-100, Roberts and co-workers (1989b) proposed that the mechanism was linked to 
LH induction. However, despite a 90% reduction in testosterone after 4 h no effect on LH was seen. 
In a long-term study, an effect was not measurable until after 52 weeks of treatment and then only a
1.5 to 2 fold difference between treated and control animal group means was observed. Again such 
subtle differences could easily be masked by less than appropriate sample collection procedures. 
Values obtained for double antibody radioimmunoassay can vary widely between laboratories due to 
variation in technique, source of antibodies and standard reference materials. However, it is 
noteworthy that the parameters used by above authors are similar to those used in this thesis. The 
rats used were Sprague-Dawley, it is understood that antibodies and the RP2 reference preparation 
used was obtained from the same source (NIADDK). Control values for LH obtained in this thesis 
were surprisingly not variable and had values in the range 1.9 - 3.6 ng/ml. Data generated under 
similar conditions by Roberts (1989) had a group mean values less than 1 ng/ml throughout the two 
year study and were approximately 0.25 ng/ml at the 12  month stage. These observations cast doubt 
on the validity of the results obtained the two year carcinogenicity study.
Despite not having demonstrated an effect on LH in this thesis, it would seem most likely that an 
elevation of LH is the probable cause of the observed Leydig cell proliferation. A number of papers 
detail such a mechanism.
A paper by Cook et a/., (1993) gives three models of sustained LH induction leading to Leydig cell 
hyperplasia or neoplasia. They first cite treatment of humans and rats with human chorionic 
gonadotropin (HCG). HCG stimulates testosterone production by activating the LH receptor, which 
leads to hyperplasia and neoplasia.
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In the second, they give the example of male pseudohermaphroditism. In this disease, affected 
individuals have male genotype (XY) but have female phenotype due to the absence of a testosterone 
receptor. Although there is adequate circulating testosterone, it is not recognised by the pituitary due 
to the lack of receptors and LH is activated to compensate for the apparent lack of androgen. The 
resultant high levels of LH present in the plasma constantly stimulate the testis and lead to 
hyperplasia and adenoma formation.
In the final example, Flutamide, a pharmaceutical antiandrogen, used in the treatment of acne, 
precocious puberty and carcinoma of the prostate, was seen to cause Leydig cell adenomas in a 1 
year feeding study in Sprague-Dawley rats. The compound is a hon-steroidal, androgen receptor 
agonist that blocks the formation of the testosterone-androgen receptor complex. In this example, the 
pituitary is unable to detect circulating testosterone levels because the receptor is present but 
blocked. The result is the same, high levels of plasma LH are produced in an attempt to rectify an 
apparent lack of androgen and such constant LH stimulation of the testis leads to hyperplasia and 
adenoma formation.
It would appear from the above studies that any mechanism that leads to an elevated LH level could 
lead to potential Leydig cell proliferation. Other factors should also be considered.
Hypophysectomy of male rat leads to a reduction in LH receptors that is not reinstated by the 
administration of either LH or FSH. The administration of oestradiol and testosterone or anti-GnRH to 
inhibit FSH or LH secretion also does not result in a loss of testicular LH receptors. This suggests that 
another pituitary hormone might be involved in the maintenance of Leydig cell receptors. 
Administration of ergot alkaloids that reduce prolactin (PRL) secretion also reduce Leydig cell LH 
receptors, whereas administration of PRL to hypophysectomised rats prevents the loss of LH 
receptors. These observations suggest that PRL might be the pituitary hormone involved.
Hormone measurements presented above show that prolactin is reduced by treatment with 
phénobarbital. Values obtained for females were higher than those for males (350%) but treated
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animals of both sexes had mean values that were half those of the corresponding control. Prolactin 
and FSH are required for the maintenance of testicular LH receptors (Zipf et al., 1977). As such, the 
reduction in prolactin seen in males at the 1 2  month stage of the two year study could have led to the 
reduction in LH receptors on the testis. Roberts and workers measured such as reduction receptors in 
their study with SDZ 200-110  and concluded that a similar reduction in prolactin was a contributory 
factor in the mechanism.
In conclusion, phénobarbital was shown to lead to Leydig cell tumours in animals treated for 2 years 
with a dietary concentration of 50 mg/kg. It is proposed that the mechanism for such a finding may 
be related to a complex endocrine imbalance involving at least, enhanced metabolism of testosterone 
and effects on certain pituitary gonadotrophins such as LH and prolactin.
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CHAPTER 5: DISCUSSION
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5.1. Introduction
Discussion of the results of this thesis is conducted at the end of each experimental section. 
This allows the reader review of the information in the context of the data presented. For that 
reason, the follow ing section w ill comprise a general review and discussion of key aspects of 
the work, recommendations for future work and a suggested algorithm for testing mechanisms 
of thyroid toxicity.
The current interest and increasing requirement for definitive information in cancer research 
and carcinogenicity testing is a clear reflection of the growing awareness of cancer as a major 
cause of death. In the mid eighteenth century, life expectancy was approximately 50 years 
and most people died of infectious diseases. Cancer was not of major concern. As a result of 
advances in the control of infectious disease, more deaths are now due to accidental or 
violent causes than occur due to infection. Hence, in general, life expectancy has risen and 
the main cause of death is now cardiovascular disease and cancer. In the developed world, 
two out of three people die from these two causes and one in five die of cancer.
If one excludes tobacco (lung cancer) and sunlight (melanoma) as causes, cancer incidence, 
in the past 50 years, has stabilised and in some tissues the incidence of cancer is reducing 
(Roe, 1987). Although it is true that more people die of cancer than ever before, this is 
believed to be because cancer is age-related and in the developed world people now live 
long enough for this to be the case.
A significant problem for the toxicologist is the manner in which carcinogenicity testing 
protocols have evolved. During the late 1970's, the US National Cancer Institute published 
their "Guidelines for Carcinogen Bioassay in Small Rodents", (1976). These stated that "Most 
human cancers are believed to be caused by exposure to extrinsic factors, among which 
chemical agents are thought to be a major contribution. These factors must be identified, 
evaluated and controlled if the incidence of human cancer is to be reduced". Such a
viewpoint is now outdated since it is thought that such a simplistic approach cannot lead to a 
significant reduction in cancer incidence (Higginson and Muir, 1979).
In the industrialised society of the developed world, there are increasing demands for novel 
chemical agents and processes to provide sufficient energy, food, building materials and land 
for subsequent generations. Such requirements are bound to have an impact on the 
environment and human exposure. For this reason, a scientifically sound method of assessing 
the potential risk of xenobiotics to man and the environment has had to be developed.
5.2. Carcinogenicity Testing: A Perspective
In the past, it was argued that on one hand, all human carcinogens were carcinogenic in 
animals and on the other hand, many of the compounds that cause cancer in rodent toxicity 
studies would also produce tumours in man. It is now obvious that there are "too many 
rodent carcinogens" (Ames and Gold, 1990). Critical reviews of the carcinogen databases 
have shown that approximately half of the chemicals tested to date in rodent toxicity studies 
are shown to be carcinogenic. Ames and Gold suggest that because of the requirement to 
meet contemporary maximum tolerated dose (MTD) criteria, chemicals have to be tested at 
toxic doses. This toxicity can cause chronic tissue damage and is a known risk factor for 
cancer in both animals and humans due to potential promotional effects. Hence, a large 
proportion of chemicals tested at toxic doses in rodent toxicity studies are likely to be 
inappropriately defined as carcinogens rather than as indirectly acting promoters of 
carcinogenesis. How therefore does one regulate potential risk to human health, when the 
outcome of rodent toxicity studies suggest that 50% of all synthetic chemicals (such as 
pesticides) and 50% of all natural products (such as components of vegetables, mushrooms, 
coffee, chocolate and barbecued food) are carcinogenic? If this was true, surely cancer 
incidence would be higher than it actually is?
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In the past, the American method of regulating 'carcinogenic' products in the pesticide 
industry has been to adopt a zero risk approach. That is the incidence of tumours observed at 
high doses in toxicity studies have been extrapolated to the low doses that the population is 
exposed to as residues in crops. This assumes that the incidence of cancer w ill reduce 
linearly as the dose is reduced and that in the extreme, one molecule of a rodent carcinogen 
w ill lead to cancer if consumed by man. Indeed, the US FDA Delaney clause considered 
pesticide residues to be food additives. This was a distortion of the intended definition of the 
Act and totally prevented registration of compounds that were known to be rodent 
carcinogens for food use, if they were likely to be concentrated by processing. In 1958, when 
this bill was introduced analytical techniques were far less sensitive and it was relatively easy 
to meet zero risk criteria. There was no risk, if residues could not be detected. As analytical 
technology has advanced, and bench-top, mass-spectrometry has become a commonplace 
feature in residue laboratories and the limits of detection have been dramatically reduced. It 
is currently possible to analyse residues to approximately 1 part per billion by such 
techniques.
In contrast, to register a product in Europe and to register non-carcinogens in America, a 
margin of safety (MOS) approach was employed. Such schemes, which are based on 
'uncertainty-factors', have required a clean threshold dose separating effect from no- 
observab I e-effect levels (NOEL). An acceptable daily intake (ADI) is then calculated by 
dividing the NOEL by a safety factor, which in conventional toxicology is usually taken to be 
100. It assumes man to be 10-times more sensitive than the most sensitive species tested and 
that certain individuals may be 10-times more sensitive than the least susceptible man.
Where concern exists for a particular toxicological event the MOS can be increased from the 
usual 100 to 1000
These factors allow the registration of rodent carcinogens providing a mechanistic background
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to the biological processes of carcinogenesis is presented. This should show that tumours do 
not occur by genotoxic (DNA-reactive) mechanisms and that they are unlikely to occur below 
a threshold dose. Examples of such threshold mediated effects would be cell proliferation, 
cytotoxicity, hormonal effects and species specific mechanisms such as the renal tumours 
caused by male rat a  2-urinary microglobulin (Swenberg, 1992).
In line with current thinking, the Delaney clause has recently been revoked for pesticide 
residues and their degradation products and has been replaced by the new Food Quality 
Protection Act, (1996). This brings US legislation in line with much of the rest of the world. 
Statistically, pesticide residues must represent less than a one-in-a-million risk of causing 
cancer in a lifetime. This risk estimate is defined in plain English as a "reasonable certainty 
that no harm" w ill arise from exposure to such chemicals. The rule w ill be applied differently 
to threshold and non-threshold effects and the Environmental Protection Agency is thought 
likely to apply a 100-fold safety factor to the NOEL when data are extrapolated from animal 
studies.
5.3. Background To Thesis
The author became interested in thyroid follicular cell neoplasia by the repeated observation 
that in rats treated with certain compounds, increased weight and cellular hypertrophy of the 
liver often occurs in association with thyroid hypertrophy, hyperplasia and sometimes 
neoplasia. Thyroid effects were never observed in the absence of liver effects.
It was appreciated that thyroid effects might have been the result of direct action on the gland 
or could have been caused by some secondary mechanism. I therefore became interested in 
the mechanistic cause of thyroid follicular cell proliferation in rats treated with pesticides, 
which also had effects on the liver. Studies with different compounds showed a relatively
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reproducible sequence of events in the thyroid. These ranged from colloid depletion, to 
hypertrophy, to hyperplasia and thence to neoplasia, particularly in male rats. In parallel with 
these observations, the effects seen in the liver suggested that all the compounds concerned 
were hepatic microsomal inducing agents. From a historical review of the literature, it was 
concluded that these effects must be the outcome of enhanced hepatic metabolism of thyroid 
hormones which was goitrogenic and gave the animal relative hypothyroid status.
The same literature had shown that in the rat microsomal enzyme induction and certain 
aspects of thyroid physiology were different to other species and in particular to man. In the 
rat, clear sex differences in hepatic and thyroid biochemistry were also noted. It was therefore 
considered that associated mechanisms of thyroid toxicity or carcinogenesis might make the 
rat a poor predictor for risk to man.
To test this theory it was decided that the classical microsomal enzyme inducing agent 
phénobarbital (Conney, 1967) could be used in a rat carcinogenicity study. The compound 
has been negative in tests of genotoxicity and has been used safely in human medicine for 80 
years without signs of thyroid cancer. For this reason it was considered to be an ideal 
compound with which to investigate links between microsomal enzyme induction and 
thyroid follicular cell neoplasia in rats
The literature had shown that short-term treatment of rats with phénobarbital was goitrogenic 
and led to loss of colloid, follicular cell hypertrophy and hyperplasia (Japundzic, 1969). This 
effect was believed to be due to greater metabolic turnover of thyroid hormones 
(Oppenheimer et al., 1968, McClain et al., 1989). Any modification of thyroid function by 
'goitrogenic procedures' had been shown to lead to an elevation of TSH and ultimately 
thyroid follicular cell tumours (Morris, 1955). Such tumours are believed to be caused by 
constant thyrotropin (TSH) stimulation brought about by modification of the hypothalamic- 
pituitary-thyroid axis in response to a hypothyroid state.
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The fact that elevated endogenous TSH levels can, without additional treatment by chemical 
agents, lead to neoplasia has been well documented (Bielschowsky, 1953, Furth, 1954,
Axe I rad and Leblond, 1955, Leblond et al., 1957 and Isler et al., 1958). Thus it can be 
proposed that any procedure that leads to sustained hypothyroidism and elevated TSH levels 
may lead to tumours in rats.
Despite such detailed information on the goitrogenic nature of phénobarbital (Japundzic,
1969) and the tumourigenic effects of a goitrogenic regimen (Morris, 1955), no report could 
be found in the literature, which showed conclusively that phénobarbital was capable of 
causing thyroid follicular cell neoplasia.
Hiasa and his co-workers (1982, 1983) had shown phénobarbital to be a tumour promoter 
and the recent work of McClain et al., (1988) supported this observation. But both studies 
required the use of initiating agents to induce tumours. McClain's group observed that 
thyroxine (T4) administration effectively blocked the promotional effect. This supported the 
hypothesis that the promoting effect of phénobarbital is the consequence of increased 
pituitary secretion of TSH, which is switched off by T4 administration. For this reason, the 
author proposed that at a high enough dose level phénobarbital treatment alone would lead 
to tumours in rats.
5.4. Review O f Results O f Thesis
In a two year study designed to test the above theory, rats of both sexes were given 
phénobarbital at a maximally tolerated dose level. The results obtained give the first evidence 
that the author is aware of, that phénobarbital leads to neoplasia in male rat thyroid follicular 
cells without the involvement of other xenobiotic agents as initiators, promoters or 
progressors. This contradicts the assumption by Johnson et a i, (1993), who suggested that 
prolonged dosing with phénobarbital was unlikely to produce neoplasia.
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Curiously there was no effect apparent on circulating thyroid hormone levels. This was 
thought to be due to the perfectly functional thyroid gland being able to compensate for an 
assumed increase in thyroid hormone metabolism and disposal by secreting hormones at a 
higher rate. This effect is consistent with the observations of others (McClain et al., 1988). 
The mechanism involved is believed to be via normal hypothalamic-pituitary-feedback 
control. TSH levels observed in the two year study supported this belief. Despite normal 
circulating thyroid hormone levels, TSH was elevated in both sexes, although very few 
females had values that were outside concurrent or background control limits. In males, 
however, values 2.5-fold higher than controls were seen on some occasions.
In frank thyroid disease there is an inverse relationship between circulating thyroid hormones 
and TSH. This does not appear to hold true for the 'metabolic' hormone deficiency seen with 
microsomal enzyme induction and highlighted in this thesis. Here TSH is elevated due to 
perturbed hormone levels, but the functionality of the thyroid gland is not impaired. It 
operates at a higher functional level, due to TSH stimulation, but there is no direct thyroid 
toxicity. Hence, plasma thyroid hormones are maintained at the normal set-point. This 
contradicts conventional wisdom, in that it is assumed that a reduction in circulating thyroid 
hormones is required to trigger TSH secretion via the hypothalamic-pituitary-thyroid axis.
The mechanisms involved concern appear to be as follows. Triiodothyronine (T3) receptor 
occupancy controls the release of TSH from the pituitary gland (Larson, 1982). This T3 is 
thought to be derived from locally deiodinated T4 not from circulating T3. As plasma T4 
levels decline, due to an initial increased rate of plasma clearance by hormone disposal 
mechanisms, TSH is switched on via the hypothalamic pituitary feedback mechanism. This 
leads to increased production of hormones by the thyroid gland that corrects the circulating 
deficit. At this point, the circulating T4 level would be at the normal set-point and should be 
sufficient to reinstate pituitary receptor occupancy and TSH release should be switched off.
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However, since there is assumed to be sustained hormone metabolism and disposal, the 
plasma levels need constant replenishment. Set-point levels are kept constant by this 
mechanism, yet TSH is still excreted in excess.
The author believes that this effect might be due to different mechanisms controlling the set- 
poin t of plasma thyroid hormones and the rate of thyroid hormone production. TSH is 
assumed to control the rate of thyroid hormone production but not the set-point. Re­
establishment of the set-point of plasma thyroid hormones after the acute effects of 
microsomal enzyme inducing agents often leads to over compensation and results in higher 
than normal plasma T4 (Rush, unpublished observation). It is interesting that the magnitude 
of this event correlates with liver weight.
It is well documented that thyroid hormones are metabolised principally by 
monodeiodination and glucuronidation. Other metabolic routes exist such as sulphation, 
deamination and decarboxylation but these are considered minor pathways (Robbins, 1981). 
The two principal enzymes involved in thyroid hormone metabolism are T4-UDPGT and a 
monodeiodinase. These are located in the smooth endoplasmic reticulum that constitutes 
hepatic microsomes and that would be affected by microsomal enzyme inducing agents.
Data presented in Chapter 3 show increased liver weight, induced p-nitrophenol-UDPCT, 
increased microsomal protein content and higher cytochrome P450 activities in the livers of 
animals treated with phénobarbital. These data suggest an enhanced metabolic potential of 
the liver and hence may explain the cause of thyroid hormone disposal. It was not the 
intention of this thesis to confirm this by repeating studies of thyroid hormone disposal 
conducted by other authors, who clearly demonstrated increased hormone disposal 
(Oppenheimer, 1968; McClain, 1989).
The data recorded in this thesis shows an interesting effect on plasma phénobarbital that was 
believed to show the generally enhanced metabolic potential of the induced liver and the sex
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related difference in such potential. Throughout the two year study females consumed 1.4- 
fold more test material than males. However, plasma phénobarbital values in females were 
2.8-fold higher in this sex, which is twice as high as the intake would suggest. If it is assumed 
that there are no differences in absorption and distribution between sexes, the lower 
circulating phénobarbital seen in males must be due to higher metabolic clearance rate in this 
sex. Detailed studies of the absorption, distribution and excretion of phénobarbital in each 
sex would confirm this.
Interestingly, the long-term effects of treatment in this study, such as general incidence of 
masses and specific incidence of thyroid follicular neoplasia, were lower in females. If 
phénobarbital caused direct effects on the thyroid gland, either as a direct acting goitrogen or 
carcinogen, it seems logical to assume that the effect should be more apparent in the presence 
of higher chemical intake and circulating plasma levels of test material in females. This was 
not the case.
Twice the normal incidence of benign and malignant thyroid follicular cell neoplasia was 
observed in males. No effect was seen in females. Phénobarbital is not known to affect the 
thyroid gland directly (McClain, 1989) or as discussed, to directly cause the increased tumour 
incidence seen in this organ, In males.
5.5. Genotoxicity Vs Non-Genotoxicitv
Carcinogenic agents are believed to fall into one of two classes genotoxic or non-genotoxic. 
Genotoxic chemicals generally interact with DNA or have DNA-reactive metabolites (Miller 
and Miller, 1981). A battery of tests is available for the definition and evaluation of end­
points such as reactivity with DNA, induction of mutations, induction of DNA repair or 
cytogenetic effects (Kirkland, 1990, Kirkland and Fox, 1993). The classic Ames test is 
designed to be very sensitive for the detection of mutations. Hence, reasonable assurance
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that a chemical is not genotoxic can be obtained, phénobarbital and the novel pesticide! 
products investigated have been shown to be essentially negative in such assays (IARC, 1977 
and 1987).
Testing for non-genotoxic mechanisms is not as well defined. It is increasingly assumed that 
non-genotoxic carcinogens affect the incidence of tumours by modulation of the expression of 
the products of the genome, whilst carcinogenic chemicals act by reorganisation of the 
genome. The problem for the toxicologist is to define how much and what type of data is 
required to define non-genotoxic mechanisms.
Non-genotoxic agents are not reactive with DNA and do not alter the structure of 
chromosomes directly. Many researchers are now of the opinion that the majority of rodent 
carcinogens act through non-genotoxic mechanisms. A study by the US National Toxicology 
Program and National Cancer Institute (Tennant, 1987), showed that half of the 73 rodent 
carcinogens tested were negative in Ames Salmonella typhimurium  mutagenicty tests.
Butter worth et al., (1992) suggest that the many different types of non-genotoxic carcinogens 
can be grouped as follows:
• Mitogens, which induce cell proliferation without cytotoxicity
• Cytotoxicants, which kill cells and could lead to regenerative cell proliferation
In both cases, naturally occurring mutations are presumed to take place at a higher rate. This 
is because such enhanced cell proliferation increases the chance of spontaneous mutations 
(caused by natural errors in DNA replication or the conversion of natural DNA-adducts to 
mutation before repair is effected), becoming incorporated into the proliferating tissues.
Indeed, Butterworth et al., (1992), suggest that cancerous or precancerous cells have a 
preferential growth advantage under such conditions due to a modification of the normal rates 
of cell birth (mitosis) and cell death (apoptosis). They suggest that "Predictive assays and risk 
assessments for the various classes of nongenotoxic carcinogens should be dealt with
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individually and require understanding of the mechanism(s) of action, reason for target organ 
and species specificity between end-points". In other words, for every chemical suspected of 
causing non-genotoxic carcinogenesis detailed investigation of the mechanistic toxicology 
leading to such an outcome must be provided. ~
A number of agents are known to cause thyroid follicular cell neoplasia in rodents. These can 
be broadly divided into two types:
• Direct acting carcinogens (e.g., radiation, Lindsay and Chaikoff, 1964; polycyclic 
hydrocarbons, Esmarch, 1942; 2-acetylaminofluorene, Cox et al., 1947; and 
dichlorobenzidine Pliss, 1959)
• Indirectly acting treatment regimes that cause endocrine imbalance leading to neoplasia 
via non-genotoxic mechanisms (partial thyroidectomy, natural goitrogens, Kennedy and 
Purves, 1941; sulphonamides, Swarm et a i, 1943; iodine deficiency, Bielchowsky, 1953).
In the rat, goitrogenic regimes are known to cause non-genotoxic follicular cell 
carcinogenesis. Such effects have been shown to occur by direct chemical blockage of the 
thyroid or by extrathyroidal effects. A number of mechanisms lead to direct chemical 
blockage of the gland. Such blockage, leads to a reduction in circulating plasma thyroid 
hormone levels, which initiate the pituitary feedback mechanism and switches on TSH 
production. A number of other chemicals affect the thyroid gland by indirect peripheral 
effects. Such mechanisms include displacement of hormone from binding proteins, enhanced 
deiodination, reduced enterohepatic circulation and increased biliary excretion (Hill et a i,
1989). The end-point is a reduction in circulating plasma thyroid hormone levels, which 
initiates the pituitary feedback mechanism and switches on TSH production.
These two classes of thyroid effects, direct and indirect goitrogenesis, have the same endpoint 
- an elevation of plasma TSH. This is known to lead to thyroid follicular cell neoplasia in rats 
(Hill et a i, 1989). Direct goitrogens are likely to cause thyroid effects and may lead to
follicular cell neoplasia in a number of different species, although the rat is known to be more 
susceptible (Swarm, 1973; Takayama, 1986). Such an end-point would not be acceptable or 
defensible in the development of novel plant protection products and the compound would 
not be developed or registered for use on food crops. On the other hand, indirect goitrogens 
are more likely to have threshold or species-specific mechanisms. Providing the mechanism 
of effect can be elucidated, registration is feasible with "a reasonable certainty of no harm" to 
humans. The key element is the differentiation of direct and indirect acting goitrogens. In this 
thesis, the perclorate discharge test was used to differentiate direct thyroid blockage from 
other mechanisms of TSH elevation. Studies were conducted with phénobarbital, 
propylthiouracil and several plant protection products for which a mechanism of thyroid 
interference had not been defined.
Propylthiouracil was shown to be directly goitrogenic. It is known to directly inhibit thyroid 
peroxidase (Rang and Dale, 1987) and has been previously shown to be positive in the 
perchlorate discharge test (Atterwill, 1986).
The novel pesticides tested were all shown to be mild goitrogens of varying magnitude that 
acted by an extra thyroidal mechanism.
Although, the perchlorate discharge test is an ideal tool with which to differentiate and define 
the magnitude of effect of direct and indirect acting goitrogenic chemicals. It does not give 
detailed information of the mechanism of such effects. To further clarify the mechanism of 
thyroid follicular cell neoplasia seen in the two year study, phénobarbital was administered to 
rats at the MTD and at a level equivalent to the human therapeutic dose. Ideally, novel 
compounds would be tested at a range of doses in order to obtain clear no effect levels with 
which to define thresholds that can be used in the risk assessment process.
The results obtained showed no significant effect of treatment at the human therapeutic dose 
level in either sex, but a mild and clear reduction in plasma thyroxine was seen throughout
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the treatment period in males treated at the MTD. When all the results obtained were 
reviewed data clearly fitted a picture of enhanced hepatic metabolism. The raised UDPGT 
seen early in the study was thought to have been the mechanism of T4 metabolism and 
reduction. This is presumed to have depleted reserves of thyroid hormones and precipitated 
an effect via the hypothalamic-pituitary axis leading to an elevation of TSH in the latter stages 
of the study. UDPGT was elevated and T4 was reduced prior to an increase in plasma TSH. 
This was taken as good evidence that phénobarbital does not have a direct effect on higher 
neural centres and /  or thyroid hormone synthesis and secretion (Harvey et al., 1994). It is 
assumed that TSH would have been elevated in the early stages of the study if the effect was 
due direct stimulation of TRH or TSH release. The fact that thyroid hormones are held at or 
near the normal set-point levels and that plasma thyroxine decreases prior to the subsequent 
rise in TSH levels also supports this theory.
In the author's laboratory a number of compounds tested have shown similar results. Some 
have been marked microsomal enzyme inducing agents but have not resulted in thyroid 
follicular cell neoplasia; whilst others with mild induction properties have lead to colloid 
depletion, hypertrophy, hyperplasia and neoplasia. None of the compounds have been 
shown to be direct acting goitrogens and the mechanism of thyroid perturbation believed to 
be due to their known microsomal enzyme induction properties. Why some compounds 
cause neoplasia at lower dose levels is not known but is the key element that requires 
definition if prediction of neoplasia is to be possible.
In the penultimate studies described in this thesis, a detailed comparison of thyroid effects on 
a number of differing compounds was undertaken. T4, T3, TSH and UDPGT levels were 
compared in the first eight days of treatment. Most of the compounds tested affected UDPGT 
levels and could be graded according to their known enzyme induction potential. The 
parameters tested could be used to support an indirect mechanism of thyroid fo llicu lar cell
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neoplasia induced by enzyme inducing agents. They could not however be used as 
predictive markers of the future potential of such compounds to increase the incidence of 
thyroid neoplasia. It can be concluded that if paranitrophenol-UDPCT is elevated there is a 
potential for thyroid follicular cell neoplasia. However, all the microsomal enzyme inducing 
agents tested appeared to affect UDPGT but this did not correlate with the outcome of 
carcinogenicity studies with respect to thyroid neoplasia. It must be concluded that this 
parameter adds no more information to the prediction of neoplasia than the increased liver 
weight that would be seen at necropsy.
5.6. Aspects O f Enzyme Induction
Consideration of the literature showed that the principal classes of enzyme inducing agent 
have been shown to result in enhanced thyroid hormone metabolism and disposal. Polycylic 
aromatic hydrocarbons, the IA1 inducers increase biliary excretion of T4 (Goldstein and 
Taurog, 1968; Bastomsky and Papapetrou, 1973; Bastomsky and Murphy, 1976; Collins and 
Capen, 1980; Bastomsky, 1977, Johnson etal., 1993). The IIB1/2 inducers such as 
phénobarbital and DDT do likewise but to a lesser extent (Bastomsky and Papapetrou, 1973, 
McClain, 1989) whilst the peroxisome proliferators have been seen to reduce serum thyroxine 
(Price et a i, 1984, Hinton et a i, 1986). Thus it would appear that all compounds which 
increase liver size due to enzyme induction have the potential to cause thyroid fo llicu lar cell 
neoplasia.
In studies of hepatic microsomal enzyme induction, there is a tendency to classify compounds 
according to principal sub-class and to ignore (or not measure) more subtle changes in the 
proteins or specific enzymes. A good example of this is phénobarbital itself. Protein levels 
of some cytochromes P450 are dramatically influenced by treatment with phénobarbital. The 
principal cytochrome IIB1 may be elevated 50 to 100-fold by treatment whereas only a 2-4-
215
fold increase of IIC6 and no increase of IIB3 are observed (Waxman and Azaroff, 1992). 
Perhaps more significantly phénobarbital is also a IA1 (cytochrome R448) inducer, a IIIA1 
(glucocorticoid) inducer and a IIIA2 inducer. The final example cited is not part of a 
'classified' group of inducing agents but is known to be expressed only by male rats. These 
low order (2-10-fold) effects are known, but not usually considered because for example a 
"true" P448 inducer such as dioxin would elevate IA1 by 100-fold. If dioxin is considered a 
R448 inducer and elevates IA1 by a factor of 100 and phénobarbital is not considered 
classically to be a P448 inducer at a 10-fold induction level, where does one draw the line? 
Perhaps more importantly where does perturbed physiology draw the line? To complicate the 
picture further cytochrome P450's are not the only enzymes induced by chemicals. Aldehyde 
dehydrogenase, epoxide hydrolase, glutathione-S-transferase and of course UDPGT are also 
elevated by phénobarbital and other inducing agents and many are regulated by thyroid 
hormones.
It puzzles me why the thyroid gland is so intimately linked to the liver and microsomal 
enzyme induction. Why do all classes of inducing agents lead to thyroid hormone disposal 
and thence a potential for thyroid follicular cell neoplasia? It is known that the rodent 
thyroid gland is particularly sensitive to the effects of xenobiotics. This is surprising given the 
millions of years that metabolic processes have had to evolve a protective response to the 
toxicity of xenobiotics. There is a tendency to consider xenobiotics as a new phenomenon, 
which is the result of the industrial age. It is not, rodents have had always to combat potent 
and evolving plant toxins consumed in the normal diet. So why have they evolved with such 
vulnerability?
Thyroid hormones control and regulate growth, development and metabolic activity of all 
cells. In particular, they have key regulating effects on phase 1 and phase 2 metabolism in 
the liver. Thyroxine is known to suppress the basal expression of IIIA2 mRNA and the
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maintenance of low IIB levels in the non-induced rat (Waxman and Azaroff, 1992). In these 
cases, enhanced thyroxine disposal and relative hypothyroidism in the liver would 
presumably lead to de-repression and therefore induction of these enzymes. Thyroid 
hormone metabolism and disposal are orchestrated by monoiodinases (Phase 1) and UDPCTs 
(Phase 2) enzymes. It is paradoxical, that they appear to be regulated by the very enzyme 
systems that they regulate. This suggests to the author that there is an intimate and as yet 
undefined link between these processes and the regulation of growth and development. 
Perhaps the disposal of thyroid hormones is not an effect of microsomal enzyme induction but 
the cause.
Consider the following hypothesis. The liver is a known extra-thyroidal storage site for 
thyroid hormones (Oppenheimer, 1969). Suppose that these hormones are weakly bound to a 
biochemical moiety. It is known that only free thyroid hormones have metabolic activity and 
so in this state they would be inactive and the status quo would be maintained. When a 
lipophilic toxicant is administered it could displace the thyroid hormone from the binding 
site; liberating free and active hormones. These hormones could then activate phase 1 and 
phase 2 enzymes and other systems such as those required for energy generation and cell 
proliferation. If sustained, this would produce more liver cells with more metabolic enzymes, 
in an attempt to excrete the toxic compound. As a secondary effect the thyroid hormones 
themselves are metabolised in a biochemical attempt to regulate or switch off the enhanced 
metabolic processes.
There are two outcomes to this supposition. First, the toxic compound is cleared and the 
binding site is re-occupied by 'dormant' thyroid hormone and the whole process switches off. 
Metabolism is reduced and the liver returns to normal size. Second, the toxic compound 
continues to occupy the binding site, liver metabolism is sustained at a high level, thyroid 
hormones continue to activate phase 1 and 2 enzyme systems and in turn continue to be
217
metabolised themselves. Hence, microsomal enzyme induction leads to enhanced thyroid 
hormone disposal and enhanced thyroid hormone disposal leads to enhanced microsomal 
enzyme induction. Investigation of this hypothesis would be complex. An initial study could 
be undertaken to see where thyroid hormone is "stored" in the liver and whether this storage 
site could be occupied by phénobarbital or other enzyme inducing agents. To the knowledge 
of the author, no cellular phénobarbital receptor has yet been identified.
In Chapter"!, it was seen that, the potential physiological effects of microsomal enzyme 
induction are numerous and complex. The cytochrome P450 superfamily is comprised of at 
least 27 gene families (Nebert et a/., 1991) Ten of these are found in mammals and the 
physiological role of the majority is not known. Subtle changes may therefore have sublime 
effects on fundamental biochemical processes, e.g., cell proliferation and neoplasia. 
Pathological end-points, such as the porphyria seen in the two year study with phénobarbital 
are known to be the result of hepatic microsomal enzyme induction (Rang and Dale, 1986) 
but not all inducing agents cause porphyria.
In short, it may be that specific chemical compounds have their own complex enzyme 
induction or resultant pharmacokinetic finger-prints. The pattern of these, in respect to the 
classes of enzymes induced and the array of physiological or pathological events that may 
result should be considered specific and unique to each compound.
The final investigations conducted as part of this thesis include a detailed investigation of the 
hepatic enzyme induction subclasses of the various compounds studied. The aim was to 
compare the enzyme induction profile seen for each compound in the hope that specific 
markers or patterns for prediction of potential to induce thyroid follicular cell neoplasia might 
be found. Results clearly showed the effects of the positive control materials, phénobarbital, 
clofibrate, P-napthaflavone, isosafrole and pregnenolone-16a-carbonitrile induced large 
changes in IIB1/2, IVA, IA1/2, and IIIA respectively. The novel pesticide! products gave a
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range of results and could be grouped in a number of ways. None induced significant 
increases in peroxisomal enzymes of the IVA class. Most of the compounds studied had 
comparable but lower magnitude induction profiles to phénobarbital. However, no 
significant pattern could be identified that would link the induction profile with the likelihood 
of thyroid effects. It was concluded that additional testing would be required in order to 
prove that thyroid follicular cell neoplasia seen in rats was of no consequence to man.
Having further reviewed the literature, the author came to the conclusion that a detailed and 
systematic testing protocol was required. The following section describes a suggested 
algorithm by which compounds can be tested to show mechanisms of thyroid toxicity. A 
similar approach was suggested by Atterwill and Cockburn (1996).
5.7. Algorithm To Investigate Interference With Thvroid Function
Hepatic enzyme induction is a known risk factor for thyroid neoplasia (Hill et al., 1989). 
Although a number of mechanisms have been suggested as the cause of such neoplasia, 
research conducted as part of this thesis and elsewhere (Cockburn et al., 1990), show that a 
great deal of data is required to support the hypothesis that effects seen in rodents are of no 
risk to man. In order to meet stringent safety requirements, it is important to conduct detailed 
research into the mechanistic action of each specific compound or agent studied. General 
assumptions about mode of action related to mechanisms should not be made.
In 1988, Hill et al., the US ERA published a draft review in which they concluded that an 
essential factor, in the assessment of chemicals thought to act via non-genotoxic mechanisms 
of thyroid follicular cell neoplasia, is the demonstration of disruption of the hypothalamic- 
pituitary-thyroid axis. They proposed that demonstration of the follow ing six key elements 
was required:
1. Goitrogenic activity in vivo (i.e. thyroid follicular cell hypertrophy and hyperplasia).
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2. Clinical chemistry indication of changes in thyroid and pituitary functional parameters (e.g. 
reduced thyroid hormone and increased TSH serum concentrations).
3. Specific evidence that the agent reduces thyroid hormone synthesis (e.g., inhibits iodine 
uptake) or increases hormone clearance (e.g., enhances biliary excretion).
4. A progression of lesions under long-term exposure to the agent, showing cellular 
hypertrophy and hyperplasia, nodular hyperplasia and neoplasia (benign and possibly 
malignant tumours).
5. Other studies bearing on the hypothesis that thyroid-pituitary imbalance may be operative, 
like reversibility of lesion follow ing cessation of the treatment.
6. Structure-activity analysis of the agent under review to see if it belongs to a class of 
compounds that show correlation with the induction of thyroid tumours.
Based on these recommendations and on the review of interference with thyroid function 
conducted as part of this thesis I recommend the following diagnostic algorithm. Figure 5.1, 
which is based on Figure i in the Introductory Section of this thesis, defines mechanisms of 
cellular proliferation and shows a path by which these can be investigated. The reader is 
referred to chapter 2 for a detailed review of the potential sites of interference with thyroid 
function and hence the relevance of some of details pertaining to the algorithm.
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Figure 5.1 : A diagnostic A lgorithm  For Investigating Mechanisms of Thyroid Follicular Cell 
Neoplasia
Mechanisms of Thyroid Follicular Cell Proliferation 
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It is essential in the risk assessment process to ensure that the substance suspected of being a 
non-genotoxic carcinogen has been proven to be negative in a battery of genotoxicity tests. 
For the purpose of this algorithm, it w ill be assumed that testing for genotoxic potential has 
been performed and that compounds under test have been shown to be negative. Testing 
protocols for the definition of genotoxic carcinogens are well defined and w ill not be 
reviewed In this thesis. For details see (Kirkland, 1990; Kirkland and Fox, 1993)..
The algorithm describes procedures to test mechanisms of non-genotoxic carcinogenesis - the 
end-point for such carcinogenesis in the thyroid is an elevated plasma TSH. For clarity of 
description, it is assumed that compounds with a positive risk to man w ill not be further 
developed. Judgement on the relative benefits of such an approach in a regulatory 
environment, w ill need to be undertaken. Consideration of product use and the magnitude 
of the adverse effect w ill need to be taken into consideration.
5.7.1 Stage 1 : Review O f The Existing Toxicology Data
If thyroid follicular cell tumours have been observed in a routine regulatory toxicology 
package, data w ill be available for a variety of species at a range of dose levels. These studies 
w ill have been conducted at 28 and 90 days as well as over a chronic period of compound 
administration. Absolute organ weights and weights relative to brain and bodyweight w ill 
have been recorded and histopathology of the thyroid gland w ill have been reported. These 
data should be reviewed for evidence of a clear pattern of effects. The following questions 
should be asked:
Did the compound alter thyroid weights and lead to colloid depletion, hypertrophy and 
hyperplasia, prior to the formation of neoplastic lesions?
Is there clear evidence of cytotoxicity or does the thyroid contain abnormal pigment?
Is there a dose-response threshold and a clear no effect level?
Does the effect involve one or more species?
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Are there structural alerts due to chemical class that suggest that the compound:
a) Is likely to lead to direct thyroid inhibiting effects,
b) Is an uncoupler of oxidative phosphorylation,
c) Contains iodine that may be metabolically released,
d) Has structural similarities to the thyroid hormones?
Is the compound pharmacologically active?
Does j t  cause direct, receptor-stimulated effects such as dopaminergic or adrenergic activity?
5.7.1.1 Outcome 1 - Primary Goitrogen
Chemical alerts - Probable primary goitrogen - Positive risk to man
5.7.1.2 Outcome 2 - Primary Goitrogen
Multiple species affected - Probable primary goitrogen - Positive risk to man
5.7.1.3 Outcome 3 - Secondary Goitrogen
Species-specific effect in the rat (particularly males) - Indirect goitrogen - Minimal risk to man. 
Pass to stage two of algorithm
5.7.2 Stage 2: Review Links With Other End-Points Of Toxicity
Review all toxicologically significant end-points.
Was the compound seen to cause liver enlargement?
5.7.2.1 Outcome 4 - Probable Indirect Acting Goitrogen
Liver enlargement observed - Minimal risk to man of thyroid toxicity.
Possible secondary effect of liver enzyme induction - Indirect acting goitrogen.
Review histopathology of liver.
Consider electron microscopy.
223
Consider in vitro testing of hepatocyte iodine accumulation (Ay I ward et al., 1994)
5.7.2.2 Outcome 5 - Further testing required.
No liver enlargement. Do not exclude enzyme induction as a cause. Compounds that cause 
a low grade increase in liver weight may still lead to thyroid follicular cell neoplasia. Review 
and consider other options such as enhanced urinary or faecal disposal routes Indirect acting 
goitrogen? - Risk to man not defined.
Pass to stage three of algorithm
5.7.3 Stage 3: Differentiation Of Direct And Indirect Goitrogenesis
Perform perchlorate discharge test (Atterwill, et al., 1987)
5.7.3.1 Outcome 6 - Direct Acting Goitrogen
Reduced iodine uptake and increased discharge - Hypoactive thyroid and reduced 
organification - Direct acting goitrogen - Positive risk to man.
If further evaluation is required the use of cultured thyrocytes might be considered (Atterwill 
and Fowler, 1990).
5.7.3.2 Outcome7 - Indirect Acting Goitrogen
Increased iodine uptake and no discharge - Hyperactive thyroid - Normal organification 
processes- Indirect acting goitrogen - Minimal risk to man 
Test mechanism
5.7.4 Stage 4: Investigation Of Indirect Acting Goitrogens
The test compound is suspected of being a goitrogen by an indirect effect on the thyroid
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gland.
Perform short-term toxicity test (At least 14 days and in sexually mature animals).
Multiple interim kills and bleed points should be considered 
Testing required 
Plasma T3, T4
T4-UDPGT (McClain, 1989) and 5' deiodinase activity in hepatic microsomes.
Thyroid peroxidase activity (Remember direct measurement of peroxidase may be misleading) 
Perform histopathology of (at least) liver, thyroid and pituitary glands. Image analysis of 
thyroid may be required to differentiate subtle hypertrophic and hyperplastic effects 
(Gopinath, 1992). Plot progression of effects
Consider immunohistochemical differentiation of pituitary thyrocytes.
Consider electron microscopy of both organs.
5.7.4.1 Outcome 8 - Further Testing Required
1. No effect of treatment - Check dose. Repeat at higher level?
2. No effect on T4-UDPGT or 5' Deiodinase
Consider hormone displacement from plasma binding proteins 
Consider enhanced deiodination in kidney - measure urine hormones 
Consider electron microscopy of the thyroid gland.
5.7.4.2 Outcome 9 - Proven Indirect Acting Goitrogen.
Reduced circulating thyroid hormone levels and increased TSH together with elevated T4- 
UDPCT or 5' monoiodinase levels. Suggests thyroid hormone disposal mechanisms active. 
Indirect acting goitrogen - Minimal risk to man 
Test mechanism.
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5.7.5 Stage 5: Confirmation Of Mechanism
The compound under test is suspected of having an indirect mode of action on the thyroid 
gland. Confirmation of this can be obtained from the follow ing assays.
Perform T4 clearance rate in thyroidectomised animals.
Perform biliary cannulation study- measure bile flow and metabolite excretion profiles.
With certain product categories a primate study might be advised.
5.7.6 Summary
The principal steps in a diagnostic algorithm designed to prove the mechanism of non- 
genotoxic, thyroid follicular cell neoplasia has been described. It is suggested that by the use 
of such a testing sequence a clear definition of the mechanism of effect would be obtained. 
Such information could be used to support the registration of non-genotoxic rodent 
carcinogens.
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5.8. Conclusions to Thesis
Carcinogenesis is a highly complex, long-term, multistep process with numerous causes.
Many of the phases involved are not avoidable and may occur spontaneously in normal 
tissues as a result of natural errors in DNA replication. As a result it is difficult to prove, 
without question, that the process occurs in a specific series of discrete steps.
In the case of thyroid follicular cell neoplasia in rats, sufficient evidence has been gathered 
over many of years to suggest that one major cause is an elevation of plasma TSH. The actual 
mechanism of TSH-mediated carcinogenesis in the rat has not been defined. It is clear, 
however, that tumours can occur in the absence of exogenous test materials.
A number of novel plant protection products tested in the author's laboratory have been 
shown to cause thyroid follicular cell neoplasia. This was thought to be due to enhanced 
peripheral metabolism of thyroid hormones, which leads to an elevation of plasma TSH.
The aim of this thesis was to provide evidence to support the hypothesis that:
"Rat follicular cell proliferative lesions observed in toxicity studies involving novel, 
microsomal enzyme inducing, plant protection products and shown to be mechanistically due 
to secondary effects is of no consequence to man".
It was decided that good evidence might be provided by conducting a carcinogenicity in rats 
with the sedative, phénobarbital. This material has been used in human medicine for some 
80 years and is not a thyroid carcinogen in man. If therefore, it could be shown that the 
material was carcinogenic in rats by a mechanism linked to microsomal enzyme induction, it 
was thought that this would help prove the hypothesis.
Phénobarbital was shown to cause thyroid follicular cell neoplasia in rats treated at a 
maximum tolerated dose level. This effect was shown to be associated with the known effects 
of microsomal enzyme inducing agents. Studies to clarify the mechanism were conducted 
with phénobarbital and a number of novel pesticidal products. All compounds were proven
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to be indirect acting goitrogens in the rat.
There are marked species differences in thyroid gland physiology and the rat is particularly 
unique when compared to man.
Phénobarbital and other microsomal enzyme inducing agents are believed to lead to thyroid 
follicular cell neoplasia in the rat. Such an outcome appears to be the result of an indirect 
mechanism of hypothyroidism caused by enhanced metabolism and excretion of thyroid 
hormones. The rat is particularly sensitive to this type of modulation of endocrine function 
due to higher metabolic potential of the drug metabolising enzymes and due to marked 
species differences in thyroid gland physiology. Males are more prone to effects than females 
due to sexually differentiated hepatic metabolism. Neoplasia that is the consequence of such 
mechanisms in rodents is of no consequence to man because simple hypothyroidism is not a 
known aetiological factor for thyroid cancer in humans.
It is believed that treatment with phénobarbital and other enzyme inducing agents leads to 
thyroid neoplasia - but TSH is the cause.
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